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Preamble 
The hypothalamic hormones TRH, LHRH and somatostatin, isolated in the 
late sixties and early seventies, are very useful in many clinical conditions. In 
1981 the structure of a fourth hypothalamic peptide hormone, corticotropin-
releasing hormone (1) was elucidated from ovine hypothalami by Vale et al 
(2), followed by the characterization of the structure of human CRH by 
Shibahara et al (3) in 1983. 
In this thesis the hormonal and hemodynamic effects of the intravenous 
administration of ovine and human CRH in man are studied. When we 
started our CRH programme in May 1982 only one brief report had been 
published on the effects of ovine CRH administration in man (4). Therefore 
we decided to investigate first, which factors determine the response of the 
pituitary to CRH administration in healthy subjects. In the second half of 
this thesis the ACTH and Cortisol responses to CRH in patients with hypo-
and hypercorticism, both before and after treatment are reported. The 
outcome of our studies lead to the conclusion that CRH provides not only a 
new tool in the study of the physiology and pathophysiology of the 
hypothalamic-pituitary-adrenal axis, but is also an aid in the clinical work­
up of the patient with hypo- or hypercorticism. 
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Chapter 1 
Review of animal studies 

Review of animal studies 
1.1 ISOLATION AND CHARACTERIZATION OF CRF 
Fifty years ago Harris (1) was the first to suggest that the secretion of 
hormones by the anterior pituitary was governed by humoral factors from 
the hypothalamus. In 1950 De Groot and Harris (2) showed that electrical 
stimulation of the hypothalamus led to a remarkable increase in the activity 
of the adrenal cortex. They postulated that the hypothalamus released a 
humoral factor into the hypothalamo-hypophyseal portal vessels, which 
stimulated ACTH release by the pituitary. In 1955 Saffran and Schally (3) 
and Guillemin and Rosenberg (4) independently demonstrated the presence 
of such a factor, which they called corticotropin-releasing factor (CRF). 
It was not until 1981, however, that Wylie Vale and co-workers from the 
Salk Institute in La Jolla isolated from 490.000 ovine hypothalami, earlier 
used for the isolation of TRH and LHRH, a polypeptide of 41 amino acids 
(molecular weight 4671) which fulfilled the criteria of a corticotropin-
releasing factor (5,6). The biological activity of the molecule was found to 
depend on the integrity of the C-terminal 27 amino acids (5,7). The isolation 
of ovine CRF (oCRF) was followed by the characterization of rat CRF 
(rCRF, molecular weight 4758) in 1983 by Rivier et al (8,9) and the 
elucidation of the structure of human CRF by analysis of the human pre-pro 
CRF gene by Shibahara et al (10). Both appeared to be peptides of 41 amino 
acids with identical amino acid sequences, differing from ovine CRF in 7 
amino acid residues. Recently the structures of bovine (11) and caprine CRF 
(12) were elucidated. CRF has a 50% homology with two non-mammalian 
CRF-like peptides, namely sauvagine, a polypeptide of 40 amino acids, 
isolated from the skin of the South American frog Phylomedusa sauvagei 
(13) and Urotensin I, a polypeptide, isolated from the urophysis of two 
species offish, Cyprinus carpio and Catostomus commersoni (14,15). CRF 
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is derived from a precursor molecule. The structure of this precursor (pre-
pro CRF) has been elucidated in sheep ( 190 amino acids) ( 16), rat ( 187 amino 
acids) (17) and man (196 amino acids) (10). 
1.2 DISTRIBUTION OF CRF IN THE BRAIN 
Like most other neuropeptides, CRF is widely distributed throughout the 
brain (18-28). Using antisera directed against ovine or rat CRF, major 
concentrations of CRF immunoreactive neurons in the rat brain have been 
described in: 
1. the hypothalamus, especially in the paraventricular nucleus. In the 
colchicine treated rat approximately 2000 of the 10.000 perikarya in this 
nucleus contain CRF (18). 80% of the CRF positive cell bodies are 
localized in the parvocellular division and 15% in the magnocellular 
division of this nucleus. The great majority of CRF neurons in the 
paraventricular nucleus projects to the external layer of the median 
eminence. This system is responsible for regulating the release of 
proopiolipomelanocortin (POMC) derived peptides from the pituitary. A 
minority of CRF neurons from the hypothalamus projects to the 
neurointermediate lobe of the hypophysis (29,30). 
Fibres from other parts of the hypothalamus, from the nucleus tractus 
solitarius, from the subfornical organ and the limbic system supply neural 
input to the parvocellular division of the paraventricular nucleus (18). 
2. parts of the limbic system and several nuclei of the basal forebrain and 
brain stem, which are known to be involved in the mediation of a variety 
of autonomic responses to stress. 
3. the cerebral cortex. 
Studies of CRF immunoreactivity in various regions of the brain using 
radioimmunoassays provided data fairly consistent with immunohistoche-
mical findings (26,27,31,32). In rats and in sheep the highest concentrations 
of CRF-like immunoreactivity were found in the median eminence, whereas 
the concentrations in other brain regions were at least two orders of 
magnitude lower (26,27,32). High affinity CRF receptors have been 
demonstrated in the anterior and intermediate pituitary, the external layer of 
the median eminence, parts of the limbic system and in the forebrain (33-35). 
After bilateral adrenalectomy CRF immunostaining in cell bodies of the 
paraventricular nucleus is enhanced, whereas CRF immunoreactivity in the 
median eminence is decreased, suggesting a high state of activity of CRF 
containing neurons (36). Recently Jingami et al (37) found that adrenal-
ectomy increased hypothalamic pre-pro CRF mRNA content. Moldow and 
Fishman (38) showed that treatment with dexamethasone reduced CRF-like 
immunoreactivity of the rat hypothalamus two fold, while Suda et al (39) 
demonstrated the same for the median eminence. These observations 
7 
illustrate that glucocorticoids can exert a negative feedback effect on the 
hypothalamus. 
A number of studies have demonstrated the colocalization of other 
neuroactive substances in individual parvocellular CRF neurons (40-48). In 
the colchicine treated rat there is extensive colocalization of CRF with 
metenkephalin and peptide histidine isoleucine (PHI) immunoreactivity 
(40), whereas a smaller subset of CRF neurons contain both CRF and 
neurotensin (41 ) or CRF and oxytocin or vasopressin (41 ). Colocalization of 
CRF and vasopressin immunoactivity is enhanced after adrenalectomy (42-
45), whereas in the adrenalectomized, colchicine treated rat individual 
neurons contain both CRF and dynorphin (47) or angiotensin II (48). 
1.3 ACTION OF CRF ON THE ANTERIOR LOBE 
Ovine and rat CRF exhibit high potency and intrinsic activity to stimulate 
release of ACTH and /3-endorphin in vitro (5,8,49-53) as well as in vivo 
(54-57). oCRF and rCRF have similar potencies in stimulating ACTH 
release from cultured rat pituitary cells (minimal effective concentration 
1-I0xl0-12M, ED50value 20-200x10-|2M, plateau response l-lOxlQ-'M) 
(5,8,53). In freely moving rats (54) and in stalk-sectioned cynomolgus 
monkeys (55) bolus injections of oCRF with doses as low as 0,5 //g/kg 
produce a significant activation of the pituitary-adrenal axis. In sheep 
(56,57) equivalent doses of oCRF stimulate ACTH and ^-endorphin 
secretion. CRF not only stimulates the release of ACTH and the other 
POMC derived peptides from the anterior pituitary, but also promotes their 
synthesis, as derived from the increase of POMC mRNA levels after oCRF 
administration (58,59). The effect of CRF on ACTH secretion is mediated 
via Ca dependent (60,61) generation of cAMP (7,62-64). After binding to 
specific receptors (33) located in the plasma membrane of corticotrophs, 
CRF is rapidly internalized and migrates to the Golgi apparatus and 
lysosomes, where degradation may occur (65,66). 
In rats ovine CRF specifically stimulates the release of POMC fragments 
in the anterior pituitary, whereas in cynomolgus and rhesus monkeys (55,67) 
the peptide also causes dose-dependent prolactin and growth hormone 
responses. After intravenous administration of oCRF to rats not only an 
increase of corticosterone, but also of aldosterone and its precursor 18-
hydroxycorticosterone has been described (68,69). 
It has been shown that dexamethasone modulates the response of cultured 
rat anterior pituitary cells to ovine CRF by a non-competitive interaction 
(53). The inhibitory effect of dexamethasone on the response to CRF is 
dose-dependent as well as time-dependent (53). Maximum inhibition of CRF 
induced ACTH release was observed after 4 hours of preincubation with 
dexamethasone. Bilezikjian et al (70) and Shimizu et al (71) showed that the 
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inhibitory influence of dexamethasone on CRF induced ACTH secretion in 
vitro is mediated, at least in part, by a negative effect on cyclic AMP 
formation. However, a site of action distal to cyclic AMP production has 
been claimed by Giguère et al (64). 
In vivo, Rivier et al (54) showed that pretreatment with 20 μg dexame­
thasone intraperitoneally 4 hours before ovine CRF administration almost 
completely abolished the ACTH response to CRF in doses of up to 3 μg in 
anaesthetized rats. A 95% decrease in ACTH response to 10//g ovine CRF 
after pretreatment with 100 //g dexamethasone 15 and 3 hours before CRF 
injection in rats has been shown by Proulx-Ferland et al (72). In sheep, 
Donald et al (73) demonstrated that 0,4 - 4 mg dexamethasone, intrave­
nously administered 2 hours before injection of 200//g ovine CRF, abolished 
ACTH and Cortisol responsiveness. 
It has been demonstrated that repeated injections or a continuous infusion 
(24 hr - 7 days) of oCRF in rats causes some decrease of the pituitary 
response to CRF (74,75). However, this loss of response is small when 
compared to the degree of pituitary desensitization observed during 
repeated exposure to other releasing factors, e.g. GnRH. This decrement of 
the response to CRF is in part caused by increased negative feedback, due to 
elevation of glucocorticoid levels. 
1.4 ACTION OF CRF ON THE INTERMEDIATE LOBE 
Peptides, derived from the precursor molecule proopiolipomelanocortin 
(POMC) are produced in the anterior as well as in the intermediate lobe of 
the pituitary. However, the processing of POMC is different in both 
hypophyseal compartments. ACTH, /3-endorphin and /3-lipotropin are the 
main products of the pars anterior, whereas in the pars intermedia ACTH is 
further cleaved in a-MSH and CLIP (corticotropin like intermediate 
peptide) (76). 
The rate of secretion of POMC derived peptides in rat pars intermedia 
cells results from a balance between the stimulatory effects of ^-adrenergic 
agents (epinephrine) and the inhibitory influence of dopamine. Recently, 
however, it has been demonstrated that in addition to /J-adrenergic agents 
CRF also has a stimulatory effect on the rat intermediate pituitary 
(53,72,77,78). 
Meunier et al (77) showed that oCRF stimulates a-MSH release in rat pars 
intermedia cells in culture. The effect of CRF on a-MSH release in these cells 
is observed at an ED50 value of 10"
9M and is mediated by an increase of 
adenylate cyclase activity (78). Whereas the dopaminergic agonist bromo­
criptine inhibits the CRF induced a-MSH release, dexamethasone pretreat­
ment, under conditions which lead to an almost complete inhibition of 
ACTH secretion in corticotrophs of the anterior pituitary gland, has no 
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inhibitory effect on either spontaneous or CRF induced a-MSH secretion in 
vitro (77). 
In vivo Proulx-Ferland et al (72) showed that in freely moving rats 
intravenous administration of 10 /ug oCRF not only leads to a sixfold 
increase of the plasma concentration of ACTH, but also to a similar 
stimulatory effect on plasma a-MSH. Moreover, these authors demon­
strated that administration of 100 //g of dexamethasone 15 and 3 hours 
before the injection of CRF led to a 95% decrease in the ACTH response to 
oCRF, while the a-MSH response remained unchanged. Vale et al (53), 
studying ^-endorphin release from rat intermediate lobe cells in culture, 
demonstrated that the sensitivity of intermediate lobe cells for CRF is at least 
one order of magnitude less than that of adenohypophyseal cells and that 
maximally effective CRF concentrations stimulated /J-endorphin secretion 
in rat intermediate lobe cells to a lesser degree than did epinephrine. Gibbs et 
al (79) found that oCRF had no effect on ^-endorphin, /3-lipotropin or 
a-MSH secretion from neurointermediate lobes of human fetuses, regardless 
of age. 
From this data one might infer that CRF, at least in the rat, can interact 
with dopamine in the physiological control of the intermediate lobe, 
although, based on the above mentioned and other data (80,81 ), epinephrine 
seems to be more important than CRF as a regulator of intermediate lobe 
function. 
1.5 INTERACTIONS OF CRF WITH OTHER HYPOTHALAMIC FACTORS IN THE 
CONTROL OF ACTH RELEASE 
The rat hypothalamus and portal blood contain a number of other factors in 
addition to CRF, capable of inducing ACTH release from cultured anterior 
lobe cells. This paragraph summarizes some recent studies on the ACTH 
releasing and CRF potentiating properties of these factors, which have a 
lower potency and intrinsic activity than CRF for the release of ACTH (53). 
The ACTH releasing capacity of vasopressin, known for many years, is 
illustrated by the observation that in vitro preincubation of stalk median 
eminence extracts of Wistar rats with an antibody to vasopressin reduces its 
ACTH releasing ability by 60% (82). The role of vasopressin in ACTH 
secretion is probably complex, since apart from increasing pituitary ACTH 
secretion (53,83), it has also been reported to cause the release of endogenous 
CRF (84,85) and to potentiate the action of this peptide on the anterior lobe 
(53,83,86-89). However, a facilitatory action of vasopressin on the release of 
CRF has been questioned by others (90). The action of vasopressin on the 
corticotropic cell is probably mediated by V! (pressor-like) receptors 
(91,92), although a novel ( з= non-pressor, non-antidiuretic) type of 
receptor is assumed to be involved in this action by others (93,94). 
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Vasopressin itself acts through a cAMP independent pathway (95), although 
it can potentiate the CRF induced cAMP accumulation in corticotropic cells 
(87,95). 
Interactions between CRF and other factors have also been demonstrated. 
The weak ACTH secretagogues angiotensin II (96,97), peptide histidine 
isoleucine (PHI) (98,99) and oxytocin (53,96,100,101) markedly potentiate 
CRF activity on the anterior lobe in vitro. Furthermore epinephrine and 
norepinephrine have a weak ACTH releasing activity in vitro (53) by means 
of an Oj-adrenergic receptor, whereas both in vitro and in vivo admini-
stration of these catecholamines enhance the effect of CRF on ACTH release 
(53,83,102). It was shown that somatostatin inhibits CRF induced ACTH 
secretion in mouse pituitary tumor cells (103,104). 
Finally, it has to be stressed that immunoneutralization of endogenous 
CRF either markedly reduces (vasopressin) or completely abolishes (oxy-
tocin, angiotensin II, epinephrine) the ACTH release induced by the 
administration of these factors in vivo (83,105,106). This illustrates the vital 
role for CRF in regulating ACTH release. 
1.6 LEVELS OF CRF AND OTHER PUTATIVE ACTH REGULATING FACTORS IN 
HYPOPHYSEAL PORTAL BLOOD 
Using antisera directed against ovine or rat CRF, CRF-like immuno-
reactivity has been demonstrated in portal plasma of anaesthetized rats in 
concentrations as low as 10"10Mol (450 pg/ml; secretory rate 1,5 pg/min) 
(107-115). It has to be noted that concentrations of other hypothalamic 
hormones involved in the control of ACTH secretion are about 10-fold 
(arginine-vasopressin, oxytocin) or even 100-fold (epinephrine) higher (108-
115). These portal blood levels are significantly higher (2x for epinephrine, 
lOx for arginine-vasopressin and 30x for oxytocin) than those in the 
peripheral plasma of the rat, in which no CRF immunoactivity has been 
detected up till now (108,113). These systemic to portal concentration 
gradients strongly support a central origin for each of these factors. 
Moreover, the hormone levels in portal plasma are well within the range of 
concentrations shown to evoke ACTH secretion by pituitary cells in vitro, 
when presented alone or in combination. 
Table 1 illustrates the changes of portal blood levels of these 4 hormones in 
anaesthetized rats in 4 situations known to alter ACTH secretion. Surpris-
ingly, significant changes of CRF levels were only observed after volume 
depletion (hemorrhage of 15% of blood volume), whereas significant 
changes of AVP levels occurred in all experimental conditions. However, it is 
thought that in situations with pituitary-adrenal activation without a rise in 
portal CRF levels, CRF plays at least a permissive role, as is illustrated by the 
fact that no ACTH rise occurs after insulin-induced hypoglycemia following 
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pretreatment with an antiserum to rat CRF (113,114). The significant role 
for CRF in mediating ACTH secretion is also illustrated by the complete 
abolishment of CRF and ACTH stimulation by hemorrhage stress following 
pretreatment with dexamethasone or by lesions of the paraventricular 
nucleus (113,115) 
Table 1 Relative changes of penpheral ACTH levels and portal CRF, AVP, ОТ, and E levels to 
4 different stimuli in anaesthetized rats 
Depletion of blood volume108·113 
Insulin-induced hypoglycemia113 
Hypothermia1 0 ' ·"2 
Expansion of blood volume1 0 8 '1 1 3 
Peripheral 
ACTH 
+300% 
+ 150% 
- 62% 
- 70% 
CRF 
+ 140% 
Portal blood 
АУР 
+ 110% 
+ 80% 
- 35% 
- 49% 
ОТ 
+ 110% 
η m 
- 35% 
E 
+230% 
η m 
η m 
= no significant changes 
η m not measured 
AVP = arginine vasopressin, OT= oxytocin, Ε= epinephrine 
This data favour the concept that CRF is not the only corticotropin-
releasing factor. It seems most likely that the hypothalamo-hypophyseal-
adrenal axis can be activated in different ways in response to different 
stimuli. Although CRF seems to be the central hormone in the hypothalamic 
control of ACTH secretion, additional hypothalamic hormones, including 
argimne-vasopressin, oxytocin, epinephrine, and possibly other factors 
(112), may in some conditions play a role in the stimulation of ACTH In the 
next paragraph we will look, in more detail, into the respective roles of these 
factors in the activation of the pituitary-adrenal axis during stress 
1 7 THE ROLE OF CRF AND OTHER FACTORS IN THE RELEASE OF ACTH DURING 
STRESS 
The concept that stress induced ACTH release is not controlled by a single 
factor, but by the interaction of several substances, including CRF, 
vasopressin and catecholamines is now widely recognized. Of these ACTH 
releasing factors CRF has the highest potency, intrinsic activity and 
specificity for the stimulation of the release of ACTH and other POMC 
derived peptides (53). This paragraph briefly summarizes evidence of the 
significance of CRF, vasopressin and catecholamines respectively in the 
stress induced activation of the pituitary-adrenal axis 
The pivotal role of CRF during stress was demonstrated by Rivier et al 
(116) and Rivier and Vale (117), who showed that intravenous admini-
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stration of rabbit antiserum to ovine or rat CRF blocked 85% of the ACTH 
release observed in rats exposed to ether stress. Linton et al (118), using an 
antiserum to ovine CRF, observed that the rise in plasma ACTH induced by 
formalin stress was reduced to 28% in rats pretreated with anti CRF as 
compared to the response in normal rabbit serum treated animals, whereas 
the ACTH response to restraint stress was attenuated to 13%. Bilateral 
lesions of the paraventricular nucleus (PVN), leading to a 90% reduction of 
CRF-like immunoreactivity content of the median eminence, attenuate the 
ACTH response to ether stress by 70-85%, whereas when PVN lesioned rats 
were treated with the ganglionic blocker chlorisondamine - a blocker of 
peripheral catecholamine secretion - or with the vasopressin antagonist 
desaminopenicillamine-1 (O-methyl) tyrosine-2-aVP the ACTH response to 
ether stress was completely abolished (119). Moreover, pretreatment of rats 
with the CRF antagonist α-helical CRFc^jj prevented most, but not all, of 
the increase in ACTH caused by ether stress (120). Direct evidence of the 
vital role of CRF was also obtained from the observation that production of 
an antiserum to ovine CRF led to severe secondary adrenal failure in a rabbit 
(121). 
Although this data strongly suggests that increased CRF secretion is the 
cause of the activation of the pituitary-adrenal axis during stress, a number 
of observations support the notion that other factors play at least a 
modulatory role (122). 
The role of vasopressin in the control of the pituitary-adrenal response to 
stress is supported by the observation that in the intact rat treatment with an 
antiserum to vasopressin reduced the rise in plasma ACTH during formalin 
stress to 53% and in restraint stress to 37% (118). Rivier and Vale (117) and 
Bruhn et al (119) showed that the a VP antagonist desaminopenicillamine-1 
(O-methyl) tyrosine -2-aVP had no effect on the early phase of the ACTH 
response to ether stress, but reduced this response by 45% in later (10-20 
min) phases of ether stress. However, it is most likely that, in addition to 
CRF and vasopressin, at least one other factor is relevant for the ACTH 
response during stress, since Linton et al ( 118) found that treatment with anti 
CRF together with anti vasopressin could not entirely prevent the ACTH 
response in the rat during formalin and restraint stress. 
Rivier and Vale (117) claim that circulating catecholamines play a role in 
the activation of the anterior pituitary during stress. They demonstrated that 
treatment with chlorisondamine inhibits ACTH release in rats during ether 
stress by 40-60% and by 100% when it is administered together with anti 
CRF. However, other workers (122,123) found no evidence that circulating 
catecholamines are of significance in the pituitary-adrenal response to stress, 
although circulating epinephrine seems to play a major role in the release of 
intermediate lobe peptides during emotional stress (122,123). 
Together this data favours the notion that it is highly likely that CRF is the 
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predominant regulator of stress induced ACTH secretion, but that vaso-
pressin and possibly other factors (epinephrine, oxytocin, angiotensin II) are 
also involved in mediating stress induced ACTH secretion, most probably as 
CRF potentiating agents. 
1.8 EXTRA-PITUITARY ACTIONS OF CRF 
Stressful stimuli evoke concurrent activation of the pituitary-adrenal axis 
and the sympathetic nervous system and result in metabolic, cardiovascular 
and visceral organ function changes, which can be interpreted as a 
generalized adaptive response to stress. Several studies (124-132) have 
demonstrated that CRF not only plays a key role in the hormonal response 
to stress, but also acts within the central nervous system to elicit a variety of 
effects, regularly observed during stress. 
CRF given intracerebroventricularly (i.c.v.) to rats or dogs not only 
activates pituitary-adrenal function, but also elicits dose related elevations 
of plasma epinephrine and norepinephrine concentrations, indicating 
activation of the sympathetic nervous system and the adrenal medulla (124, 
125, 128, 130, 131). Activation of the sympathetic nervous system by 
intracerebroventricular administration of CRF in the rat results in increases 
of plasma glucose, mean arterial pressure and heart rate (124-132). CRF 
induced elevations of plasma glucose, epinephrine, norepinephrine, mean 
arterial pressure and heart rate are prevented by administration of the 
ganglionic blocker chlorisondamine (125, 126, 128, 131). Intracerebro-
ventricular administration of CRF also increases total body oxygen 
consumption ( 124), induces behavioral changes (for reviews see 133 and 134) 
and suppresses gastric acid secretion in rats and dogs (135-138). 
Apart from controlling ACTH release by a direct effect at the pituitary 
level, CRF has been found to act centrally to inhibit the secretion of LH and 
growth hormone (83,139-141). CRF induces a dose-dependent inhibition of 
LH (but not of FSH) release in gonadectomized/adrenalectomized rats, 
indicating that this effect is not mediated through steroids of either adrenal 
or gonadal origin (83,139). This deleterious effect of central CRF admini-
stration does not involve opiate or peripheral catecholaminergic pathways 
(83,139), but is probably mediated by a direct inhibitory effect on 
hypothalamic LHRH release (142). Intracerebroventricular CRF admini-
stration also inhibits growth hormone secretion (140,141). It has to be 
determined whether this effect results from inhibiting growth hormone 
releasing hormone release or from stimulating somatostatin release (143). 
Furthermore it has been demonstrated that CRF administered i.c.v. inhibits 
vasopressin and oxytocin secretion into hypophysial portal blood (110). 
These observations strongly suggest that CRF might indeed be a key signal 
in mediating and integrating an organism's endocrine, visceral and beha-
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vioral responses to stress 
Several reports have demonstrated that CRF immunoreactivity is not 
restricted to the brain, but is also found in a variety of peripheral organs Of 
special interest is localization of CRF in the stomach and small intestine 
( 144,145), pancreas ( 144,146) and adrenal medulla ( 147-149). The functional 
significance of this peripheral CRF has to be determined Paracrine effects of 
CRF are postulated in the pancreas (on insulin release (150)) and in the 
adrenal medulla (on adrenalin secretion (148)) 
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2.1 PLASMA ADRENOCORTICOTROPIN, CORTISOL, AND ALDOSTERONE RES­
PONSES TO CORTICOTROPIN-RELEASING FACTOR: MODULATORY EFFECT OF 
BASAL CORTISOL LEVELS 
A.R.M.M. Hermus, G.F.F.M. Pieters, A.G.H. Smals, Th.J. Benraad and 
P.W.C. Kloppenborg 
Division of Endocrinology, Departments of Medicine and Experimental and 
Chemical Endocrinology (T.J.B.), University of Nijmegen, Nijmegen, The 
Netherlands. 
SUMMARY 
Two hundred micrograms of ovine corticotropin-releasing factor (CRF) 
were administered as an iv bolus injection to 10 normal subjects (5 men and 5 
women). Mean plasma ACTH levels rose significantly (P < 0.0005, by 
Friedman's nonparametric analysis of variance) from a basal value of 27 ± 5 
pg/ml (mean ± SEM) to a peak value of 63 ± 8 pg/ml 30 min after CRF 
administration. This ACTH response was followed by a rise in mean plasma 
Cortisol levels (P < 0.0005, by Friedman's test) from a baseline value of 12.3 
± 1.4//g/100 ml to a peak value of 21.0 ± 0.7 jug/100 ml 60 min after CRF 
and a rise in mean plasma aldosterone levels from a basal value of 13 ± 2 
ng/100 ml to a peak value of 23 ± 2 ng/100 ml. There was no significant 
difference between men and women in the responsiveness of ACTH, 
Cortisol, and aldosterone to CRF administration. The individual basal 
Cortisol levels were highly significantly and negatively correlated with the 
areas under the individual ACTH curves (r = -0.76; Ρ < 0.005, by Pearson's 
correlation test) and Cortisol curves (r = -0.91 ; Ρ < 0.001, by Pearson's test). 
These data suggest a modulatory effect of physiological Cortisol levels on 
the response of the pituitary-adrenal axis to CRF. 
INTRODUCTION 
Shortly after the elucidation of the structure of ovine corticotropin-releasing 
factor (CRF) by Vale et al. (1), several reports appeared dealing with the 
effects of CRF on the secretion of ACTH, Cortisol, aldosterone, and various 
pituitary hormones in laboratory animals (2,3) and in normal humans (4-6). 
In patients with Cushing's disease, enhanced responsiveness of ACTH and 
J Clin Endocrinol Metab 1984; 58: 187-91 
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Cortisol to CRF generally has been found (5,7,8). In our study the 
responsiveness of Cortisol to CRF was most pronounced in those patients 
with Cushing's disease who had the highest basal plasma Cortisol levels (8). 
This prompted us to study the modulating effect of basal Cortisol levels on 
the response to CRF in normal humans. In contrast to patients with 
Cushing's disease, the magnitude of the Cortisol response to CRF was 
inversely related to the basal plasma Cortisol level, i.e. the higher the basal 
Cortisol level, the lesser its response to CRF. Furthermore, CRF stimulated 
not only ACTH, and thereby Cortisol secretion, but also the release of 
aldosterone. 
MATERIALS AND METHODS 
Ten normal subjects (five men, aged 23 ± 3 yr [mean ± SD], and five women, 
aged 31 ± 14 yr) received 200 μg ovine CRF (Bachern, Torrance, CA) 
dissolved in 2 ml acid-saline (pH 2) as a bolus injection. Informed consent 
was obtained from all volunteers, and the protocol was approved by the 
hospital ethical committee. All tests were performed at 09.00 h with the 
subjects fasting and at bed rest. Previous sodium intake was normal. Blood 
samples for hormone assay were collected at -30,0, 1.5, 3, 5,7.5,10, 20, 30, 
60, 120, 180 and 240 min via an indwelling iv cannula kept open with a 
diluted ( 10%) solution of heparin. The cannula was inserted 1 h before CRF 
administration. Plasma ACTH [intraassay coefficient of variation (CV), 
12%] (9), Cortisol (CV, 8%) (10), LH (CV, 7%), FSH (CV, 9%) (11), TSH 
(CV, 6%) (12), PRL (CV, 6%) (13), human GH (CV, 15%) (14), and 
aldosterone (CV, 8%) (15) were determined by specific RIAs, as described 
previously. Statistical analyses were performed using Wilcoxon's paired 
rank test (P values denoted by P), Friedman's nonparametric analysis of 
variance (P = P*), and Pearson's correlation test (P = P**). Unless otherwise 
stated, the mean values ± 1 SEM are given. 
RESULTS 
Side effects 
Flushing, mild dyspnea, and small decreases in diastolic blood pressure 
occurred in most subjects immediately after CRF administration. Major 
complications did not occur in these normal subjects (16,17). 
Responses of PRL, TSH, LH, FSH, and human GH(hGH) 
Mean plasma PRL levels significantly (P* < 0.0005) decreased throughout 
the test from 343 ± 51 mU/liter at -30 min to 255 ± 36 mU/liter at 0 min (Ρ < 
27 
0.01 vs. -30 min) and 125 ± 23 mU/liter at 120 min (Ρ < 0.01 vs. 0 min). Mean 
plasma TSH levels also significantly (Ρ* < 0.001) decreased from 3.2 ± 0.4 
mU/liter at -30 min to 2.9 ± 0.4 mU/liter at 0 min (Ρ < 0.01 vs. -30 min) and 
2.1 ± 0.3 mU/liter at 120 min (Ρ < 0.02 vs. 0 min). Mean plasma levels of LH, 
FSH, and hGH did not change. 
ACTH (Fig. 1) 
After a statistically significant fall between -30 and 0 min from 41 ± 14 to 27 
± 5 pg/ml (P < 0.01 ), mean plasma ACTH levels rose without exception (P* 
< 0.0005). At 1.5 and 3 min, the mean values of 27 ± 4 and 26 ± 3 pg/ml, 
respectively, did not differ from the basal ACTH level, whereas 5 min after 
CRF injection, the mean plasma ACTH level was significantly higher (39 ± 6 
pg/ml; Ρ < 0.02). Figure 1 shows that the mean plasma ACTH level reached 
its maximum of 63 ± 8 pg/ml at 30 min and thereafter gradually declined to 
40 ± 4 pg/ml at 240 min (Ρ < 0.01 vs. 30 min). At that time, 8 of 10 subjects 
had ACTH levels higher than their baseline values. At 60, 120 and 180 min, 
the mean ACTH levels were still significantly higher than the baseline value 
(Fig. 1). The individual peak levels were achieved at variable intervals (from 
10 to 120 min) after the administration of CRF. 
Cortisol (Fig. 1) 
Mean (± SEM) plasma Cortisol levels decreased significantly between -30 
min and 0 min from 14.4 + 1.8/yg/100 ml (0.40 ± 0.05 jumol/liter) to 12.3 + 
1.4//g/100 ml (0.34 ± 0.04/imol/liter) (P < 0.01 ). After CRF administration, 
Cortisol levels rose without exception (P* < 0.0005), and at 10 min, they were 
significantly higher ( 14.1 ± 1.4/ug/100 ml; 0.39 ± 0.04/лпоі/liter; Ρ < 0.05) 
than the basal value. Figure 1 illustrates that the mean plasma Cortisol level 
reached its maximum at 60 min (21.0 ± 0.7 /ig/100 ml; 0.58 + 0.02 
/mol/liter) and thereafter gradually declined to 17.0 ± 1.1 /yg/100 ml (0.47 ± 
0.03 //mol/liter) at 240 min (Ρ < 0.05 vs. 60 min; Ρ > 0.10 vs. 0 min). 
Individual peak levels again were achieved at variable intervals between 20 
and 180 min after CRF injection. 
Aldosterone (Fig. 1) 
Mean plasma aldosterone, like Cortisol, decreased significantly (P < 0.01) 
between -30 and 0 min. After CRF administration, aldosterone levels rose 
significantly (P* < 0.0005). The mean plasma aldosterone levels after CRF 
treatment remained unchanged through 10 min, but at 20, 30, and 60 min, 
aldosterone levels were significantly higher than the basal value (21 + 3,21 + 
2, and 23 + 2 ng/100 ml, respectively, vs. 13 + 2 ng/100 ml at 0 min). Figure 1 
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shows that the mean plasma aldosterone level reached its maximum of 23 ± 2 
ng/100 ml at 60 min and thereafter gradually declined to 17 ± 2 ng/100 ml at 
240 mm (Ρ > 0.10 vs. 0 min). Individual peak levels were achieved between 20 
and 180 min after CRF injection. In 8 of the 10 subjects, the peak levels of 
ACTH preceded or coincided with the peak levels of Cortisol and aldos-
ACTH ( p g / m l ) -
CRF 200/ug tv 
80 
60 
40 
20 
Cortisol (/jg/IOOml) 
195-
13 
65 
Aldosterone 
( n g / 100 ml) 
30 
2 0 
1 0 
ττ—ι—ι г-
- 3 0 30 60 120 1Θ0 240 
Time (mm) 
Figure 1 Mean ± SEM plasma ACTH, Cortisol and aldosterone levels after an iv bolus injection 
of CRF (200 μ% ovine CRF, Bachem) in 10 normal subjects. 
The stars indicate statistical significance (*, Ρ < 0.05, Î, P < 0 01) 
Table I. ACTH, Cortisol, and aldosterone levels (mean, SEM, and range) after ovine CRF administration (200 цс) in normal subjects 
ACTH (pg/ml) 
Mean 
SEM 
Range 
Cortisol G"g/I00 
Mean 
SEM 
Range 
ml) 
Aldosterone (ng/100 ml) 
Mean 
SEM 
Range 
ACTH (pg/ml) 
Mean 
SEM 
Range 
Cortisol (/ig/100 
Mean 
SEM 
Range 
ml) 
Aldosterone (ng/100 ml) 
Mean 
SEM 
Range 
-30 mm 
50 
29 
19-166 
13.0 
2.6 
6.6-22.4 
15 
3 
6-26 
-30 min 
33 
5 
15-45 
15.5 
2.6 
8.7-23.9 
14 
3 
2-22 
0 mm 
28 
11 
<15-71 
10.9 
2.1 
6.6-18.1 
12 
3 
5-23 
0 mm 
26 
5 
15-40 
13.7 
2.1 
7.4-19.5 
14 
3 
3-23 
10 mm 
41 
13 
31-76 
12.2 
1.4 
10.1-18.1 
11 
3 
5-23 
10 min 
51 
12 
28-85 
15.9 
2.1 
9.1-19.6 
17 
4 
6-27 
20 min 
61 
13 
40-104 
15.9 
0.4 
13.3-18.1 
18 
4 
9-34 
20 min 
51 
8 
33-78 
19.1 
1.4 
14.1-22.8 
23 
4 
14-36 
Women 
30 mm 
70 
14 
42-119 
17.9 
1.4 
14.4-20.4 
20 
3 
12-33 
Men 
30 min 
57 
12 
37-97 
22.9 
1.4 
15.9-21.5 
22 
3 
13-29 
60 min 
71 
15 
46-129 
20.9 
1.0 
17.9-23.1 
23 
4 
15-39 
60 min 
51 
8 
34-75 
21.1 
1.0 
19.0-25.6 
23 
2 
16-27 
120 mm 
53 
8 
34-72 
19.1 
0.7 
17.2-21.8 
17 
3 
10-23 
120 min 
37 
4 
27^5 
18.2 
1.4 
13.4-22.1 
15 
2 
8-21 
180 mm 
48 
8 
25-71 
19.6 
1.0 
17.2-22.9 
19 
3 
8-25 
180 min 
38 
3 
31-45 
17.6 
1.0 
14.4-21.1 
19 
2 
10-22 
240 mm 
49 
8 
30-67 
18.6 
1.4 
16.1-22.4 
19 
2 
14-24 
240 min 
31 
3 
25-41 
15.1 
21 
12.0-17.2 
16 
3 
9-24 
30 
terone. In the 2 other individuals, the maximal ACTH rises were the lowest 
of the group (16 and 24 pg/ml, respectively, vs. 56 ± 7 pg/ml in the 
remaining 8 subjects). 
Sex differences (Table 1) 
There were no significant differences between men and women in the 
responses of ACTH, Cortisol, or aldosterone to CRF administration. 
Relationships between basal Cortisol and aldosterone levels and CRF-induced 
changes in A CTH and Cortisol (Figs. 2 and 3) 
When the areas under the ACTH curve were calculated from the differences 
between the individual ACTH values at the various time points and the 
individual zero values and expressed as square millimeters (1 pg/ml = 1 mm 
and 1 mm = 1 mm), there was a highly significant and negative correlation 
between the areas under the individual ACTH curves and the basal Cortisol 
levels at 0 mm (r = -0 76, P** < 0 005), ι e. the lower the basal plasma 
Cortisol, the greater the rise in ACTH levels (Fig. 2). The ACTH released in 
response to CRF injection clearly stimulated Cortisol secretion, as indicated 
ACTH area under 
the curve m m 2 
10 000 -
Θ000-
6 0 0 0 -
A000-
2000 
r=.0 76 
P**<0 005 
τ 
T 
65 13 19 5 26 32 5 
Basal Cortisol (^ід/ЮО m l ) 
Figure 2 Intravenous bolus injection of 200 μ§ ovine CRF, relation between individual basal 
Cortisol levels and the areas under the individual ACTH curves 
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by the highly significant correlation between the areas under the ACTH 
curves and those under the Cortisol curves (calculated in the same way as for 
ACTH, 0.01 //mol/liter = 1 mm (0.36//g/dl = 1 mm) and 1 min is 1 mm; г = 
0.87; Ρ** < 0.001). Therefore, it is not surprising that the basal Cortisol levels 
were highly negatively correlated with the areas under the Cortisol curves (r 
= -0.91; P * * < 0.001; Fig. 3). The basal aldosterone levels also tended tobe 
negatively related to the areas under the ACTH curves (r = -0.51; P** < 
0.10). After correcting this relation for the basal Cortisol levels, the resulting 
partial correlation coefficient between the basal aldosterone level and the 
area under the ACTH curve was not statistically significant (P** > 0.10). 
The basal levels of aldosterone were closely correlated to the basal levels of 
Cortisol (r = 0.90; P** < 0.001). There was no significant correlation between 
the areas under the ACTH curves and those under the aldosterone curves (r 
= 0.13; P * * > 0.10). 
DISCUSSION 
The present study is the first to demonstrate concurrent increases in 
plasma ACTH, Cortisol, and aldosterone levels after the administration of 
ovine CRF to healthy subjects on a regular salt intake. In the first report on 
the effect of ovine CRF on ACTH and Cortisol levels, Grossman et al. (4) 
Cortisol area under 
the curve m m 2 
10.000 τ 
ΘΟΟΟ-
6 0 0 0 -
4 0 0 0 
2 0 0 0 
r = . 0 . 9 1 
P"' 
6.5 13 19.5 26 32.5 
Basal Cortisol (^ jg/IOOml) 
Figure 3. Intravenous bolus injection of 200 ¿/g ovine CRF; relation between individual basal 
Cortisol levels and the areas under the individual Cortisol curves. 
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reported a maximal rise of ACTH levels of about 40 pg/ml and of plasma 
Cortisol levels of about 7.2 /ug/100 ml after the administration of 100 μg 
CRF. We found similar increases in plasma ACTH and Cortisol levels using a 
2-fold higher dose of CRF. Therefore, this higher dose of CRF influenced the 
results to only a small degree, as also can be deduced from the meticulous 
study by Orth et al. (6). This study further showed that the higher the basal 
plasma Cortisol level, the smaller the CRF-induced secretion of ACTH and, 
subsequently, of Cortisol. This intriguing observation is circumstantial 
evidence in favour of a role for physiological Cortisol levels in the activation 
of the hypophyseal-adrenal axis induced by CRF and is similar to the earlier 
described relation between circulating T4 and the activity of the TRH-TSH 
axis ( 18). Obviously, these data do not allow any conclusion about the exact 
mechanism by which Cortisol plays such a modulatory role. It cannot be 
totally excluded that the high inverse correlation between the individual 
basal plasma Cortisol levels and the responses of the pituitary-adrenal axis to 
CRF is only the reflection of an inverse correlation between the individual 
endogenous basal CRF levels and the response of the pituitary-adrenal axis 
to exogenously administered CRF, i.e. in the presence of lower endogenous 
CRF activity exogenously administered CRF results in greater stimulation 
of the pituitary-adrenal axis. 
In contrast to the negative modulatory effect of basal plasma Cortisol 
levels in these normal subjects on the stimulatory effect of CRF on ACTH 
and subsequent Cortisol secretion, in a limited number of patients with 
Cushing's disease, we did not find such a negative modulatory effect of basal 
plasma Cortisol levels (8). In those patients, the stimulatory effect of CRF 
was greater when basal plasma Cortisol levels were higher. 
Another new finding of the present study was the rather brisk rise of about 
20 ng/100 ml in plasma aldosterone levels 15 min after the initial ACTH 
increase. These data are at variance with those of Müller et al. (5), who found 
that 100 μ£ CRF had no effect on plasma aldosterone levels. Our data on 
aldosterone are in accordance with the known stimulatory effect of ACTH 
on aldosterone secretion in man (19,20). 
The absence of a stimulatory effect of CRF on LH, FSH, and hGH 
secretion and the minor but significant fall in PRL and TSH levels strongly 
indicate that CRF is a specific stimulator of ACTH release. 
To conclude: 
1 ) the responses of ACTH and Cortisol to CRF were inversely related to the 
basal plasma Cortisol levels; 
2) CRF elicited a rise not only in circulating ACTH and Cortisol but also an 
increase in plasma aldosterone levels; and 
3) there was no stimulatory effect of CRF on the other pituitary hormones 
in normal subjects. 
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2.2 DIFFERENTIAL EFFECTS OF OVINE AND HUMAN CORTICOTROPHIN-RE-
LEASING FACTOR IN HUMAN SUBJECTS 
A.R.M.M. Hermus, G.F.F.M. Pieters, G.J. Pesman, W.C.A.M. Buijs, 
A.G.H. Smals, T.J. Benraad and P.W.C. Kloppenborg 
Department of Medicine, Division of Endocrinology, Department of 
Experimental and Chemical Endocrinology and Department of Nuclear 
Medicine, University of Nijmegen, Nijmegen, The Netherlands. 
SUMMARY 
Ten healthy subjects received 200 /Ug of human CRF (hCRF) and 200 μg of 
ovine CRF (oCRF) as an intravenous bolus injection on two different 
occasions. After hCRF plasma ACTH levels rose significantly ( P < 0.0005, 
by Friedman's nonparametric analysis of variance) from a basal value of 35 
± 3 pg/ml (mean ± SEM) to a peak value of 80 ± 7 pg/ml 30 min after hCR F 
administration. This ACTH response was followed by a rise in plasma 
Cortisol levels (P < 0.0005, by Friedman's test) from a baseline value of 0.32 
± 0.03 μτηοί/Ι to a peak value of 0.56 ± 0.02 μτηοΙΛ 60 min after hCRF. 
Ovine CRF elicited similar rises in the plasma ACTH and Cortisol levels. 
However, as derived from the faster rate of decline of ACTH and Cortisol 
after hCRF than after oCRF, human CRF had a significantly shorter 
duration of action than ovine CRF in humans. Human CRF not only 
stimulated ACTH release by the human pituitary gland but also prolactin 
release. After hCRF administration prolactin levels rose significantly (P < 
0.005, by Friedman's test) from a basal value of 179 ± 18 mU/1 to a peak 
value of 288 ± 34 mU/1 at 10 min. 
INTRODUCTION 
In 1981 Vale et al. isolated and characterized a 41 amino-acid peptide from 
ovine hypothalami that fulfilled the criteria of a corticotrophin-releasing 
factor. In the last few years ample studies demonstrated that synthetic ovine 
CRF is a specific stimulator of ACTH release in laboratory animals (Rivier 
et al., 1982) and in man (Grossman et al., 1982; Orth et al., 1983; Hermus et 
al., 1984). In 1983 Rivier et al. showed that rat CRF, like ovine CRF a 
polypeptide of 41 amino-acids, differed from ovine CRF by seven amino-
Clin Endocrinol 1984; 21: 589-95 
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acid residues. These workers also showed that rat CRF and ovine CRF have 
a similar potency in stimulating ACTH secretion by cultured rat pituitary 
cells (Rivier et al., 1983). 
Very recently Shibahara et al. (1983) demonstrated the structure of human 
CRF by analysis of the human prepro-CRF gene. From the data of both 
studies one may derive that the amino-acid sequences of human CRF, as 
reported by Shibahara et al., and of rat CRF, as reported by Rivier et al., are 
identical. 
The present study compares the effects of intravenous bolus injections of 
human and ovine CRF in a group of healthy human subjects. Our data 
demonstrate that both peptides elicit a similar rise of ACTH and Cortisol. 
However, as derived from the ACTH and Cortisol profiles after admini-
stration of each peptide, this study provides strong evidence that human 
CRF has a significantly shorter duration of action than ovine CRF in 
humans. Secondly, human CRF administration stimulated not only ACTH 
release, but also, to a minor degree, prolactin release. 
SUBJECTS AND METHODS 
Ten healthy subjects (eight men and two women, aged 26 ± 10 years, mean ± 
SD) volunteered in this study after approval of the study protocol by the 
hospital ethical committee. All ten subjects received 200 ¿ug of human CRF 
(hCRF, Bachern, Torrance, CA) and 200 /ig of ovine CRF (oCRF, Bachern) 
intravenously as a bolus injection on two different occasions with an interval 
of at least three days. Both peptides were dissolved in 2 ml acid-saline (pH 2) 
immediately before administration. 
The CRF tests were performed at 09.00 h with the subjects fasting and in 
bed since 08.00 h. Blood samples for hormone assay were collected at -30,0, 
5,10,20,30,60,120,180, and 240 min via an indwelling i.v. forearm cannula 
kept open with minute amounts of a diluted (10%) solution of heparin. The 
cannula was inserted 1 h before CRF administration. Plasma ACTH, 
Cortisol and human growth hormone (hGH) and serum LH, FSH, TSH and 
PRL were determined by specific RIA's, as described previously (Hermus et 
al., 1984). ACTH and Cortisol levels were measured at all time intervals, both 
after hCRF and oCRF. Prolactin, TSH, LH, FSH and hGH levels were 
measured only after hCRF injection (-30, 0, 10, 30, 60 and 120 min). The 
areas under the individual Cortisol curves were calculated by planimetry 
using only the parts of the curves above the baseline values. Statistical 
analyses were performed using Wilcoxon's paired rank test (P values 
denoted by P), Friedman's nonparametric analysis of variance (P = P*) and 
Pearson's correlation test (P = P**). The mean values ± 1 SEM are given. 
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RESULTS 
Responses of ACTH and Cortisol to human CRF administration 
After a statistically significant fall between -30 and 0 min from 40 ± 3 to 35 ± 
3 pg/ml (P < 0.01), plasma ACTH levels rose without exception (P* < 
0.0005) after the injection of hCRF. At 5 min plasma ACTH levels were 
already significantly higher (50 ± 4 pg/ml, Ρ < 0.01) than the basal values. 
O-20 
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Figure I. Mean ± SEM plasma ACTH and Cortisol levels after i.v. bolus injections of a. 200//g 
ovine CRF and of b. 200 μg human CRF in 10 healthy subjects. Arrows mark injection. 
Statistical significance, *P < 0.05, **P < 0.01. 
38 
Figure 1 shows that the plasma ACTH level reached its maximum of 80 ± 7 
pg/ml at 30 min and thereafter rapidly declined to 36 ± 2 pg/ml at 180 min (Ρ 
< 0.01 vs 30 min) and 36 ±3 pg/ml at 240 min (Ρ < 0.01 vs 30 min). The 
ACTH concentrations at 180 and 240 min did not differ significantly from 
the basal ACTH concentrations. The individual peak levels were achieved at 
variable intervals (from 10 to 60 min) after the administration of hCRF. 
Plasma Cortisol levels decreased significantly between -30 min and 0 min 
from 0.40 ± 0.03 /imol/litre to 0.32 ± 0.03 //mol/litre (P < 0.01) before 
hCRF injection. Thereafter, Cortisol values rose without exception (P* < 
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Figure 2. Changes (Δ) in the concentrations of plasma ACTH and Cortisol after the i.v. 
administration of 200/ig ovine CRF ( · ) and 200/ig human CRF (o) to 10 healthy subjects. The 
mean values ± SEM are given. Significant differences between the changes after oCRF and 
hCRF, *P < 0.05. 
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0.0005) and at 10 min they were significantly higher (0.36 ± Ο.ΟΙμτηοί/Ι, Ρ < 
0.01) than the basal values. Figure 1 illustrates that plasma Cortisol reached 
its maximum at 60 min (0.56 ± 0.02 μτηοΙΑ) and thereafter very rapidly 
declined to 0.23 ± 0.02μνηοΙΔ at 240 min (Ρ < 0.01 vs 60 min, Ρ < 0.05 vs 0 
min). At that time, all subjects except two had Cortisol concentrations lower 
than their baseline values. Individual peak levels were achieved again at 
variable intervals between 20 and 60 min after hCRF injection. 
In seven of the 10 subjects the Cortisol peak was achieved at a later time than 
the ACTH peak and in three subjects at the same time. 
Responses of ACTH and Cortisol to ovine CRF administration 
After oCRF injection ACTH levels rose without exception (P* < 0.0005) 
from a basal level of 28 ± 3 pg/ml to a peak level of 79 ± 16 pg/ml at 30 min. 
Figure 1 shows that the plasma ACTH values at 180 and 240 min after oCRF 
administration, in contrast to those after hCRF, were still significantly 
higher than the baseline values. This ACTH response was followed by a rise 
in plasma Cortisol levels (P* < 0.0005) except in one subject, who had the 
highest basal Cortisol level of the group. Cortisol rose from a basal level of 
0.34 ± 0.03 /L/mol/l to a peak of 0.58 ± 0.03 //mol/l at 60 min. 
Figure 1 clearly shows that the plasma Cortisol concentrations at 180 and 
240 min after oCRF administration in contrast to those after hCRF were still 
significantly higher than the baseline values. 
Comparison between the ACTH and Cortisol responses after hCRF and oCRF 
Figure 2 shows that hCRF and oCRF elicited similar rises in the plasma 
ACTH and Cortisol levels. Maximum ACTH levels were reached at 30 min 
after both oCRF and hCRF. Thereafter both ACTH curves ran a 
significantly dissociated course. 
At 180 and 240 min the ACTH levels after hCRF were significantly lower 
than the corresponding levels after oCRF (both Ρ < 0.05). Maximum 
Cortisol levels were reached at 60 min, after both oCRF and hCRF. 
Thereafter, like the ACTH curves, both Cortisol curves ran a significantly 
dissociated course. At 180 and 240 min the Cortisol levels after hCRF were 
significantly lower than the corresponding levels after oCRF (both Ρ < 0.05). 
At 240 min the plasma Cortisol levels after oCRF injection were still higher (P 
< 0.05) than the basal values, whereas after hCRF administration these 
levels were significantly lower (P < 0.05) than the basal levels. 
There was a significantly negative correlation between the basal Cortisol 
concentrations and the areas under the individual Cortisol curves, both after 
hCRF (r = -0.80; P** < 0.01) and oCRF (r = -0.80; P** < 0.01). 
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Responses ofPRL, TS H, LH, FSH and hGH to human CRF administration 
After a statistically insignificant fall between -30 and 0 min from 213 + 28 
mU/1 to 179 ± 18 mU/1 prolactin levels rose without exception (P* < 0.005). 
The prolactin level reached its maximum of 288 ± 34 mU/1 at 10 min (Ρ < 
0.01 vs 0 min) and thereafter gradually declined to 113 + 8 mU/1 at 120 min 
(Ρ < 0.01 vs 10 min, Ρ < 0.02 vs 0 min). At that time, seven of nine subjects 
had prolactin levels lower than their baseline values. The individual peak 
levels for prolactin were achieved at variable intervals (from 10 to 60 min) 
after the administration of hCRF. The concentrations of hGH, TSH, LH 
and FSH remained unchanged after hCRF injection. 
Side effects 
After administration of both hCRF and oCRF flushing and mild dyspnoea 
(subjective sensation of shortness of breath, accompanied by the objective 
finding of deep and more rapid respirations, lasting 30 sec or less) occurred 
in most subjects. Mean diastolic blood pressure was significantly lowered 
after both oCRF and hCRF (Hermus et al., 1983b). Major complications did 
not occur in these healthy subjects (Hermus et al., 1983a). 
DISCUSSION 
Human CRF and ovine CRF, both peptides of 41 amino-acids, differ in 
seven amino-acid residues, six of seven replacements occurring in the 
carboxy-terminal half of the molecule. Rivier et al. (1983) have demon­
strated that rat CRF, which has an amino-acid sequence identical to human 
CRF, is equipotent to ovine CRF in stimulating ACTH release from rat 
pituitary cells in monolayer culture. However, so far no data have been 
published systematically comparing the effects of human and ovine CRF in 
humans in vivo. 
The present study demonstrates that human CRF, like ovine CRF, 
stimulates ACTH and thereby Cortisol release in healthy human subjects and 
that both releasing factors elicit similar increases of plasma ACTH and 
Cortisol after an intravenous bolus injection of 200 /yg. Furthermore, we 
show that the Cortisol response after human CRF administration is 
negatively correlated with the basal Cortisol concentration, as has already 
been noted for ovine CRF by Hermus et al. (1984) and Lytras et al. (1984). 
However, this study provides strong evidence that human CRF has a much 
shorter duration of action than ovine CRF in man. After ovine CRF 
administration plasma Cortisol levels remained significantly elevated until 
240 min. In contrast, after human CRF, the Cortisol levels had already 
returned to baseline values 180 min after injection of the peptide, whereas at 
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240 min the plasma Cortisol levels were even significantly lower than the 
basal concentrations. Comparing the ACTH profiles after injection of each 
peptide, a similar statistically significant divergence can be observed, i.e. at 
180 and 240 min the ACTH levels after hCRF were significantly lower than 
the corresponding levels after oCRF. 
It has clearly been demonstrated in laboratory animals and in man that 
ovine CRF, when injected as an intravenous bolus, has a remarkably long 
plasma half-life compared with those of TRH (Morley et al., 1979) and 
LHRH (Pimstone et al., 1977). There is no doubt that this long half-life is 
responsible for the prolonged biological effects of ovine CRF injected 
intravenously. In man Nicholson et al. (1983) and Tsukada et al. (1984) 
calculated that IR-ovine CRF disappeared biexponentially after a single 
intravenous bolus injection following a decay curve characterized by t1^ 
values of 6 min for the fast phase and of 50 min for the slow phase. Our data 
do not allow an estimation of the disappearance half-time of human CRF. 
However, the much shorter duration of hypophyseal-adrenal axis stimu-
lation after human CRF in comparison to after ovine CRF injection strongly 
suggests a shorter half-life for human CRF. Such shorter duration of action 
would also be more in line with those of other releasing hormones such as 
TRH and LHRH. 
Another interesting observation in this study is that human CRF 
stimulates prolactin secretion in humans although to a minor degree. This is 
in contrast to ovine CRF administration (Grossman et al., 1982; Hermus et 
al., 1984). In an earlier study from our laboratory (Hermus et al., 1984) 
prolactin levels significantly decreased after ovine CRF injection. In sheep 
(Donald et al., 1983) ovine CRF is unable to stimulate prolactin secretion. 
However, Schulte çt al. showed that ovine CRF caused dose-dependent 
prolactin and even growth hormone responses in cynomolgus (Schulte et al., 
1982) and rhesus monkeys (Schulte et al., 1983). In the rhesus monkey it was 
also demonstrated that pretreatment and simultaneous treatment with 
naloxone inhibited both growth hormone and prolactin responses without 
affecting the activation of the pituitary-adrenal axis by ovine CRF (Schulte 
et al., 1983). Obviously our data do not allow any conclusion about the 
mechanism of this slight prolactin release by human CRF. 
Human and ovine CRF differ in 17% of the amino-acid residues. This 
marked nonalignment between releasing factors of different mammalian 
species has not been seen for the smaller hypothalamic releasing factors. Our 
study indicates that these structural differences have an important effect on 
biological activity, as was predicted on theoretical grounds by Rivier et al. 
(1983). 
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2.3 HYPOTENSIVE EFFECTS OF OVINE AND HUMAN CORTICOTROPHIN-RE-
LEASING FACTOR IN MAN 
A.R.M.M. Hermus, G.F.F.M. Pieters, J.J. Willemsen*, H.A. Ross, A.G.H. 
Smals, Th.J.Benraad* and P.W.C.Kloppenborg 
Department of Medicine, Division of Endocrinology and Department of 
Experimental and Chemical Endocrinology*, University of Nijmegen, 
Nijmegen, The Netherlands. 
SUMMARY 
The hemodynamic effects of i.v. bolus injections of 100 and 200//g ovine or 
human CRF in man were compared. After 100/ig ovine CRF as well as after 
100 μ% human CRF no significant change occurred in blood pressure. 
However, in all individuals pulse rate increased. The mean maximum 
increase in pulse rate after hCRF was almost twice that after oCRF (21 ± 5 vs 
12 + 4 beats/min; P* < 0,05). After 200 //g oCRF diastolic blood pressure 
declined gradually in all subjects from 77 ± 3 mmHg to a nadir of 67 ± 3 
mmHg at 22 min (Ρ < 0,002). After 200 /yg hCRF diastolic blood pressure 
decreased more precipitously from 78 + 3 mmHg to a nadir of 61 + 3 mmHg 
at 6 min (Ρ < 0,002). The fall in diastolic blood pressure after hCRF was 
significantly greater than after oCRF (P* <0,05). After 200¿fg oCRF a slight 
increase in pulse rate was found, lasting for 6 minutes. However, after 200//g 
hCRF marked (reflex)tachycardia occurred lasting for 30 minutes. Only 
after the highest dose of hCRF a slight increase in systolic blood pressure 
occurred. Hemodynamic effects after both doses of human CRF were 
accompanied by significant increases in plasma norepinephrine levels, which 
were significantly more pronounced after the higher dose. 
INTRODUCTION 
Several studies have claimed that the administration of corticotrophin-
releasing factor can unravel the cause of hyper- and hypocortisolemic 
conditions in man (Chrousos et al 1984; Müller et al 1983; Tsukada et al 
1984; Hermus et al 1985). So far, in most studies ovine CRF, which became 
available first, has been used. Human CRF - like ovine CRF a polypeptide of 
41 amino-acids - differing from the latter by 7 amino-acid residues, would be 
preferable on theoretical grounds, especially because of its shorter duration 
Submitted for publication 
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of action (Hermus et al 1984), caused by its shorter plasma half-life 
(Schürmeyeretal 1984). 
Ovine CRF, like the non-mammalian CRF-like peptides sauvagine and 
urotensin I, causes hypotension and tachycardia when injected intrave-
nously in rats (Fisher et al 1983), dogs (MacCannell et al 1982; Brown et al 
1982; Brown and Fisher 1983), rhesus monkeys (Kalin et al 1982) and 
humans (Orth et al 1983; Hermus et al 1983), but not in sheep (Kalin et al 
1983a; Scoggins et al 1984). 
A systematic study comparing the hemodynamic effects of ovine and 
human CRF in man is not available. The present study demonstrates that 
both human and ovine CRF have a significant hypotensive effect in man, 
which is most pronounced for the human peptide. In addition we show that 
human CRF causes a dose-dependent rise of plasma norepinephrine and not 
of epinephrine levels, most probably reflecting activation of the sympathetic 
nervous system. 
SUBJECTS AND METHODS 
Thirty-one healthy subjects (20 men and 11 women) volunteered for this 
study after approval of the study protocol by the hospital ethical committee. 
Informed consent was obtained from all participants. Twenty-five subjects 
were studied once and six twice. The volunteers were divided in four groups. 
Group I (n = 10, age 42 + 12 years, mean ± SD) received 100//g ovine CRF, 
group II (n = 8, age 23 ± 4 year; ) 100//g human CRF, group III (n = 10, age 
27 ±9 years) 200 //g ovine CRF and group IV (n = 9, age 24 + 7 years) 200/ig 
human CRF. 
Ovine CRF (oCRF) and human CRF (hCRF) were obtained from 
Bachern Inc. (Torrance, CA). CRF was dissolved in a 2% aqueous solution 
of lactose and sterilized by passage through a 0,2 /яп cellulose acetate filter 
(Schleicher und Schuell, FPO 30/3) and was found to be pyrogen free 
('Pyrogent test', Mallinckrodt). CRF was stored at - 180C in lyophilized form 
in sterile vials under vacuum. Immediately before administration lyophilized 
material was dissolved in 1-2 ml acid-saline (pH 2). 
CRF was injected at 09.00 h with the subjects supine since 08.00 h after an 
overnight fast. Blood samples for hormone assays were collected at -30,0,5, 
10, 20, 30, 60, 120, 180 and 240 min via an indwelling i.v. forearm cannula 
kept open with a diluted solution of heparin. The cannula was inserted 1 h 
before the administration of CRF as an i.v. bolus injection of 30 seconds. 
Blood pressure and pulse rate were measured every two minutes from 10 
minutes before to 30 minutes after CRF administration and afterwards at 15 
minute intervals for 240 minutes after CRF injection (Roche 'Arteriosonde' 
1225, monitor 103). The mean values calculated from 5 consecutive 
measurements before CRF administration were considered as the basal 
47 
values. In 7 subjects of group II ( 100//g hCRF) and in 6 subjects of group IV 
(200 /ug hCRF) plasma norepinephrine and epinephrine levels were determ­
ined at -30, 0, 5,10, 20, 30, 60 and 120 min, using a specific radioenzymatic 
assay as described previously (Hoffmann et al 1982) with some modifi­
cations. Mean responses at each point of time after CRF administration were 
compared with the mean basal value by Student's t-test for paired 
observations (P values denoted by P). In order to reduce the overall 
probability of a type I error to Ρ < 0,03 a level of significance of Ρ < 0,002 
was employed (Bonferroni's correction). In addition, statistical analyses 
were performed using Wilcoxon's two sample test (P = P*), and Friedman's 
nonparametric analysis of variance (P = P**) and by testing the means of 
Spearman's rank correlation coefficients (P = P***). Mean values ± 1 SEM 
are given. 
RESULTS 
Basal blood pressure and pulse rate did not differ between the four groups. 
Figures 1 and 2 illustrate the changes in mean blood pressure and pulse rate 
during the first 30 minutes following CRF injection. After that time the mean 
blood pressure and pulse rate did not differ from the baseline. 
Figure 1 shows that no significant changes in systolic or diastolic blood 
pressure occurred after either 100//g ovine or human CRF. In all individuals 
pulse rate increased after administration of both CRF's, and the mean peak 
increases in pulse rate were twice as high after hCRF as after oCRF ( 2 1 + 5 
vs. 12 ± 4 beats/min; P* < 0,05). Individual peak levels were achieved at a 
median time of 6 min (range 2-28 min) after 100 /ug oCR F and at 3 min (range 
2-18 min) after 100//g hCRF. In two subjects, one in the oCRF and one in the 
hCRF group pulse rate increased dramatically by 50 and 59 beats/min 
respectively. 
After 200 /ug oCRF (Figure 2), diastolic blood pressure dropped in all 
subjects from 77 ± 3 mmHg to a nadir of 67 ± 3 mmHg at 22 min (Ρ < 0,002). 
Individual nadirs were achieved at a median time of 14 min (range 2-24 min) 
and individual decreases in blood pressure varied widely between 3 and 25 
mmHg (mean 14 + 2 mmHg). After 200/ughCRF diastolic blood pressure 
declined more sharply from 78 ± 3 mmHg to a nadir of 61 + 3 mmHg at 6 
min (Ρ < 0,002). Individual nadirs were achieved at a median time of 4 min 
(range 2-26 min) and individual decreases in blood pressure varied between 
12 and 34 mmHg (mean 23 + 2 mmHg). The mean decrease of diastolic 
blood pressure in the first 10 min after 200/yg hCRF was significantly larger 
than after 200 ¿ig oCRF (P* < 0,05). Figure 2 also illustrates that systolic 
blood pressure rose after 200/i/g hCRF, but not after 200¿/g oCRF. Pulse rate 
increased in all subjects after 200 μg oCRF. Individual peak levels were 
achieved at a median time of 7 min (range 2-28 min) and the individual peak 
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Figure I. Response of blood pressure and pulse rate (mean + SEM) after a bolus injection of 100 
//g oCRF (left panel; η = 10) and 100 //g hCRF (right panel; η = 8). Asterisks, statistical 
significance (P < 0,002) vs. basal value. 
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Figure 2. Response of blood pressure and pulse rate (mean ± SEM) after a bolus injection of 200 
/ig oCRF (left panel; η = 10) and 200 /ig hCRF (right panel; η = 9). Asterisks, statistical 
significance (P < 0,002) vs. basal value. 
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increases varied widely between 2 and 27 beats/min (mean 16 ± 3 
beats/min). After 200 //g hCRF marked tachycardia occurred in all 
individuals. Individual peak levels were achieved at a median time of 10 min 
(range 4-24 min) and the individual peak increases varied between 15 and 52 
beats/min (mean 35 ± 4 beats/min). The mean increase of pulse rate in the 
first 10 min after 200/ug hCRF was significantly higher than after 200 μg 
oCRF (P* < 0,01). The individual changes in diastolic blood pressure and in 
pulse rate in the first 4 minutes after CRF were significantly and inversely 
correlated, both after 200 μg oCRF (r = -0,49; P*** < 0,05) and 200 /ug 
hCRF (r = -0,69; P*** < 0,01). 
Figure 3 gives the results of the plasma catecholamine levels after 100 and 
200 μg hCRF administration. After 100 μg hCRF plasma norepinephrine 
rose significantly (P** < 0,025) from a basal level (= the mean of the -30 and 
0 value in each subject) of 1,05 ± 0,14 nM/1 to a peak level of 1,24 ± 0,17 
nM/1 at 10 min, whereas after 200 μg hCRF plasma norepinephrine 
increased significantly (P** < 0,025) from a basal level of 1,19 ± 0,20 nM/1 
to a peak level of 2,11 ± 0,49 nM/1 at 10 min. Maximum norepinephrine rises 
following 200/ug hCRF were significantly (P* < 0,05) higher than after 100 
μg hCRF. Plasma epinephrine levels did not change after either dose of 
hCRF. 
DISCUSSION 
The present study demonstrates that in healthy subjects bolus injections of 
200//g of both ovine and human CRF cause a significant decrease in diastolic 
blood pressure, which was not observed after the 100 μg doses. This study 
also shows, for the first time, that human CRF causes greater hypotension 
than ovine CRF in man. 
After the administration of \00μg ovine or human CRF in all individuals 
pulse rate increased without significant changes in blood pressure. Maxi­
mum increase in pulse rate after hCRF was almost twice that of oCRF. After 
the administration of the higher dose of ovine CRF diastolic blood pressure 
declined gradually in all individuals, whereas after the same dose of human 
CRF diastolic blood pressure dropped more abruptly and to a significantly 
lower level. Again, hCRF accelerated the pulse rate significantly more than 
the ovine peptide. The significant and inverse correlation between the 
decline in diastolic blood pressure and the increase in pulse rate during the 
first four minutes after the injection of 200 μg CRF, strongly suggests 
activation of the sympathetic nervous system. 
In laboratory animals ovine CRF causes hypotension and tachycardia 
when injected intravenously in rodents (Fisher et al 1983), dogs (MacCannell 
et al 1982; Brown et al 1982; Brown and Fisher 1983) and rhesus monkeys 
(Kalin et al 1982), but remarkably, not in sheep (Kalin et al 1983a, Scoggins 
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et al 1984). In contrast, intracerebroventricular administration of ovine CRF 
causes increases in blood pressure and heart rate in rodents (Fisher et al 
1982; Fisher et al 1983),.dogs (Brown and Fisher 1983), rhesus monkeys 
(Kalin et al 1983b) and also in sheep (Scoggins et al 1984). 
Data published about hemodynamic effects of CRF in man is scarce. Orth 
et al (1983) measured pulse rate and blood pressure at frequent intervals after 
ovine CRF injection and found an increase in pulse rate after 3//g/kg oCRF 
comparable with our data, whereas marked tachycardia (pulse rate increas­
ed with 35 beats/min) lasting for more than 30 min occurred after 30 /ig/kg 
oCRF. In the limited number of subjects they tested, a significant decline in 
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Figure 3. Plasma epinephrine and norepinephrine levels (mean ± SEM) after a bolus injection of 
100 /yg hCRF (left panel) and 200 ¿ig hCRF (right panel). 
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diastolic blood pressure could only be demonstrated after 30μg/kg oCRF. 
However, individual subjects showed decreases in mean blood pressure of 
15-29 mmHg after 10 or 30 /ig/kg oCRF, despite recumbency and 
replacement of lost volume. In contrast to the present study Schürmeyer et al 
(1984), using CRF from the same source as ours, found no significant effect 
on blood pressure, after even 5 //g/kg human CRF, although pulse rate 
increased by 26%. However, these authors measured blood pressure and 
pulse rate only at 15-30 min intervals with baseline values based on only two 
measurements. 
The present study also demonstrates significant rises in plasma norepine-
phrine levels immediately after human CRF administration, which were 
highest after the higher dose, whereas plasma epinephrine did not change. 
The hemodynamic profile of CRF in man together with the rise of 
norepinephrine levels fits well into the concept that the hypotensive action of 
CRF in mammals is caused by vasodilatation of resistance vessels (Mac-
Cannell et al 1982). 
REFERENCES 
Brown, M , Fisher, L (1983) Central nervous system effects of corticotropin releasing factor in 
the dog Brain Research, 280, 75-79 
Brown, M , Fisher, L , Spiess, J , Rivier, J , Rivier, С , Vale, W (1982)Comparison of the 
biologic actions of corticotropin-releasing factor and sauvagine Regulatory Peptides, 4, 
107-114 
Chrousos, G , Schulte, H , Oldfield, E , Gold, Ρ , Cutler, G , Loriaux, D (1984) The 
corticotropin-releasing factor stimulation test an aid in the evaluation of patients with 
Cushing's syndrome New England Journal of Medicine, 310, 622-626 
Fisher, L , Jessen, G , Brown, M (1983) Corticotropin-releasing factor (CRF) mechanism to 
elevate mean arterial pressure and heart rate Regulatory Peptides, 5, 153-161 
Fisher.L ,Rivier,J ,Rivier,C ,Spiess,J ,Vale,W ,Brown,M (1982)Corticotropin-releasing 
factor (CRF). central effects on mean arterial pressure and heart rate in rats Endocrinology, 
110,2222-2224 
Hermus.A ,Pieters,G ,Pesman,G .Buijs, W , Smals, A ,Benraad,T , Kloppenborg, Ρ (1984) 
Differential effects of ovine and human corticotrophin-releasing factor in human subjects 
Clinical Endocrinology, 21, 589-595 
Hermus, A , Pieters, G., Pesman, G , Smals, A , Benraad, Τ , Kloppenborg, Ρ (1985) ACTH 
and Cortisol responses to ovine corticotrophin-releasing factor in patients with primary and 
secondary adrenal failure Clinical Endocrinology, 22, 761-769 
Hermus, A , Raemaekers, J , Pieters, G , Bartelink, A , Smals, A , Kloppenborg, Ρ (1983) 
Safety of corticotropin-releasing factor Lancet 2, 112 
Hoffmann, J , Willemsen, J , Thien, Τ , Benraad, Τ (1982) Radioenzymatic assay of plasma 
adrenaline and noradrenaline evidence for a catechol-O-methyl-transferase (COMT) 
inhibiting factor associated with essential hypertension Clinica Chimica Acta, 125,319-327 
Kalm, N , Gonder, J , Shelton, S (1983a) Effects of synthetic ovine CRF on ACTH, Cortisol, 
and blood pressure in sheep Peptides, 4, 221-223 
Kalin.N ,Shelton,S ,Kraemer,G ,McKinney,W (1982)Corticotropin-releasingfactorcauses 
hypotension in rhesus monkeys Lancet 2, 1042 
52 
Kalm, Ν , Shelton, S Kracmer, G., McKinney, W. (1983b) Corticotropin-releasing factor 
administered intraventncularly to rhesus monkeys. Peptides, 4, 217-220. 
MacCannell, K., Lederis, К , Hamilton, Ρ , Rivier, J. (1982) Amunine (ovine CRF), urotensin I 
and sauvagine, three structurally-related peptides, produce selective dilation of the 
mesenteric circulation Pharmacology, 25, 116-120 
Muller, О., Stalla, G , von Werder, К. ( 1983a) Corticotropin-releasing factor: a new tool for the 
differential diagnosis of Cushing's syndrome. Journal of Clinical Endocrinology and 
Metabolism, 57, 227-229 
Orth, D., Jackson, R., De Cherney, G., De Bold, С , Alexander, Α., Island, D., Rivier, J., 
Rivier, C , Spiess, J., Vale, W. (1983) Effect of synthetic ovine corticotropin-releasing factor 
Dose response of plasma adrenocorticotropin and Cortisol Journal of Clinical Investi­
gation, 71, 587-595. 
Schurmeyer, T., Avgennos, P., Gold, P., Galluci, W., Tomai, Τ, Cutler, G., Loriaux, D , 
Chrousos, G (1984) Human corticotropin-releasing factor in man: pharmacokinetic 
properties and dose-response of plasma adrenocorticotropin and Cortisol secretion. Journal 
of Clinical Endocrinology and Metabolism, 59, 1103-1108 
Scoggins, В , Coghlan, J., Denton, D., Fei, D., Nelson, M , Tregear, G , Tresham, J., Wang, 
X-M.(I984). Intracerebroventncular infusion of corticotrophm-releasing factor (CRF) and 
ACTH raise blood pressure in sheep. Clinical and Experimental Pharmacology and 
Physiology, 11,365-368 
Tsukada, Τ , Nakai, Y , Koh, T., Tsujn, S , [nada, M., Nishikawa, M., Shmoda, H., Kawai, J., 
Takczawa, N., Imura, H. (1984) Plasma adrenocorticotropin and Cortisol responses to ovine 
corticotropin-releasing factor in patients with adrenocortical insufficiency due to hypo­
thalamic and pituitary disorders. Journal of Clinical Endocrinology and Metabolism, 58, 
758-760. 
53 
2 4 ESCAPE FROM DEXAMETHASONE INDUCED ACTH AND CORTISOL SUP­
PRESSION BY CORTICOTROPIN-RELEASING HORMONE (CRH) MODULATORY 
EFFECT OF BASAL DEXAMETHASONE LEVELS' 
A.R.M.M. Hermus,G.F.F.M. Pieters,G.J. Pesman*, J.A. Hofman, A.G.H. 
Smals, Th.J. Benraad* and P.W.C. Kloppenborg 
Department of Medicine, Division of Endocrinology and Department of 
Experimental and Chemical Endocrinology*, University of Nijmegen, 
Nijmegen, The Netherlands. 
SUMMARY 
The response of ACTH and Cortisol to CRH after pretreatment with various 
doses of dexamethasone was investigated in five healthy subjects. The five 
subjects participated in six experiments. In each experiment 200 //g ovine 
CRH was administered as an i.v. bolus injection at 09.00 h after pretreatment 
with respectively: A) 1 mg dexamethasone orally at 23.00 h on the evening 
before CRH injection, B) idem, 2 mg dexamethasone, C) idem, 4 mg 
dexamethasone, D) idem, 2 mg dexamethasone, followed by 2 mg dexa­
methasone orally 1 hour before CRH , E) no dexamethasone and F) 1 mg 
dexamethasone orally 1 hour before CRH injection. In spite of overnight 
suppression with dexamethasone CRH elicited Cortisol rises in all indivi­
duals (experiments A to C). Dexamethasone pretreatment in experiment D 
abolished the CRH induced stimulation of the pituitary-adrenal axis. There 
was a significant and negative correlation between the basal dexamethasone 
levels (i.e. the dexamethasone levels immediately before CRH administra­
tion) in the experiments A to D and the areas under the individual ACTH (r 
= -0.62; Ρ < 0.01 by Spearman's rank correlation test) and Cortisol (r = -0.81 ; 
Ρ < 0.001 by Spearman's test) curves, i.e. the lower the basal dexamethasone 
levels, the greater the rise in ACTH and Cortisol levels after CRH 
administration. Prctreatment with a single dose of 1 mg dexamethasone 1 
hour before CRH injection (experiment F) led to a significant inhibition of 
the CRH induced ACTH and Cortisol response, despite unsupprcssed pre-
CRH ACTH and Cortisol levels. 
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We conclude that CRH is able to overrule the inhibition of the pituitary-
adrenal axis by overnight suppression with pharmacological doses of 
dexamethasone. The strongly negative correlation between the basal 
dexamethasone levels and the CRH induced pituitary-adrenal responses 
argues for the primacy of circulating glucocorticoid levels in the modulation 
of the response of ACTH and Cortisol to CRH. 
INTRODUCTION 
In previous studies (1,2) we have shown that the response of the pituitary-
adrenal axis to exogenous CRH in healthy man highly depends on the 
individual basal Cortisol level, i.e. the higher the basal plasma Cortisol level, 
the lower the response of ACTH and Cortisol after CRH administration. At 
present it is not known by which mechanism the basal Cortisol level 
modulates the response to CRH. It is attractive to assume that the basal 
Cortisol levels themselves determine the ACTH response to CRH by their 
negative feedback to the corticotrophs. However, the possibility remains 
that the observed correlation between the individual basal Cortisol levels and 
the ACTH and Cortisol responses to exogenous CRH is in fact a spurious 
one, primarily dictated by an underlying correlation between the individual 
endogenous CRH levels and the response of the pituitary to exogenous 
CRH. 
In the present study we demonstrate a highly significant and negative 
correlation between the plasma ACTH and Cortisol responses to CRH in 
healthy subjects after overnight suppression with pharmacological doses of 
dexamethasone, and the plasma level of the synthetic glucocorticoid 
immediately before injection of CRH. It is known from studies in rodents 
(3-7) that pharmacological doses of dexamethasone suppress endogenous 
CRH activity. Therefore, the demonstration of a negative correlation 
between the level of this synthetic glucocorticoid and the response of the 
pituitary-adrenal axis to CRH provides an argument that the level of 
circulating glucocorticoids per se determines the response to CRH in man. 
SUBJECTS AND METHODS 
Five healthy subjects (four men and one woman, aged 23 ± 2 yr, mean ± SD) 
participated in this study. Informed consent was obtained from all 
volunteers after approval of the study protocol by the hospital ethical 
committee. The five subjects participated in six experiments. In each 
experiment 200 //g ovine CRH (Bachern, Torrance, CA) was administered as 
an intravenous bolus injection at 09.00 h after pretreatment with, respec-
tively: 
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A) 1 mg dexamethasone (Oradexon, Organon, Oss) orally at 23.00 h on the 
evening before CRH injection. 
B) idem, 2 mg dexamethasone 
C) idem, 4 mg dexamethasone 
D) idem, 2 mg dexamethasone, followed by 2 mg dexamethasone orally 1 
hour before CRH injection 
E) no dexamethasone 
F) 1 mg dexamethasone orally 1 hour before CRH injection 
Moreover, in a seventh experiment three of the five subjects received 2 ml 
saline, instead of CRH, after pretreatment with 1 mg dexamethasone at 
23.00 h on the evening before the experiment. All experiments were 
separated from each other by at least 4 days. Ovine CRH was dissolved in 2 
ml acid-saline (pH 2) immediately before administration. All tests were 
performed after an overnight fast with the subjects supine since 08.00 h. 
Blood samples for plasma ACTH and Cortisol assay were collected at -30,0, 
5, 10, 20, 30, 60, 120, 180, and 240 min through an indwelling i.v. cannula 
kept open with small amounts of a diluted (10%) solution of heparin. The 
cannula was inserted 1 hour before CRH (or saline) administration. 
Plasma ACTH and Cortisol were measured by specific RIA's as described 
previously (8). Plasma dexamethasone levels were measured by radio­
immunoassay after extraction with dichloromethane and paperchromato-
graphic purification in a Bush С type solvent system (methanol: toluol: 
ethylacetate: water = 250:450:50:250; Rf DXM = 0,35). The antiserum 
(kindly donated by Prof.P.Vecsei, University of Heidelberg, FRG) was 
raised in rabbits against dexamethasone-3 carboxy-methyloxime coupled to 
bovine serum albumine. 3H-dexamethasone was used as the tracer (NEN, 
NET 467). At the extremely low plasma levels of Cortisol during suppression 
with dexamethasone no interference of Cortisol with the antibody to 
dexamethasone (cross-reactivity 0,05%) can be expected. The mean intra-
assay coefficient of variation of a plasma pool was 6,5% (mean level 252 
ng/100 ml, η = 10). The interassay coefficient of variation was 8,3% (mean 
level 258 ng/100 ml, η = 8). To avoid this interassay variation all-samples 
were measured in the same assay. 
The areas under the individual ACTH and Cortisol curves were calculated 
by planimetry using only the parts of the curves above the baseline values. 
(ACTH: 1 pg/ml = 1 mm; Cortisol: 0.01 //mol/1 = 0.362 ¿/g/100 ml = 1 mm; 1 
min = 1 mm). 
Statistical analysis was performed using Student's t-test for paired obser-
vations (P values denoted by P), Friedman's nonparametric analysis of 
variance (P = P*) and Spearman's rank correlation test (P = P**). Unless 
otherwise stated, the mean values ± 1 SEM are given. 
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Figure I. Mean + SEM plasma ACTH and Cortisol responses to an i. v. bolus injection of 200/Jg 
ovine CRH at 09.00 h in 5 normal subjects after pretreatment with, respectively: 
A) 1 mg dexamethasone orally at 23.00 h on the evening before CRH injection 
B) idem, 2 mg dexamethasone 
C) idem, 4 mg dexamethasone 
D) idem, 2 mg dexamethasone, followed by 2 mg dexamethasone orally 1 hour before CRH 
injection 
E) no dexamethasone 
F) 1 mg dexamethasone orally 1 hour before CRH injection. 
The asterisks indicate statistical significance (* Ρ < 0.05; ** Ρ < 0.01). 
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RESULTS 
1. Suppression of the ACTH and Cortisol responses to CRH after pretreat­
ment with dexamethasone 
1.1 Responses of A CTH and Cortisol to CRH after overnight suppression with 
dexamethasone (experiments A to D) 
Figure 1 (left panel) illustrates the mean ACTH and Cortisol responses to a 
bolus injection of 200 μ% ovine CRH after overnight suppression with 
increasing doses of dexamethasone. In all experiments overnight suppres­
sion with dexamethasone resulted in ACTH values below the detection limit 
of the assay ( 15 pg/ml), whereas all basal Cortisol values were 1,4 //g/100 ml 
or less. The figure clearly shows that in spite of overnight suppression with 1 
mg dexamethasone, CRH induced a marked Cortisol rise (P* < 0.001) in all 
individuals with a mean peak value of 9,4 ± 1,8μ%/100 ml at 180 min. After 
overnight suppression with 2 mg or even 4 mg dexamethasone, CRH was still 
able to raise Cortisol levels in all individuals (experiment B, P* < 0.01; 
experiment C, P* < 0.025). 
It also appears that overnight suppression with dexamethasone changes 
the time-course of the Cortisol response, i.e. the CRH induced increase of the 
Cortisol level after dexamethasone pretreatment is slower in comparison 
with the rather brisk rise of plasma Cortisol without dexamethasone 
pretreatment (experiment E, vide infra). Without dexamethasone pretreat­
ment a significant increase of plasma Cortisol was reached at 10 min, whereas 
after overnight treatment with dexamethasone, the increases of plasma 
Cortisol reached statistical significance only after 120 min (experiment A) 
and 180 min (experiments В and C). 
The ACTH values, measured in the experiments A to С are lower than or 
near to the detection limit of the assay. In the experiments A and С a 
significant ACTH rise preceded the rise in plasma Cortisol. The figure also 
shows that 2 mg dexamethasone given orally one hour before CRH injection 
in addition to 2 mg dexamethasone at 23.00 h on the previous evening 
(experiment D) abolished the CRH induced stimulation of the pituitary-
adrenal axis. Saline injection instead of CRH after overnight suppression 
with 1 mg dexamethasone did not produce an increase in the suppressed 
ACTH (< 15 pg/ml) and Cortisol (< 0,7 yug/luO ml) levels in the three 
individuals tested until 240 min after the injection (data not shown). This 
proves that the ACTH and Cortisol responses observed in the experiments A 
to С were not due to cessation of the suppressive effect of dexamethasone 
and excluded aspecific stress as the cause of pituitary-adrenal activation in 
these experiments. 
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1.2 Responses of ACTH and Cortisol to CRH after pretreatment with 
dexamethasone in the presence of unsuppressed ACTH and Cortisol levels 
(experiment E and F) 
Figure 1 (right panel) illustrates the ACTH and Cortisol responses to a bolus 
injection of 200 //g ovine CRH with and without pretreatment with 1 mg 
dexamethasone given orally one hour before CRH injection. Basal ACTH 
and Cortisol levels did not differ significantly in either experiment. 
After dexamethasone pretreatment (experiment F) the initial rise of plasma 
ACTH and Cortisol was not statistically significant. The maximal ACTH ( 13 
±5vs44±5pg/ml;P<0.05)andcort i sol(2.5±l . lvs9.8+l . l//g/100ml; 
Ρ < 0.005) increments after CRH were significantly lower after 1 mg 
dexamethasone one hour before CRH. The integrated ACTH response to 
CRH was almost three times lower after dexamethasone pretreatment (1483 
± 794 mm2 vs 4180 ± 697 mm2; Ρ > 0.10), the integrated Cortisol response to 
CRH was more than ten times lower after dexamethasone (300 ± 181 mm2 vs 
3222 ± 6 1 2 mm2; Ρ < 0.02). 
2. Relationship between basal dexamethasone levels and CRH induced 
changes in ACTH and Cortisol after overnight suppression with increas­
ing doses of dexamethasone 
Individual basal plasma dexamethasone levels (i.e. the dexamethasone levels 
immediately before CRH administration at 09.00 h after overnight suppres­
sion with dexamethasone) were the higher, the higher the dose of dexa­
methasone (Table 1). 
Figures 2 and 3 illustrate that there was a significant and negative correlation 
between the basal dexamethasone levels in the experiments A to D and the 
areas under the individual ACTH (r = -0.62; P** < 0.01) and Cortisol (r = 
-0.81; P** < 0.001) curves, i.e. the lower the basal dexamethasone level, the 
greater the rise in ACTH and Cortisol levels after CRH administration. 
DISCUSSION 
In previous studies (1,2) we have shown that in healthy subjects the basal 
plasma Cortisol level determines the response of the pituitary-adrenal axis to 
CRH. So far it has not been proven that the inverse correlation between the 
basal plasma Cortisol level and the response of ACTH and Cortisol to CRH in 
man is indeed the result of a direct feedback effect of Cortisol at the level of 
the corticotrophs. One might wonder whether this correlation is only 
spurious, dictated by an, as yet undetected underlying correlation between 
the individual endogenous CRH levels and the responses of ACTH and 
Cortisol to exogenous CRH. 
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Table APre-CRH dexamethasone levels (ng/dl) in five healthy subjects after overnight 
suppression with different doses of dexamethasone (DXM) 
Subject 
no 
Experiment A 
(ImgDXM) 
Experiment В 
(2mg DXM) 
Experiment С 
(4mg DXM) 
Experiment D 
(2+2mg DXM) 
1 
2 
3 
4 
5 
100 
210 
230 
302 
118 
207 
227 
360 
331 
506 
212 
755 
746 
419 
-
946 
1270 
1869 
1271 
947 
Mean±SEM 192 ± 33 326 ± 48 533 ± 115 1261 ± 150a 
a
 Ρ < 0.005 vs experiment A and C; Ρ < 0.01 vs expenment B. 
( mm2). 
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Figure 2. Intravenous bolus injection of 200 /jg ovine CRH after overnight suppression with 
various doses of dexamethasone (experiments A to D, see text) in 5 normal subjects; relation 
between basal dexamethasone levels and the areas below the individual ACTH curves. 
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The present study demonstrates a highly significant and negative corre­
lation between the responses of ACTH and Cortisol to CRH and the levels of 
the synthetic glucocorticoid dexamethasone, measured immediately before 
the injection of CRH after overnight suppression with this steroid Studies in 
rodents have demonstrated that pharmacological doses of dexamethasone 
suppress endogenous CRH activity (3-7) Under the proviso that in man 
overnight treatment with pharmacological doses of dexamethasone will also 
suppress endogenous CRH activity, our study demonstrates that the level of 
circulating glucocorticoids per se determines the response to CRH in man. 
The observation that a single dose of 1 mg dexamethasone one hour before 
CRH injection leads to a significant inhibition of the CRH induced ACTH 
and Cortisol response - despite unsuppressed basal ACTH and Cortisol levels 
- also agrees with this conclusion 
We found that ovine CRH in all individuals caused an escape from the 
inhibitory effects of overnight suppression with single doses of dexa­
methasone of up to 4 mg 
AUC Cort isol a f t e r oCRH 
(mm 2 ) 
7 0 0 0 - · 
6000-
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3 0 0 0 -
2000-
1000-
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Figure 3 Intravenous bolus injection of 200 //g ovine CRH after overnight suppression with 
various doses of dexamethasone (experiments A to D, see text) in 5 normal subjects, relation 
between basal dexamethasone levels and the areas below the individual Cortisol curves 
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This data is seemingly in contrast with that of Lytras et al (9) and Copinschi 
et al (10), who showed that the Cortisol response to 100 and 50/yg ovine CRH 
respectively, is completely prevented by overnight treatment with 1/2 and 1 
mg dexamethasone respectively, followed by 1/2 and 1 mg respectively, on 
the morning of the CRH injection. However, unpublished data from our 
laboratory shows that their regimes of dexamethasone treatment cause 
higher dexamethasone levels than overnight suppression with a single dose 
of 4 mg dexamethasone. These higher dexamethasone levels may account for 
the prevention of activation of the pituitary-adrenal axis by CRH, compar-
able to our results after pretreatment with 2 doses of 2 mg dexamethasone. 
Our data is also seemingly in contrast with a recent study of Von Bardeleben 
et al (11). In this study CRH alone was not able to produce a marked 
elevation of plasma ACTH and Cortisol in healthy subjects after overnight 
suppression with 1,5 mg dexamethasone. It has to be stressed, however, that 
peak responses in all individuals in our study occurred in the third or fourth 
hour after CRH injection after overnight suppression with dexamethasone. 
Von Bardeleben and co-workers used human CRH, which has a significantly 
shorter duration of action than the ovine peptide used in our study, and 
measured ACTH and Cortisol levels only during the first two hours after 
CRH. Moreover, in our study a twice higher dose of CRH was given. The 
results of our study are in line with those of De Bold et al. (12), who found a 
significant negative correlation between plasma dexamethasone levels and 
peak ACTH and Cortisol levels after CRH administration after pretreatment 
with replacement doses (0,5 mg) of dexamethasone, given at various time-
intervals before CRH injection. 
It has been suggested that the absence of plasma Cortisol suppression the 
day after an evening dose of 1 or 2 mg dexamethasone in patients with 
endogenous depression is caused by exaggerated CRH drive in this disorder. 
Our observation that ovine CRH caused an escape from the inhibitory effect 
of overnight suppression with dexamethasone demonstrates that excessive 
CRH drive is able to override the inhibitory effects of relatively high doses of 
dexamethasone and that this mechanism indeed can be the cause of the 
abnormal dexamethasone suppression test results in depressed patients. 
We conclude that CRH overrules the inhibition of the pituitary-adrenal 
axis by physiological and pharmacological doses of dexamethasone. The 
strongly negative correlation between the basal dexamethasone levels and 
the CRH induced pituitary-adrenal response argues for the primacy of 
circulating glucocorticoid levels in the modulation of the response of ACTH 
and Cortisol to CRH. 
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2.5 ENHANCEMENT OF THE ACTH RESPONSE TO HUMAN CRH BY PRETREAT­
MENT WITH THE ANTIGLUCOCORTICOID RU-486 
A.R.M.M. Hermus, G.F.F.M. Pieters, G.J. Pesman*, A.G.H. Smals, Th.J. 
Benraad* and P.W.C. Kloppenborg 
Department of Medicine, Division of Endocrinology and Department of 
Experimental and Chemical Endocrinology*, University of Nijmegen, 
Nijmegen, The Netherlands. 
SUMMARY 
The response of ACTH to an i.v. bolus injection of 100//g human CRH at 
09.00 h was investigated in five healthy men, with and without pretreatment 
with 100 mg of the antiglucocorticoid RU-486, administered orally seven 
hours before CRH injection. In all five subjects the plasma Cortisol level 
immediately before CRH administration at 09.00 h was higher after 
pretreatment with the antiglucocorticoid (17,1 ±2,1 vs 11,1 ± l,l/ig/100ml; 
Ρ < 0.05). Despite this higher baseline Cortisol level, in all subjects the 
maximal CRH induced ACTH increase was more pronounced after RU-486 
loading (Δ max ACTH 39 ± 14 vs 26 ± 13 pg/ml; Ρ < 0.05). This observation 
proves that ,in man, physiological concentrations of Cortisol determine the 
response of the pituitary to CRH. Furthermore, these findings suggest 
deficient circulating glucocorticoid activity after the administration of 100 
mg RU-486, not completely compensated for by the increase of plasma 
Cortisol levels after RU-486. 
INTRODUCTION 
In previous studies (1,2) we have shown that the response of the pituitary-
adrenal axis to CRH in healthy man is modulated by the individual basal 
Cortisol level, i.e. CRH administration results in the lesser stimulation of the 
pituitary-adrenal axis when basal Cortisol levels are the higher. This 
observation is compatible with, but does not prove, the concept that the level 
of circulating Cortisol itself determines the response of the pituitary to CRH 
in man (1). 
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The recently developed steroid RU-486 (17/5-hydroxy-l l/3-[4-di-methyl-
aminophenyl]17a-[l-propynyl] estra-4,9-dien-3-one) is the first glucocorti­
coid antagonist active in vivo in rodents (3), nonhuman primates (4,5) and 
man (6). 
If it is indeed true that physiological concentrations of Cortisol inhibit the 
response of the pituitary to CRH, blockade of this negative feedback action 
on the corticotrophs by using sufficient amounts of a competitive antagonist 
should increase the response of ACTH to CRH. Therefore we investigated 
whether after pretreatment with the antiglucocorticoid RU-486 the CRH 
induced ACTH increase in man is enhanced. 
SUBJECTS AND METHODS 
Five healthy men (aged 22 + 3 years, mean ± SD) volunteered in this study 
after approval of the protocol by the hospital ethical committee. The five 
subjects participated in two experiments. In both experiments lOO^g human 
CRH (Bachern, Torrance, CA) was administered as an i.v. bolus injection at 
09.00 h (t = 0 min), either without (experiment A) or with (experiment B) 
oral pretreatment with 100 mg RU-486 (Institut Roussel Uclaf, Paris, 
France) seven hours before the injection of CRH. Both experiments were 
performed on separate occasions with an interval of at least three days. 
Three subjects took experiment A first, and the remaining two subjects 
experiment B. 
CRH was given after an overnight fast with the subjects supine since 08.00 
h. The peptide was dissolved in 1 ml acid-saline (pH 2) immediately before 
administration. Blood samples for plasma ACTH and Cortisol assay were 
collected at -30, 0, 5, 10, 20, 30, 60, 120, 180 and 240 min through an 
indwelling i.v. catheter kept open with small amounts of a diluted (10%) 
solution of heparin. The catheter was inserted one hour before CRH 
administration. Plasma ACTH and Cortisol were measured by specific Rl A's 
as described previously (7). 
Statistical analysis was performed using Student's t-test for paired 
observations. The mean values ± 1 SEM are given. 
RESULTS (Figure 1, Table 1) 
Figure 1 shows that RU-486 pretreatment significantly increased the mean 
plasma ACTH and Cortisol levels both before and after CRH admini­
stration. Table 1 illustrates that in all five subjects the basal (t = 0 min) 
Cortisol level was higher after pretreatment with the antiglucocorticoid (17,1 
± 2,1 vs 11,1 ± 1,1 //g/100 ml; Ρ < 0.05). Despite this higher baseline Cortisol 
level, in all subjects the maximal CRH induced ACTH increase was more 
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pronounced after RIM86 loading (Δ max ACTH 39 ± 14 vs 26 ± 13 pg/ml; Ρ 
< 0.05 ; table 1). 
DISCUSSION 
Pharmacological doses of glucocorticoids inhibit the pituitary-adrenal axis 
in man. In addition, it has been demonstrated that physiological concen­
trations of circulating corticosteroids suppress the basal and/or stimulated 
ACTH secretion in rodents (8, 9), dogs (10-12) and ovine fetuses (13-15). 
However, the physiological significance of corticosteroid-mediated negative 
feedback in man is still a matter of debate (16). 
The present study shows that a single oral dose of 100 mg of the 
antiglucocorticoid RU-486 at 02.00 h leads to a significant increase in the 
mean ACTH and Cortisol level six to seven hours later. Most probably the 
increase of ACTH and Cortisol after RU-486 is caused by blockade of the 
negative feedback action of circulating Cortisol at the pituitary and/or 
hypothalamic level. This demonstrates that physiological concentrations of 
Cortisol can inhibit the hypothalamic-pituitary-adrenal system in man. In 
addition we demonstrate that loading with the antihormone significantly 
increases the mean maximal CRH induced ACTH rise, despite a signifi­
cantly higher circulating basal Cortisol level. In our opinion this observation 
provides compelling evidence that in man physiological concentrations of 
Cortisol also determine the response of the pituitary to CRH. 
As a final comment, this study may be of clinical interest, because RU-486 
is not only an antagonist of Cortisol, but also of progesterone and as such is in 
Table I Individual basal plasma Cortisol levels (i.e plasma Cortisol levels immediately before 
CRH administration) and maximal ACTH increases after an ι ν bolus injection of 100 /ig 
human CRH in five men with and without oral pretreatment with 100 mg RU-486 seven hours 
before the injection of CRH 
basal Cortisol (/ig/100 ml)
 Δ max ACTH after 100 jug hCRH 
(pg/ml) 
control 
7,6 
12,3 
14,8 
10,5 
10,1 
11,1 ± 1,1» 
on RU-486 
10,5 
24,6 
16,3 
19,5 
14,8 
17,1 + 2,1 
control 
79 
11 
5 
28 
7 
26 +13а 
on RU-486 
99 
23 
9 
31 
33 
39 ± 14 
a) Ρ < 0 05 vs on RU-486 
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A C T H -
(pg/ml) 
Cortisol ¡ 
( ^g /100ml ) 
180 240 
time (min ) 
Figure I. Mean + SEM plasma ACTH and Cortisol levels before and after an i.v. bolus injection 
of 100 /yg human CRH in five healthy men: 
• without pretreatment with RU-486 
О after oral pretreatment with 100 mg RU-486 seven hours before the injection of CRH. 
Asterisks indicate statistical significance between RU-486 and control (*) Ρ < 0.10 ; * Ρ < 0.05 ; 
:P<O.OI. 
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use as a contragestive agent (17). The ACTH response to exogenously 
administered CRH has been recommended as a bio-assay for circulating 
glucocorticoid activity (18), i.e. the lesser the circulating glucocorticoid 
activity, the higher the ACTH response to CRH. We observed that a single 
dose of 100 mg RU-486 significantly enhances the ACTH response of the 
pituitary to CRH. We interpret this as an indication of deficient gluco­
corticoid activity after RU-486 administration, not fully compensated for by 
the increased levels of plasma Cortisol after administration of the antigluco-
corticoid. 
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3.1 RESPONSIVITY OF ACTH TO CRH AND LACK OF SUPPRESSIBILITY BY 
DEXAMETHASONE ARE RELATED PHENOMENA IN CUSHING'S DISEASE· 
Ad R.M.M. Hermus, Gerlach F.F.M. Pieters, Gerard J.Pesman**, Anthony 
G.H. Smais, Theo J. Benraad** and Peter W.C. Kloppenborg 
Department of Medicine, Division of Endocrinology and Department of 
Experimental and Chemical Endocrinology**, University of Nijmegen, 
Nijmegen, The Netherlands. 
SUMMARY 
The ACTH and Cortisol responses to 100 /ug ovine CRH in 19 consecutive 
patients with Cushing's disease were compared with those in 13 normal 
subjects. In two patients with Cushing's disease plasma ACTH and Cortisol 
did not increase after CRH administration. As compared to the normal 
subjects maximal ACTH increments (135 + 25 (SEM) vs 42 ± 6 pg/ml; P* < 
0,001) and maximal Cortisol increments (17,7 ± 1,8 vs 9,4 ± 1,1 μg/100 ml; 
P* < 0,01) after CRH were significantly higher in the 17 CRH-responsive 
patients with Cushing's disease. In the normal subjects there was a 
significant negative correlation between the basal Cortisol level and the 
maximal ACTH (r = -0,65, P** <0,05) and Cortisol (r = -0,95, P** <0,001) 
responses to CRH. In contrast, in the CRH-responsive Gushing patients 
there was no significant correlation between the basal Cortisol level and the 
maximal ACTH (r = +0,10,P**>0>10)and Cortisol (r = +0,14;P**>0,10) 
increments after CRH. In the normal subjects there was no significant 
correlation between the basal ACTH level and the maximal ACTH 
increments after CRH (г = -0,24, Ρ** > 0,10). Again in contrast, in the 
CRH-responsive Gushing patients maximal ACTH increments after CRH 
correlated positively with the basal ACTH levels (r = +0,69, P** < 0,005). 
Moreover, in these patients the maximal ACTH increments after CRH were 
positively correlated with the ACTH levels after suppression with higher and 
lower doses of dexamethasone. We conclude that in Cushing's disease -
unlike in normal subjects -circulating Cortisol is not the major modulator of 
the ACTH and Cortisol response to CRH and that in these patients 
* Presented in part at the 67th Annual Meeting of the Endocrine Society (Abstract 1004), 
Baltimore, June 19-21, 1985. 
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responsiVity of ACTH to CRH and lack of suppressibility by dexamethasone 
are related phenomena. 
INTRODUCTION 
We previously demonstrated that in normal subjects the ACTH and Cortisol 
responses to ovine or human corticotropin-releasing hormone (CRH) 
depend on the baseline Cortisol level, i.e. the higher the baseline Cortisol level, 
the lesser the response to CRH (1,2). Most patients with pituitary-dependent 
Cushing's disease have ACTH responses to CRH (3-7), although the 
individual ACTH and Cortisol increases after CRH are highly variable, and 
small (8) or even absent responses (4,9-11) to CRH have been reported. So 
far, the factors determining pituitary-adrenal responsiveness to CRH in 
patients with Cushing's disease have not been evaluated. Therefore, we 
compared the ACTH and Cortisol responses to CRH to the basal ACTH and 
Cortisol levels and their responses to dexamethasone in 19 such patients. 
METHODS 
Patients 
Pituitary-adrenal responsiveness to ovine CRH was studied in 19 conse-
cutive patients with pituitary-dependent Cushing's disease. The study 
protocol was approved by the hospital ethical committee and informed 
consent was obtained from all subjects. The results in the patients were 
compared with data from 13 normal subjects (8 men, aged 24 ± 4 years 
(mean ± SD) and 5 women, aged 31 ± 14 years). The clinical data of the 
patients are given in Table 1. All female patients except numbers 7,17 and 19 
were premenopausal. None of the patients had visual field defects and none 
had sellar destruction, except patient 17, who had a macroadenoma. 
Fourteen patients were studied before they received any therapy. The other 
five patients (1,4, 7, 14 and 17) had previously (i.e. before they were tested 
with CRH) undergone pituitary surgery, which was unsuccessful despite 
partial removal of a pituitary adenoma in patients 4, 7 and 17. These 5 
patients, except patient 4, were cured after participating in this study by 
bilateral adrenalectomy. Patients 6,8,9,11,12,13 and 15 were cured later by 
transsphenoidal or transfrontal removal of a pituitary adenoma. Patients 10 
and 19 were treated by bilateral adrenalectomy. Patients 2, 3, 5, 16 and 18 
were not cured after transsphenoidal operation, despite partial removal of a 
pituitary adenoma in 2,3 and 5. These 5 patients then were cured by bilateral 
adrenalectomy. Table 2 summarizes the treatment modalities carried out in 
the 19 patients after the CRH test, as well as the results of histological 
examination of tissue removed during pituitary or adrenal surgery. 
Table 1 Clinical data of 19 consecutive patients with Cushing's disease 
Patient Age Sex Duration Basal plasma ACTH a Basal plasma Cortisol^ Basal urinary 17 OHCS 17 OHCS(/miol/mmol 
no of disease creatinine) after 
(years) (years) (pg/ml) (pg/100ml) (/mol/mmol creatinine)0 2 mg dexamethasone 
q.i.d. for 2 daysd 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
17 
25 
51 
39 
24 
34 
43 
38 
32 
25 
24 
20 
53 
18 
35 
54 
49 
37 
55 
M 
F 
F 
M 
F 
F 
F 
M 
F 
F 
F 
F 
M 
F 
F 
F 
F 
M 
F 
6 
1,5 
1 
3 
3 
3 
2 
5 
1 
4 
2 
2 
1 
4 
0,5 
2 
6 
2,5 
2 
103 
90 
126 
104 
117 
53 
70 
49 
62 
30 
39 
51 
85 
54 
140 
77 
151 
71 
31 
23,5 
22,4 
38.7 
14,1 
26,1 
27,5 
11,2 
15,2 
21,7 
19,5 
21,0 
21,0 
27,2 
20,6 
24,3 
16,7 
12,7 
20,6 
16,7 
9,3 
7,5 
40,0 
4,6 
9,2 
8,2 
-
14,0 
6,2 
4,8 
7,5 
6,9 
11,1 
4,2 
8,7 
8,5 
-
10,4 
11,3 
0,7 
0,3 
21,9 
0,7 
0,4 
1,7 
-
0,5 
0,9 
0,7 
0,8 
0,3 
0,6 
-
3,1 
0,1 
-
-
9,1 
a Basai plasma ACTH represents the mean of 4 samples taken at 9 a m. (normal value < 75 pg/ml). 
b Basal plasma Cortisol represents the mean of 4 samples taken at 9 a m. (normal range 6,9 -19,9 //g/100ml). 
с Normal range 0,6 - 3,0 /miol/mmol creatinine (1 /imol/mmol creatinine = 2,48 mg/g creatinine) 
d In four patients 17 OHCS excretion was not determined. Plasma Cortisol levels after 2 mg dexamethasone q.i.d. for 2 days were 0,7 //g/100 ml in 
patient 7, 9,1 jug/100 ml in patient 14, and 8,7 ^g/100 ml in patient 18. 
Table 2 Treatment modalities of the patients after the CRH- and dexamethasone-tests Results of histological examinations 
Patient Treatment3 Histological examination Histological examination Adrenal weight 
no of tissue removed during of both removed adrenals'1 (gr) 
pituitary surgery 
1 
2 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
ADX 
TS, ADX 
TS, ADX 
No further treatment 
TS, ADX 
TS 
ADX 
TS 
TS 
ADX 
TF 
TS 
TF 
ADX 
TS 
TS, ADX 
ADX 
TS, ADX 
ADX 
-
adenoma 
adenoma 
-
adenoma 
adenoma 
-
adenoma 
adenoma 
-
adenoma 
adenoma 
adenoma 
-
adenoma 
no adenoma found 
-
no adenoma found 
-
diffuse hyperplasia 
diffuse hyperplasia 
diffuse hyperplasia 
-
diffuse hyperplasia 
-
macronodular hyperplasia 
(R 2,2 cm, L 3,5 cm) 
-
-
diffuse hyperplasia 
-
-
-
diffuse hyperplasia 
-
macronodular hyperplasia 
(R 3,5 cm, L 1,0 cm) 
diffuse hyperplasia 
macronodular hyperplasia 
(R 0,4cm, L 1,0cm) 
macronodular hyperplasia 
(R 5,5 cm, L 4,0cm) 
R 
R 
R 
-
R 
-
R 
-
-
R 
-
-
-
R 
-
R 
R 
R 
R 
4,2 
7,0 
7,5 
5,7 
15,5 
9,5 
4,0 
13,9 
7,3 
7,1 
43,0 
L 5,0 
L 7,0 
L 9,0 
L 6,1 
L 37,3 
L 9,0 
L 5,1 
L 6,7 
L 7,5 
L 10,3 
L 44,5 
a ADX = bilateral adrenalectomy, TS = transsphenoidal surgery, TF = transfrontal surgery 
b maximal size of nodules in each gland (R = right, L = left) is indicated in parentheses 
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CRH test 
Ovine CRH was obtained from Bachern (Torrance, CA). It was dissolved in 
a 2% aqueous solution of lactose and sterilized by passage through a 0,2//m 
cellulose acetate filter (Schleicher und Schuell, FPO 30/3) and was found to 
be nonpyrogenic ("Pyrogent test", Mallinckrodt). CRH was stored at -180C 
in lyophilized form in sterile vials under vacuum. Immediately before 
administration it was dissolved in 1 ml acidified NaCl (pH 2). 100 /ug ovine 
CRH was given at 09.00 h as an i.v. bolus injection over 30 sec. with the 
subjects fasting and supine since 08.00 h. The cannula for blood drawing was 
inserted at this time. Blood samples for ACTH and Cortisol assay were 
collected at -30, 0, 5, 10, 20, 30, 60, 120 and 180 min via an indwelling i.v. 
cannula kept open with a diluted (10%) solution of heparin. Plasma ACTH 
and Cortisol were determined by specific RI As as described previously (12). 
To avoid interassay variations all samples of individual patients were 
analyzed in the same assay. 
Dexamethasone suppression tests 
Dexamethasone suppression tests were performed in the patients with 
Cushing's disease using 2 mg dexamethasone overnight, 0,5 mg dexame-
thasone q.i.d. for 2 days, 2 mg dexamethasone q.i.d. for 2 days, and 4 mg 
dexamethasone q.i.d. for 2 days. 24 h urinary excretion of 17-hydrocorti-
costeroids ( 17 OHCS) was measured using the method described by Van De 
Calseyde et al (13). 
Statistics 
Statistical analyses were performed using Wilcoxon's paired rank test (P 
values denoted by P), Wilcoxon's two sample test (P = P*) and Spearman's 
rank correlation test (P = P**). The mean values ± 1 SEM are given. 
RESULTS (Figure 1-4, Table 3) 
Responses of A CTH and Cortisol to CRH in patients with Cushing's disease and 
in normal subjects 
Figures 1 and 2 illustrate the relation between the basal Cortisol levels and the 
maximal ACTH and Cortisol responses to the administration of 100¿ug ovine 
CRH in the 19 patients with Cushing's disease as well as in the 13 normal 
subjects. In patients 18 and 19 (Tables 1-2) plasma ACTH and Cortisol did 
not increase after CRH injection on two separate occasions. In the remaining 
17 Gushing patients (indicated below as "CRH-responders"), mean plasma 
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Δ Max ACTH ( p g / m l ) 
300-1 
2 5 0 -
2 0 0 -
1 5 0 -
1 0 0 -
5 0 -
t 
0(0.0) 
о г =+0.10; η.s. 
• г =-0.65;p**<0.05 
• · · β 
· · · 
% 
τ 
τ 
10 
- 1 1 1 — 
15 2 0 2 5 3 0 3 5 
Basal Cortisol (j j.g /100 ml ) 
Figure I. The relation between individual basal plasma Cortisol levels and the maximal plasma 
ACTH increases after CRH (~ Δ max ACTH) in 13 normal subjects (closed symbols) and in 19 
patients with Cushing's disease (open symbols). 
β denotes patients with macronodular hyperplasia. 
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Δ Max Cortisol(jjg/KX)ml)· 
35 -
3 0 -
2 5 
2 0 -
15 
10-
5 -
o r = +0.14; n.s. 
• r = - 0 . 9 5 ; p**<0.001 
β 
—Γ­
ΙΟ 
- г " 
15 
'—г 
— ι 1 1 — 
20 2 5 3 0 3 5 
Basal Cortisol (/дд/100ті) 
Figure 2. The relation between individual basal plasma Cortisol levels and the maximal plasma 
Cortisol increases after CRH (= Δ max Cortisol) in 13 normal subjects (closed symbols) and in 19 
patients with Cushing's disease (open symbols). 
В denotes patients with macronodular hyperplasia. 
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ACTH increased after CRH from a basal value of 85 ± 10 pg/ml to a peak 
value of 197 ± 27 pg/ml at 20 min (Ρ < 0,01 vs t = 0 min). Thereafter ACTH 
levels declined significantly to 90 ± 15 pg/ml at 180 min (Ρ < 0,01 vs t = 20 
min, Ρ > 0,10 vs t = 0 min). Individual peak levels occurred between 5 and 
120 min. In all CRH-responders plasma ACTH rises were followed by 
marked increases of Cortisol from a baseline value of 20,3 ± 1,4 yug/dl to a 
peak value of 34,4 ± 3,3 /vg/dl at 60 min (Ρ < 0,01 vs t = 0 min). Thereafter 
Cortisol levels declined to 27,2 ± 2,2¿ig/dl at 180 min (0,05 < Ρ < 0,10 vs t = 
60 min; Ρ < 0,01 vs t = 0 min). Individual peak levels were reached between 
20 and 180 min. 
Both in the normal subjects (r = +0,70; P** < 0,02) and in the CRH-
responding Cushing patients (r = +0,50; P** < 0,05) there was a significant 
and positive correlation between the maximal ACTH and Cortisol responses 
to CRH. 
Table 3 illustrates that mean plasma ACTH and Cortisol levels both before 
and after CRH administration were significantly higher in the CRH-
responsive Cushing patients than in the normal subjects and that in terms of 
absolute increments these Cushing patients were hyperresponsive to CRH. 
Analysis of factors determining the ACTH and Cortisol responses in normal 
subjects and in CRH-responsive Cushing patients 
In the 13 normal subjects the maximal ACTH responses to CRH were 
significantly and negatively correlated with the basal Cortisol levels (r = 
-0,65; P** < 0,05) (Fig. 1). An even stronger correlation was found between 
the maximal Cortisol responses to CRH and the basal Cortisol levels (r = 
-0,95; P** < 0,001) (Fig.2). In the normal subjects there was no significant 
correlation between basal ACTH levels and maximal ACTH (r = -0,24; P** 
> 0,10) and maximal Cortisol (r = -0,40; P** > 0,10) increments after CRH. 
In contrast to the normal subjects there was no correlation between the basal 
Cortisol level and the maximal ACTH (r = +0,10; P** > 0,10) and maximal 
Cortisol (r = +0,14; P** > 0,10) increments after CRH in the CRH-
responsive Cushing patients (Fig.l and 2). Again in contrast to the normal 
subjects, a highly significant positive correlation was found between the 
basal ACTH levels and the maximal ACTH increments after CRH (r = 
+0,69; P** < 0,005) (Fig.3). There was no significant correlation between 
basal ACTH and the maximal Cortisol response after CRH (г = +0,25; Ρ** > 
0,10). 
The maximal ACTH increments correlated not only with the basal ACTH 
levels, but also with the ACTH levels after 2 mg dexamethasone overnight 
(62 ± 8 pg/ml; r = +0,59; P** < 0,05; η = 12), the ACTH levels after 4 χ 0,5 
mg dexamethasone for 2 days (61 ± 9 pg/ml; r = +0,49; P** < 0,05; η = 16) 
and the ACTH levels after 4 x 4 mg dexamethasone for 2 days (49 ± 15 
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Table 3 Comparison of basal plasma ACTH and Cortisol levels and responses of these 
hormones to 100 ¿/g oCRH in 13 normal subjects and 17 CRH-responding patients with 
Cushing's disease 
basal ACTH (pg/ml) 
maximal ACTH increment 
after CRH 
peak ACTH after CRH·* 
basal Cortisol (pg/dl) 
maximal Cortisol increment 
after CRH 
peak Cortisol after CRH*· 
Healthy subjects 
25 ± 2 * 
42 ± 6 
67 ± 6 
12,3 ± 1,1 
9,4 ±1 ,1 
21,7 ±0 ,7 
Patients with 
Cushing's disease 
85 ± IOC 
135 ± 25b 
220 ± 32C 
20,3 ± 1,4b 
17,7 ± 1,8» 
37,6 ± 2,5d 
mean ± SEM 
the means of individual peaks, independent of time are given 
(a, P* < 0.01 vs normal subjects; 
b , P * < 0.001, 
c ,P*< 0.0001; 
d ,P*< 0.00001) 
pg/ml; г = +0,73; Ρ** < 0,005; η =13) (Fig.4). The correlation between the 
maximal ACTH responses after CRH and the ACTH levels after 4 x 2 mg 
dexamethasone (51 ± 9 pg/ml; η = 15) was not significant (r = +0,36; P** > 
0,10). 
DISCUSSION 
We analyzed the ACTH and Cortisol responses to 100//g ovine CRH in 19 
consecutive patients with pituitary-dependent Cushing's disease and com­
pared the responses with those in 13 normal subjects. Moreover, in the 17 
CRH-responding Gushing patients ACTH responses to CRH were com­
pared with the suppressibility of ACTH levels by dexamethasone. 
As we previously demonstrated (1,2), in the normal subjects the ACTH 
and Cortisol responses to CRH were modified to a high degree by the basal 
level of circulating Cortisol, i.e. the higher the basal Cortisol, the lower the 
response to CRH. The basal ACTH levels, however, did not correlate 
significantly with the response to CRH. 
In the 17 CRH-responsive patients with Cushing's disease, individual 
ACTH and Cortisol profiles after CRH were highly variable. Compared to 
the individual responses in the normal subjects, taking into account the basal 
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Cortisol levels, a normal ACTH response to CRH was found in four and a 
normal Cortisol response in five patients with Cushing's disease. In only one 
of the 17 patients, however, were the responses of both ACTH and Cortisol to 
CRH within the range of those in the normal subjects. 
In contrast to the normal subjects, in the CRH-responsive patients with 
Cushing's disease there was no correlation at all between the basal Cortisol 
level and the ACTH and Cortisol responses to CRH, confirming preliminary 
data of Orth et al (14). Remarkably, in the CRH-responding Gushing 
patients the ACTH response to CRH was highly positively correlated with 
the basal ACTH level. The second new finding of interest was that the 
response to CRH, if present, correlated positively with the plasma ACTH 
value after dexamethasone administration, i.e. greater responses to CRH 
occurred in patients whose plasma ACTH declines the least after dexa­
methasone. 
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ACTH increases after CRH (= A max ACTH) in 17 CRH-responding patients with Cushing's 
disease 
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Lack of normal suppressibility of ACTH-release by glucocorticoids is at 
the base of the pathophysiology in the great majority of patients with 
Cushing's disease. This defect of negative feedback can explain the lack of 
correlation between basal Cortisol and CRH-induced responses of ACTH 
and Cortisol in Cushing's disease. Our observation that in Cushing's disease 
the degree of lack of suppressibility of ACTH by glucocorticoids was 
significantly correlated with the degree of ACTH responsiveness to CRH is 
intriguing. Very recently it has been demonstrated that there is heterogeneity 
among corticotrophs of the normal rat anterior pituitary (15) and that the 
adenohypophysis contains a subpopulation of corticotrophs preferentially 
stimulated by CRH and inhibited by glucocorticoids (16). We speculate that 
in Cushing's disease these corticotrophs are those that proliferate and at least 
in part lose their ability to be inhibited by glucocorticoids without losing 
their sensitivity to CRH stimulation, leading to hypersecretion of ACTH. In 
this concept of the pathogenesis of Cushing's disease, the ACTH level after 
dexamethasone administration is an index of the number of these CRH-
responsive and glucocorticoid insensitive cells. Then, it is not surprising that, 
as we found, responsivity to CRH in Cushing's disease and lack of 
suppressibility by dexamethasone are related phenomena. 
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Figure 4 The relation between individual plasma ACTH levels after administration of 4 mg 
dexamethasone q.i.d. for 2 days and the maximal plasma ACTH increases after lOOjUg CRH (= 
д max ACTH) in 13 CRH-responding patients with Cushing's disease. 
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3.2 THE CRH TEST VERSUS THE "HIGH-DOSE" DEXAMETHASONE TEST IN THE 
DIFFERENTIAL-DIAGNOSIS OF CUSHING'S SYNDROME 
Ad R.Hermus, M.D., Gerlach F.Pieters, M.D., Gerard J.Pesman*, Anthony 
G.Smals, M.D., Theo J.Benraad, Ph.D.* and Peter W.C. Kloppenborg, 
M.D. 
Department of Medicine, Division of Endocrinology and Department of 
Experimental and Chemical Endocrinology*, St.Radboud Hospital, Uni-
versity of Nijmegen, Geert Grooteplein Zuid 8, 6525 GA, Nijmegen, The 
Netherlands. 
ABSTRACT 
The diagnostic accuracy of the CRH test was compared with that of the oral 
"high-dose" dexamethasone suppression test according to Liddle in the 
differential-diagnosis of Cushing's syndrome. A false-negative response to 
CRH was present in 9% (2 of 22) of patients with pituitary-dependent 
Cushing's disease and to "high-dose" dexamethasone in 11% (2 of 18). All 
three patients with Cushing's syndrome due to an adrenal adenoma were 
unresponsive to both CRH and dexamethasone. The only patient with 
ectopic ACTH secretion in this series had a false-positive response of ACTH 
to dexamethasone and no response of ACTH to CRH. Simultaneous failure 
of both tests to indicate the cause of Cushing's syndrome did not occur in this 
series, except in one patient with Cushing's disease and overt macronodular 
hyperplasia. We conclude that the diagnostic accuracy of the CRH test in the 
work-up of the patient with Cushing's syndrome is comparable to that of the 
Liddle test and that the highest discriminatory score in the differential-
diagnosis of Cushing's syndrome is achieved by performing both a CRH test 
and a "high-dose" dexamethasone test. 
INTRODUCTION 
Cushing's syndrome is caused by primary overproduction of ACTH, either 
by the pituitary gland or by an ectopic source, or by primary overproduction 
of Cortisol due to an adrenal adenoma or carcinoma. Various diagnostic 
manoeuvres are in use to discriminate between these forms of Cushing's 
syndrome. However, not infrequently they lead to contradictory results, 
necessitating prolonged hospital stays. 
Submitted for publication 
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After the isolation of the 41 amino acid peptide corticotropin-releasing 
hormone (CRH) from ovine hypothalami by Vale et al in 1981 (1) several 
groups have assessed the value of this peptide in the differential-diagnosis of 
Cushing's syndrome (2-4). Müller et al (2) and Chrousos et al (3) 
demonstrated that after administration of ovine CRH plasma ACTH levels 
in patients with pituitary-dependent Cushing's disease rose without excep-
tion. Patients with an adrenal adenoma or untreated adrenal carcinoma were 
characterized by undetectable baseline ACTH levels unresponsive to CRH, 
while patients with ectopic ACTH secretion had increased basal ACTH 
levels, also unresponsive to CRH. This data suggests a very high specificity 
of the CRH test. 
So far, no studies have systematically compared the value of the CRH test 
with that of more conventional tests in the differential-diagnosis of 
Cushing's syndrome. The present study collates the diagnostic accuracy of 
the CRH test with that of the oral "high-dose" dexamethasone suppression 
test according to Liddle (5,6) in a group of 26 consecutive patients with 
Cushing's syndrome. In addition, we studied whether the diagnostic power 
of these tests combined is greater than that of each test alone. 
METHODS 
Patients (Table 1 and 2) 
Twenty-five consecutive patients with active Cushing's syndrome (22 with 
pituitary-dependent Cushing's disease and three with Cushing's syndrome 
due to an adrenal adenoma) participated in this study. In addition, ACTH 
responsiveness to ovine CRH and dexamethasone was determined in one 
patient with ectopic ACTH secretion due to a bronchial carcinoid. The study 
protocol was approved by the hospital ethical committee and informed 
consent was obtained from all patients. Relevant clinical and biochemical 
data of the 25 patients with active Cushing's syndrome is given in Table 1. All 
female patients except numbers 7,17 and 22 were premenopausal. None of 
the patients had visual field defects. In only one patient (number 17, Table 1 ) 
CT scanning demonstrated a macroadenoma. Nineteen patients were 
studied before they received any therapy. Five patients (1, 4, 7, 14 and 17) 
had previously (i.e. before entering in this study) undergone pituitary 
surgery, which was unsuccessful despite partial removal of a pituitary 
adenoma in patients 4,7 and 17. These five patients, except patient 4, were 
cured after participating in this study by bilateral adrenalectomy. In patient 
20 a pituitary microadenoma was removed 4,5 years earlier. Postoperatively 
all clinical signs and symptoms of Cushing's disease as well as hyper-
cortisolism disappeared. In this patient, who was never hypocortisolemic 
after surgery, signs and symptoms of Cushing's disease recurred after a 
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clinical remission of more than 4 years. After completion of this study 
patients 6,8,9, 11, 12, 13, 15,18 and 19 were treated by transsphenoidal or 
transfrontal removal of a pituitary adenoma. Patients 10, 20 and 22 were 
treated by bilateral adrenalectomy. In patients 2, 3, 5, 16 and 21 Cushing's 
disease was still active after transsphenoidal operation, despite partial 
removal of a pituitary adenoma in 2, 3 and 5. These 5 patients were then 
given relief by bilateral adrenalectomy. The patients with Cushing's 
syndrome due to an adrenal adenoma were treated by unilateral adrenal­
ectomy. Table 2 summarizes the treatment modalities carried out in the 25 
patients with active Cushing's syndrome after the CRH test and the "high-
Table 1. Clinical and biochemical data of 22 consecutive patients with Cushing's disease 
(patients 1-22) and of 3 patients with Cushing's syndrome due to an adrenal adenoma (patients 
23-25) 
Patient 
no 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
Age 
(yrs) 
17 
25 
51 
39 
24 
34 
43 
38 
32 
25 
24 
20 
53 
18 
35 
54 
49 
40 
24 
41 
37 
55 
39 
20 
30 
Sex 
M 
F 
F 
M 
F 
F 
F 
M 
F 
F 
F 
F 
M 
F 
F 
F 
F 
M 
F 
F 
M 
F 
F 
F 
F 
Duration 
of disease 
(yrs) 
6 
1,5 
1 
3 
3 
3 
2 
5 
1 
4 
2 
2 
1 
4 
0,5 
2 
6 
1 
0,5 
0,25 
2,5 
2 
2 
3 
2,5 
Basal АСТНа 
(pg/ml) 
103 
90 
126 
104 
117 
53 
70 
49 
62 
30 
39 
51 
85 
54 
140 
77 
151 
35 
37 
53 
71 
31 
< 15 
< 15 
< 15 
Basal 
Cortisol·5 
{μ%/ 100ml) 
23,5 
22,4 
38,7 
14,1 
26,1 
27,5 
11,2 
15,2 
21,7 
19,5 
21,0 
21,0 
27,2 
20,6 
24,3 
16,7 
12,7 
18,5 
27,2 
19,2 
20,6 
16,7 
20,6 
20,6 
19,5 
basal ACTH represents the mean of 4 samples taken at 9 a.m. (normal value < 75 pg/ml) 
basal Cortisol represents the mean of 4 samples taken at 9 a.m. (normal range 6,9 - 19,9 
üB/lOOml) 
a 
b 
/yg/ 100 l) 
Table 2 Treatment modalities of the 22 patients with Cushing's disease (1-22) and the three patients with Cushing's syndrome due to an adrenal adenoma 
(23-25) after the CRH test Results of histological examinations 
Patient 
no 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
Treatment3 
ADX 
TS, ADX 
TS, ADX 
No further treat-
ment 
TS, ADX 
TS 
ADX 
TS 
TS 
ADX 
TF 
TS 
TF 
ADX 
TS 
TS, ADX 
ADX 
TS 
TS 
ADX 
TS, ADX 
ADX 
left adrenalectomy 
right adrenalectomy 
left adrenalectomy 
Histological examination 
of tissue removed during 
pituitary surgery 
-
adenoma 
adenoma 
-
adenoma 
adenoma 
-
adenoma 
adenoma 
-
adenoma 
adenoma 
adenoma 
-
adenoma 
no adenoma found 
-
adenoma 
adenoma 
-
no adenoma found 
-
-
-
-
Histological examination 
of removed adrenal(s)b 
diffuse hyperplasia 
diffuse hyperplasia 
diffuse hyperplasia 
-
diffuse hyperplasia 
-
macronodular hyperplasia 
(R 2,2 cm, L 3,5 cm) 
-
-
diffuse hyperplasia 
-
-
-
diffuse hyperplasia 
-
macronodular hyperplasia 
(R 3,5 cm, L 1,0 cm) 
diffuse hyperplasia 
-
-
diffuse hyperplasia 
macronodular hyperplasia 
(R 0,4 cm, L 1,0 cm) 
macronodular hyperplasia 
(R 5,5 cm, L 4,0 cm) 
adrenal adenoma 
adrenal adenoma 
adrenal adenoma 
Adrenal weight 
(gr) 
R 4,2 
R 7,0 
R 7,5 
" 
R 5,7 
-
R 15,5 
-
-
R 9,5 
-
-
-
R 4,0 
-
R 13,9 
R 7,3 
-
-
R 6,7 
R 7,1 
R43,0 
R 13,0 
L 5,0 
L 7,0 
L 9,0 
L 6,1 
L37,3 
L 9,0 
L 5,1 
L 6,7 
L 7,5 
L 8,3 
L10,3 
L44,5 
L 7,2 
Lll.O 
00 
ON 
a ADX = bilateral adrenalectomy, TS = transsphenoidal surgery, TF = transfrontal surgery 
b in patients with bilateral macronodular hyperplasia maximal size of nodules in each gland (R : :
 right, L = left) is indicated in parentheses 
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dose" dexamethasone test, as well as the results of the histological 
examination of material removed during pituitary or adrenal surgery. 
The woman with ectopic ACTH secretion was 60 years old when severe 
Cushing's syndrome was diagnosed in 1978. Because of hyperpigmentation 
and an unusually high plasma ACTH level (700 pg/ml) the possibility of 
ectopic ACTH secretion was considered, but in spite of extensive investi-
gations (including lung planigrams) no tumor could be detected and 
therefore a tentative diagnosis of pituitary-dependent Cushing's disease was 
made, mainly because of suppression of plasma Cortisol to 30% of the basal 
value after treatment with 8 mg dexamethasone for 2 days. She was treated 
by bilateral adrenalectomy and was well until September 1984, when she 
complained of dyspnea and wheezing. A carcinoid tumor with obstruction 
of the right upper bronchus and metastases to mediastinal lymph nodes and 
to the liver was diagnosed. Immunohistochemical examination of the 
bronchial carcinoid (Dr.A.C.Nieuwenhuyzen Kruseman, University Hos-
pital, Leiden) revealed that the tumor cells contained ACTH, ^-endorphin 
and y-MSH, but no CRH. 
CRH test 
The CRH test was performed at 09.00 h with the subjects fasting and at bed 
rest. Ovine CRH (100/ig: Bachern, Torrance, CA) dissolved in 1 ml acid-
saline (pH 2) was given as an intravenous bolus injection. Blood samples for 
ACTH and Cortisol assay were collected at -30,0, 5, 10, 20, 30,60, 120 and 
180 min through an indwelling i.v. cannula kept open with minute amounts 
of a diluted (10%) solution of heparin. The cannula was inserted 30 min 
before CRH administration. Plasma ACTH and Cortisol were determined by 
specific RIAs as described previously (7). The limit of detection of the ACTH 
assay was 15 pg/ml. To avoid interassay variations all samples of individual 
patients were determined in the same run. 
"High-dose" dexamethasone suppression test 
Two mg dexamethasone was given orally q.i.d. for two days. On the second 
day 24 h urinary excretion of 17-hydroxycorticosteroids (17 OHCS) was 
measured by gaschromatography (8). 
RESULTS 
CRH test (Figure 1) 
Figure 1 illustrates the individual basal ACTH and Cortisol values (i.e. the 
levels of ACTH and Cortisol immediately before CRH injection) as well as 
the individual peak ACTH and Cortisol levels after CRH administration in 
the 22 patients with pituitary-dependent Cushing's disease. Twenty of the 22 
patients had a clear response of ACTH and Cortisol after CRH, although the 
individual responses were highly variable. Two patients (numbers 21 and 22) 
with pituitary-dependent Cushing's disease were unresponsive to CRH on 
two separate occasions. 
ACTH 
( p g / m l ) 
4 0 0 
3 0 0 
2 0 0 -
100 
Cortisol 
(>ig /100 m l ) 
6 0 -
5 0 
4 0 -
3 0 -
2 0 
1 0 -
basol peak basal peak 
Figure I. Individual levels of plasma ACTH and Cortisol before and after stimulation with 100 
μ§ ovine CRH m 22 patients with pituitary-dependent Cushing's disease Two patients 
(numbers 21 and 22, dotted lines) were unresponsive to CRH The shaded area represents the 
m e a n ± S D i n l 3 normal subjects (8 men, aged 24 + 4 years ( mean ± SD) and 5 women, aged 31 
± 14 years) 
89 
The three patients with Cushing's syndrome due to an adrenal adenoma 
(numbers 23,24 and 25, Table 1) were unresponsive to CRH (ACTH levels < 
15 pg/ml, both before and after CRH administration). The patient with 
ectopic ACTH secretion due to a bronchial carcinoid showed no response of 
ACTH after CRH (basal ACTH level 165.000 pg/ml). 
Urinary 17 OHCS 
(pM/mM creatinine) 
Basal 
θ mg 
dexamethasone 
Figure 2 Individual urinary excretion of 17-hydroxycorticostcroids (17 OHCS) before and on 
the second day of loading with 2 mg dexamethasone orally q i.d in 18 patients with pituitary-
dependent Cushing's disease Two patients (numbers 19 and 22, dotted lines) showed 
inadequate suppression to dexamethasone Normal range for basal urinary 17 OHCS excretion: 
0,6 - 3,0 /miol/mmol creatinine (1 ¿/mol/mmol creatinine = 2,48 mg/g creatinine). 
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"High-dose" dexamethasone suppression test (Figure 2) 
Figure 2 illustrates the 24 h urinary excretion of 17-hydroxycorticosteroids 
before and on the second day of loading with 2 mg dexamethasone orally 
q.i.d. in 18 patients with pituitary-dependent Cushing's disease. Sixteen of 
the 18 patients showed adequate (i.e. 40% or more of baseline) suppression 
of the urinary 17-hydroxysteroid excretion. Two patients (numbers 19 and 
22) showed inadequate suppression to dexamethasone. In the remaining 
four patients with Cushing's disease (numbers 7,14,17and21,Table l)data 
on 17 OHCS excretion was not available; plasma Cortisol levels before and 
after dexamethasone were measured in three of these patients, decreasing 
from 11,2 to 0,7 ¿ig/100ml after 2 mg dexamethasone q.i.d. for two days in 
patient 7, from 20,6 to 9,1 jug/lOOml in patient 14 and from 21,0 to 8,7 
yug/100ml in patient 21. 
The three patients with Cushing's syndrome due to an adrenal adenoma 
failed to suppress after dexamethasone. Urinary 17 OHCS excretion before 
and after dexamethasone was 4,6 respectively 4,8 ¿fmol/mmol creatinine in 
patient 23,4,4 respectively 4,4/imol/mmol creatinine in patient 24 and 7,2 
respectively 6,3 /umol/mmol creatinine in patient 25. Treatment with 2 mg 
dexamethasone q.i.d. for two days reduced plasma ACTH from 165.000 to 
69.000 pg/ml in the patient with ectopic ACTH secretion. 
DISCUSSION 
The present study compares the value of the CRH test with that of the oral 
"high-dose" dexamethasone suppression test according to Liddle (5,6) in the 
differential-diagnosis of Cushing's syndrome. Twenty of the twenty-two 
patients with pituitary-dependent Cushing's disease responded to CRH with 
an increase of plasma ACTH and Cortisol. From these CRH-responsive 
Gushing patients one (number 19, Table 1) showed inadequate suppression 
of urinary 17-hydroxycorticoid excretion in the Liddle test. Two patients 
with pituitary-dependent Cushing's disease did not respond to CRH. One of 
these patients (number 22, Table 1) was also unresponsive to dexametha-
sone. This patient had overt macronodular adrenal hyperplasia. It seems 
most likely that the unresponsiveness in both tests can be explained in this 
patient by primacy of adrenal hypercortisolism, as we discussed earlier (9). 
Very recently a similar patient with Cushing's disease and macronodular 
adrenal hyperplasia, unresponsive to both CRH and dexamethasone, was 
described (10). The second patient with unresponsiveness to CRH (number 
21, Table 1 ) also had macronodular hyperplasia, although to a lesser extent. 
In this patient, unlike in the former, plasma Cortisol was reduced consider-
ably (58%) by dexamethasone. Therefore in this case, it is improbable that 
adrenal primacy can explain unresponsiveness to CRH. In literature up till 
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now four other patients with Cushing's disease and unresponsiveness to 
CRH have been described (11-14). It has to be noted that one of these 
patients (14) did not show suppression of serum Cortisol during an 8 mg 
dexamethasone test either. No results of dexamethasone suppression tests 
are given for the other three patients. 
Our three patients with Cushing's syndrome due to an adrenal adenoma 
were unresponsive to CRH as well as to dexamethasone. So far no patients 
with Cushing's syndrome due to an adrenal adenoma or carcinoma 
responsive to CRH have been reported in literature. Our patient with ectopic 
ACTH secretion due to a bronchial carcinoid had no plasma ACTH 
response to CRH, whereas dexamethasone reduced plasma ACTH by 60%. 
It is of interest, that up till now only one patient with ectopic ACTH 
secretion responsive to CRH has been reported (15). However, this patient 
had no response on retesting. 
The value of a new diagnostic test has to be proven by comparing it with 
other diagnostic tests in common use. The oral "high-dose" (8 mg daily for 2 
days) dexamethasone suppression test according to Liddle (5,6) is at the 
present the most reliable test for the differential-diagnosis of Cushing's 
syndrome. In 1969 Liddle and co-workers (6) reported their results from this 
test in 100 patients with Cushing's syndrome: 98% of the patients with 
pituitary-dependent Cushing's disease, 6% of the patients with ectopic 
ACTH secretion, and none of the patients with adrenal tumors showed 
adequate suppression of the daily urinary 17-hydroxysteroid excretion, i.e. 
40% or more of baseline. Subsequent studies of the 8 mg dexamethasone test 
have generally shown results comparable to those in Liddle's report. Crapo 
(16), analysing the cumulative experience in literature of the "high-dose" 
dexamethasone test, calculated an 8% failure-rate of this test in pituitary-
dependent Cushing's disease and a 14% failure-rate in ectopic ACTH 
syndrome, whereas a false-positive dexamethasone test in patients with 
adrenal tumors is extremely rare. 
Our study demonstrates false-negative responses to CRH in 9% (2 of 22) 
and to "high-dose" dexamethasone in 11% (2 of 18) of patients with 
pituitary-dependent Cushing's disease. A false-positive response to dexa-
methasone occurred in one patient with ectopic ACTH secretion, whereas 
CRH revealed the cause of Cushing's syndrome in all patients with non 
pituitary-dependent disease. These results demonstrate that the diagnostic 
accuracy of the CRH test in the work-up of the patient with Cushing's 
syndrome is by no means inferior to the Liddle test. It is of interest that in our 
patients simultaneous failure of both tests to indicate the cause of Cushing's 
syndrome did not occur, except in the patient with Cushing's disease and 
severe macronodular hyperplasia. However, taking into account the pri-
macy of adrenal hypercortisolism, the results of both tests in this patient are 
intelligible. 
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We recommend to perform routinely a CRH test as well as a "high-dose" 
dexamethasone test to discriminate with the highest precision between the 
various forms of Cushmg's syndrome. Should conflicting results from both 
tests and indecisive roentgenological findings occur further diagnostic 
procedures are necessary, e.g selective venous sampling for ACTH (17). 
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3.3 ACTH AND CORTISOL RESPONSES TO OVINE CORTICOTROPHIN-RELEASING 
FACTOR IN PATIENTS WITH PRIMARY AND SECONDARY ADRENAL FAILURE 
A.R.M.M. Hermus, G.F.F.M. Pieters, G.J. Pesman, A.G.H. Smals, T.J. 
Benraad and P.W.C. Kloppenborg 
Department of Medicine, Division of Endocrinology and Department of 
Experimental and Chemical Endocrinology, University of Nijmegen, Nij-
megen, The Netherlands. 
SUMMARY 
The ACTH and Cortisol responses to an intravenous bolus injection of 100 
/ig ovine CRF were studied in 19 patients with adrenal failure. In all eight 
patients with primary adrenal failure, plasma ACTH levels increased from a 
mean basal level of 1494 ± 431 (SEM) pg/ml to a peak value of 2601 ± 1220 
pg/ml at 10 min. In comparison with healthy subjects absolute ACTH 
increments after ovine CRF were significantly augmented in the patients 
with Addison's disease (P* < 0.001 ), and the absolute ACTH responses after 
ovine CRF were positively correlated with the basal plasma ACTH levels. 
The 11 patients with secondary adrenal insufficiency could be subdivided 
into two groups: (A) those having little or no ACTH and Cortisol response to 
ovine CRF (five patients) and (B) those having prolonged and pronounced 
ACTH responses with a biphasic pattern and a delayed second peak (six 
patients), followed in all patients by a marked Cortisol increase. Clinical and 
biochemical data in these patients support the view that the CRF test can 
discriminate between hypothalamic and pituitary causes of secondary 
adrenal failure. 
INTRODUCTION 
In the last few years ample studies have demonstrated that ovine cortico-
trophin-releasing factor stimulates the secretion of ACTH and Cortisol in 
normal human subjects (Grossman et al., 1982; Orth et al., 1983; Hermus et 
al., 1984) and in the majority of patients with Cushing's disease (Orth et al., 
1982; Müller et al., 1983a; Pieters et al., 1983; Chrousos et al., 1984; Lytras et 
al., 1984). 
Clin Endocrinol 1985; 22: 761-9 
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It has been clearly proven that the response of the pituitary-adrenal axis to 
ovine CRF in healthy men is modulated to a high degree by the basal Cortisol 
level (Hermus et al., 1984; Lytras et al., 1984), i.e. the higher the basal plasma 
Cortisol level, the smaller the CRF-induced secretion of ACTH and, thereby, 
of Cortisol. 
Patients with primary adrenal failure are characterized by a normal 
hypothalamo-pituitary system, which is not -or only to a minor degree-
influenced by endogenous Cortisol feedback. Thus in these patients ACTH 
responsiveness to CRF can be studied independently of circulating Cortisol. 
The present study shows that in these patients the absolute ACTH response 
to ovine CRF is augmented and positively correlated with the basal ACTH 
level. 
Only scarce data have been published on plasma ACTH and Cortisol 
responses to ovine CRF in patients with secondary adrenal insufficiency. 
However, there is preliminary evidence that the CRF test will enable us to 
discriminate between hypothalamic and pituitary disorders in these patients 
(Tsukada et al., 1984; Schulte et al., 1984). The present study confirms these 
scarcely reported findings in a substantial group of patients with secondary 
adrenal failure and shows in addition that the ACTH response to ovine CRF 
in patients with supposedly hypothalamic adrenal insufficiency is biphasic 
and more prolonged and pronounced than in normal subjects. 
SUBJECTS AND METHODS 
Pituitary-adrenal responsiveness to ovine CRF was studied in 19 patients 
with adrenal failure after approval of the protocol by the hospital ethical 
committee and obtaining informed consent from all participants. Eight 
patients had primary and eleven had secondary adrenal insufficiency. The 
results in the patients were compared with data from ten normal subjects 
(five men, aged 23 ± 3 years [mean ± SD], and five women, aged 31 ± 14 
years). Clinical data of the patients with primary adrenal failure are given in 
Table 1. The eight Addisonian patients (except for patient 8, who had only 
partial adrenal insufficiency), were on glucocorticoid and mineralocorticoid 
replacement therapy at the time of the CRF test. Clinical data of the patients 
with secondary adrenal insufficiency are summarized in Table 2. At the time 
of the CRF test patients 9-12, 15-17 and 19 were on glucocorticoid 
maintainance therapy, whereas patients 13, 14 and 18 had never received 
glucocorticoid therapy. The CRF test was performed at 0900 h with the 
subjects fasting and at bed rest. Ovine CRF ( 100//g: Bachern, Torrance, CA) 
dissolved in 1 ml acid-saline (pH 2) was given as an intravenous bolus 
injection. Blood samples for ACTH and Cortisol assay were collected at -30, 
0, 5, 10, 20, 30,60,120 and 180 min via an indwelling i.v. cannula kept open 
with minute amounts of a diluted (10%) solution of heparin. The cannula 
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was inserted 30 min before CRF administration. Plasma ACTH and Cortisol 
were determined by specific RIAs as described previously (Pieters et al., 
1982). The limit of detection of the ACTH assay was 15 pg/ml. 
To avoid interassay variations all samples of individual patients were 
determined in the same assay. During the CRF test all patients continued 
hormonal replacement therapy, but the use of glucocorticoids stopped at 
least 24 h before each test. Statistical analyses were performed using 
Wilcoxon's test for paired observations (P-values denoted by P), Wilcoxon's 
two sample test (P — P*) and Spearman's rank correlation test (P = P**). The 
mean values ± 1 SEM are given, unless stated otherwise. 
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Figure I Individual ACTH responses to an intravenous bolus injection of 100^g ovine CRF 
(arrow) in 11 patients with secondary adrenal failure 1 he shaded area represents the mean ± 1 
SD in 10 normal subjects 
Table 1 Clinical data of the patients with primary adrenal failure 
Patient 
no 
1 
2 
3 
4 
5 
6 
7 
'8* 
Age 
(years) 
26 
21 
30 
37 
29 
41 
50 
26 
Sex 
F 
F 
M 
F 
M 
M 
M 
F 
Duration 
of disease 
(years) 
4 
1 
15 
1 
10 
8 
<1 
4 
Etiology 
Auto-immune 
Auto-immune 
Uncertain 
Auto-immune 
Uncertain 
Auto-immune 
Possibly tuberculous 
Uncertain 
Basal 
plasma ACTH 
(pg/ml) 
3900 
2500 
1860 
1950 
710 
640 
290 
98 
Basal 
plasma Cortisol 
(A/mol/l) 
0 02 
<0 02 
<0 02 
0 03 
0 12 
<0 02 
0 05 
0 39 
* This patient has only partial adrenal insufficiency Under basal conditions plasma Cortisol levels are in the normal range and plasma ACTH levels are only 
moderately elevated (100-300 pg/ml) There is no plasma Cortisol increase after insuhn-induced hypoglycaemia or ACTH administration, indicating 
diminished adrenal reserve Four years ago she had a classical Addisonian crisis, shortly after giving birth to a dead fetus At that time plasma Cortisol levels 
were very low (0.05-0 07 μπιοΙ/Ι) 
Table 2 Clinical data of the patients with secondary adrenal failure 
Patient Age Sex Diagnosis 
no. (years) 
Duration of Gluco- Hyper- Proven 
disease corticoid prolactin- deficiencies 
(years) treatment aemia 
Roentgenograms 
sellar region 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
72 
42 
58 
39 
76 
23 
58 
69 
67 
30 
15 
F 
F 
F 
F 
M 
M 
F 
F 
M 
M 
M 
Sheehan's syndrome 
Sheehan's syndrome 
Hypopituitarism 
of unknown origin 
Hypopituitarism 
of unknown origin 
Hypopituitarism, 
probably post-
encephalitis 
Hypopituitarism 
of unknown origin 
Hypopituitarism 
after removal of a 
large suprasellar 
craniopharyngioma 
Hypopituitarism 
suprasellar tumour 
Hypopituitarism 
of unknown origin 
Hypopituitarism, 
cerebral haemorrhage 
post-partum 
Hypopituitarism 
of unknown origin 
38 
2 
24 
14 
19 
14 
4 
1 
2 
14 
10 
+ 
+ 
+ 
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
ACTH, FSH, LH, TSH 
ACTH, FSH, LH, TSH, 
Prol 
ACTH, FSH, LH, TSH, 
Prol 
ACTH, TSH, Prol, hGH 
ACTH, FSH, LH, TSH, 
Prol 
ACTH, FSH, LH, TSH, 
hGH 
ACTH,FSH,LH, TSH 
ACTH, FSH, LH 
ACTH, hGH 
ACTH, hGH 
ACTH, FSH, LH, TSH, 
hGH, aVp 
Normal plain X-rays 
Normal plain X-rays 
Normal plain X-rays 
Normal plain X-rays 
Normal plain X-rays, 
normal CT 
Empty sella on CT 
Suprasellar tumour 
on CT 
Sellar enlargement 
on plain X-rays, 
suprasellar tumour 
on CT 
Normal plain X-rays, 
normal CT 
Normal plain X-rays 
Normal plain X-rays vo 
VO 
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RESULTS 
Patients with primary adrenal failure 
In all eight patients with proven Addison's disease, ACTH levels increased 
after ovine CRF injection from a basal value of 1494 ± 431 pg/ml to a peak 
value of 2601 + 1220 pg/ml at 10 min. Thereafter ACTH levels declined 
slowly to 1978 ±559 pg/ml at 180 min. Individual peak levels were obtained 
at variable intervals between 10 and 180 min. In none of the patients was the 
rise in ACTH followed by an increase in Cortisol. As compared to the healthy 
subjects, basal ACTH levels (P* < 0.001), absolute ACTH increments after 
ovine CRF (P* < 0.001) and peak ACTH levels (P* < 0.001), were 
significantly augmented in the group of patients with Addison's disease. 
o-eor 
0-50 -
О 4 0 -
О 3 0 -
0 2 0 -
O I O -
0 0 0 -
Time (mm) 
Figure 2. Individual Cortisol responses to an intravenous bolus injection of 100/ug ovine CRF 
(arrow) in II patients with secondary adrenal failure. The shaded area represents the mean + 1 
SD in 10 normal subjects. 
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However, on a percentage basis the increments of ACTH after CRF in 
Addison's disease (87 ± 20%) were not higher than in normal subjects. In the 
Addisonian patients no statistically significant correlation, as found in 
healthy subjects, could be demonstrated between basal plasma Cortisol levels 
and absolute ACTH increments (r = -0.40; P** > 0.10). However, in the 
group of Addisonian patients basal plasma ACTH levels correlated 
positively with the absolute ACTH responses after ovine CRF (r = +0.81; 
P** < 0.05). 
Patients with secondary adrenal failure 
Figure 1 and 2 show the individual ACTH and Cortisol responses to oCRF 
administration in the 11 patients with secondary adrenal failure. Figure 1 
clearly illustrates that the 11 patients can be divided into two groups, 
according to the ACTH responses after CRF administration: 
(A) those having little or no ACTH responses to ovine CR F (Patients 9-13) 
and 
(B) those having prolonged and pronounced ACTH responses with (in 
addition) in five of six cases a biphasic pattern with a delayed second 
peak (Patients 14-19). 
In four of the five patients in group A basal ACTH levels were lower than the 
limit of detection of the assay. Basal Cortisol levels in group A were 
significantly lower than in the healthy subjects (0.04 ± 0.01 //mol/1 vs 0.35 ± 
0.04 цто\Л; Ρ* < 0.01). In group В plasma ACTH levels rose without 
exception after injection of the peptide from a basal level of 24 ± 3 pg/ml to 
86 ± 14pg/ml at 20 min. Thereafter plasma ACTH levels slightly decreased 
to 79 ± 12 pg/ml at 30 min and again rose to a second peak of 144 ± 35 pg/ml 
at 180 min. In all patients of group В plasma ACTH rises were followed by 
marked increases of Cortisol from a baseline value of 0.05 ± 0.01 //mol/l (P* 
< 0.01 vs healthy subjects) to a peak level of 0.36 ± 0.04jumol/l at 180 min (Ρ 
< 0.05 vs t = 0 min). In four of the six patients of group В Cortisol levels were 
still rising at the end of the test. Maximum ACTH increases in group В (124 
± 34 pg/ml) were 2,5 times higher than those in the healthy subjects (49 ± 7 
pg/ml), although this difference lacks statistical significance (0.05 < P* < 
0.10). Maximum Cortisol increments in the patients of group В (0.32 ± 0.03 
цто\/\) were of a similar order of magnitude to those in the normal controls 
(0.26 ± 0.03 /rniol/l). 
DISCUSSION 
After the elucidation of the structure of ovine CRF by Vale et al. in 1981, 
numerous studies have been published on the effects of ovine CRF in 
patients with Cushing's syndrome (Orth et al., 1982; Müller et al., 1983a; 
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Pietersetal., 1983;Chrousosetal., 1984; Lytrasetal., 1984). However, only 
scarce and preliminary data have been presented about the use of this 
peptide as a diagnostic test in patients with adrenal failure (Tsukada et al., 
1984; Schulte et al., 1984). In this study, we report upon our experience of the 
administration of ovine CRF in 19 patients with adrenal failure, either 
primary or secondary. 
In comparison with normal subjects, eight patients with primary adrenal 
insufficiency demonstrated an elevated basal ACTH concentration and an 
augmented absolute ACTH response to ovine CRF. This finding confirms 
preliminary data of Müller et al. ( 1983b) in two, Nakahara et al. ( 1983) in two 
and Schulte et al. (1984) in three patients. Furthermore, we found in our 
patients with Addison's disease, unlike in healthy subjects, a highly 
significant and positive correlation between the basal ACTH concentrations 
and the CRF-induced absolute ACTH increments. We have recently shown 
that the ACTH and Cortisol responses to ovine CRF administration in 
healthy subjects are highly modulated by the basal Cortisol concentrations, 
i.e. the higher the basal plasma Cortisol levels, the lower the CRF-induced 
secretion of ACTH, and thereby, of Cortisol (Hermus et al., 1984). A similar 
negative correlation between these indices was also demonstrated by Lytras 
et al. (1984). 
Our findings in patients with Addison's disease are the first to demonstrate 
that, in the absence of Cortisol negative feedback, the absolute ACTH 
response to ovine CRF is augmented and determined by the basal ACTH 
concentration. It has been reported that adrenalectomy in rats is followed by 
an increase in hypothalamic immunoreactive CRF (Moldow et al., 1982) 
whereas there is very preliminary evidence that endogenous CRF levels are 
high in patients with Addison's disease (Tomori et al., 1983). Combining 
these data with our own results, it seems that exogenous CRF still stimulates 
ACTH secretion despite supposedly high endogenous CRF levels. 
In patients with secondary adrenal failure, who are known to be 
characterized by low basal ACTH and Cortisol levels unresponsive to 
insulin-induced hypoglycaemia, our study discloses two subsets of patients 
according to the ACTH responses after CRF administration: (A) those 
having little or no ACTH responses to ovine CRF and (B) those having 
prolonged and pronounced ACTH responses often accompanied by a 
biphasic pattern with a delayed second peak. It is feasible that the cause of 
adrenal insufficiency in the latter group is not at the level of the pituitary 
gland itself, but originates in the hypothalamus or at an even higher level. It 
appears that the pituitary gland of these patients -although it has probably 
not been stimulated by endogenous CRF for a long time- is still capable of a 
prompt release of large amounts of ACTH after CRF injection. The results 
of this study confirm very recent data of Tsukada et al. (1984) and Schulte et 
al. (1984), who showed a similar divergence in ACTH responses in 
103 
respectively 8 and 6 patients with secondary adrenal failure and reported a 
similar pattern of ACTH response in patients with supposedly hypothalamic 
failure. In five out of six of our patients who showed an overt ACTH increase 
after ovine CRF, a biphasic pattern was observed. This biphasic pattern of 
ACTH secretion after CRF stimulation has not been reported in healthy 
subjects tested in the morning hours, but it has been described when the CRF 
test is performed in the late afternoon (De Bold et al., 1983), at a time when 
plasma Cortisol levels are low. We therefore speculate that the exaggerated 
and possibly also the biphasic ACTH response to ovine CRF in the patients 
with presumed hypothalamic failure is uncovered by the lack of Cortisol 
feedback. Our patients with supposedly hypothalamic adrenal failure 
showed without any exception a Cortisol rise of normal magnitude after CRF 
injection. These data agree with those of Lytras et al. (1984), who 
demonstrated that six out of seven patients with secondary adrenal 
insufficiency had normal Cortisol responses to CRF. However, only shallow 
Cortisol rises occurred in most of the patients with presumed hypothalamic 
failure, reported by Tsukada et al. (1984) and Schulte et al. (1984). Our 
findings demonstrate that the adrenals of some, if not of most patients with 
secondary adrenal insufficiency maintain their ability to react to CRF-
induced ACTH increases for a long time, as has also been demonstrated for 
exogenous ACTH administration (Cunningham et al., 1983). Obviously our 
study gives no direct evidence that the patients of group A really have 
pituitary failure, whereas the patients of group В have hypothalamic or 
pituitary stalk damage. However, four out of five patients of group A had 
undetectable prolactin levels, whereas three of the patients of group В had 
hyperprolactinemia and the others had normal prolactin values. Because 
prolactin secretion by the pituitary gland is normally under tonic inhibitory 
control, this marked divergence in prolactin levels provides circumstantial 
evidence in favour of the hypothesis that patients of group A have pituitary 
lesions and patients of group В hypothalamic lesions, as was also suggested 
by Tsukada et al. (1984). Moreover, two patients of group A had Sheehan's 
syndrome, suggestive of a pituitary lesion, whereas two patients of group В 
had suprasellar tumours and one other patient of this group had diabetes 
insipidus, suggesting hypothalamic or pituitary stalk damage. 
Other releasing factors, such as TRH, LHRH and recently GHRH, have 
been used to discriminate between hypothalamic and pituitary diseases. 
However, the discriminatory power of single bolus injections of these 
hypothalamic peptides is poor. Further studies are necessary to demonstrate 
whether a single bolus injection of CRF can be reliably used to discriminate 
between primary hypothalamic or pituitary failure. However, it is clear that 
the CRF test does not make other classical tests, such as the insulin-tolerance 
test, which documents the integrity of the complete hypothalamo-pituitary-
adrenal axis, superfluous in the diagnosis of secondary adrenal insufficiency. 
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In our opinion, the combination of an insulin-tolerance test and a CRF test 
will provide optimal information; i.e. insufficient ACTH increase during the 
insulin-tolerance test will confirm the diagnosis of secondary adrenal 
insufficiency, whereas CRF administration may potentially differentiate 
pituitary from hypothalamic causes of this disorder. 
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Dr. C.W. Burke (The Radcliffe Infirmary, University of Oxford) commented 
in a Letter to the Editor in the December 1985 issue of Clinical Endo­
crinology (p.722): 
"Sirs, 
Dr. Hermus and his colleagues writing on the ACTH response to CRF in the 
June issue (pages 761-769) divide their results in ACTH deficient patients 
into two groups, on the basis of the Cortisol response to CRF. They then 
proceed to speculate that those in group A, patients 9-13, have pituitary 
failure whereas the patients in group В (numbers 14-19) who show a Cortisol 
response to CRF have hypothalamic failure; but they adduce no evidence 
whatever to distinguish the two groups pathologically. Perusal of table 1 
shows a complete overlap of diagnoses between the two groups. 
As evidence of hypothalamic damage the authors adduce the presence of 
hyperprolactinaemia in two patients, ignoring the fact that hyperprolacti-
naemia occurs in glucocorticoid insufficiency per se. For example it is seen in 
Addison's disease (Lever and McKerron, 1984; Refetoff et al 1972) and it is 
also seen in isolated ACTH deficiency (Burke et al 1979; Yamamoto et al 
1976). The presence of hyperprolactinaemia therefore does not distinguish 
primary from secondary hypoadrenalism, never mind pituitary from 
hypothalamic ACTH failure." 
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We replied (Clinical Endocrinology, 1985, 23: 724): 
"Sirs, 
Dr. Burke incorrectly states that we divided our patients with secondary 
adrenal failure on the basis of the Cortisol response to CRF. This would not 
be permissible, because in secondary adrenal insufficiency Cortisol responses 
to ACTH or CRF administration may vary, depending mainly on the 
severity and the duration of disease. Therefore we divided our patients 
Table l Clinical and biochemical data of 5 additional patients with secondary adrenal insufficiency 
Patient Age Sex 
no (years) 
Diagnosis 
Hypopituitarism 
after removal of 
a pituitary 
macroadenoma 
Hypopituitarism 
after removal of 
a large intra- and 
suprasellar cranio-
pharyngioma 
Hypopituitarism, 
large suprasellar 
craniopharyngioma 
Duration 
of disease 
(years) 
1 
15 
1 
Glucocor-
ticoid 
treatment 
+ 
+ 
-
Hyper-
prolac-
tinaemia 
-
-
+ 
Proven defi-
ciencies 
ACTH, FSH, LH, 
TSH, Prol, hGH 
ACTH, FSH, LH, 
TSH, Prol, hGH 
ACTH, FSH, LH, 
TSH, hGH 
Roentgenograms 
sellar region 
No tumour on 
CT 
Sellar enlar-
gement on 
plain X-rays, 
no tumour on 
CT 
Sellar enlar-
gement on 
plain X-rays, 
20 54 
21 30 
M 
22 22 M 
(supra (-sellar 
tumour on CT 
23 33 M Hypopituitarism, 
large suprasellar 
craniopharyngioma 
15 ACTH, FSH, LH, 
TSH, hGH 
Sellar enlar-
gement on 
plain X-rays, 
(supra )-sellar 
tumour on CT 
24 54 M Hypopituitarism 
after removal of 
a pituitary macro-
adenoma with supra-
sellar extension 
ACTH, FSH, LH, 
TSH, hGH 
Sellar enlar-
gement on 
plain X-rays 
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Table 2. Basal ACTH and Cortisol values and their increases after a bolus injection of 100//g 
oCRF in S additional patients with secondary adrenal insufficiency 
Patient no. 
20 
21 
22 
23 
24 
basal ACTH 
(pg/ml) 
< 1 5 
< 1 5 
< 1 5 
18 
< 1 5 
Δ max ACTH 
(pg/ml) 
0 
0 
136 
165 
42 
Basal Cortisol 
(//mol/l) 
<0.02 
<0.02 
0.14 
0.08 
0.06 
Û max Cortisol 
(μιηοΙ/Ι) 
0 
0 
0.49 
0.39 
0.53 
strictly according to the ACTH response after CRF. 
The vital point is to demonstrate that patients with secondary adrenal 
failure, who do not respond to CRF with an ACTH increase really have a 
pituitary lesion. Recently we have studied 5 additional patients with 
secondary adrenal failure (Table 1 and 2) and analysis of the total group of 
16 patients provides new evidence of this concept: 
I) Six of seven patients with supposedly pituitary failure (group A, 
patients 9-13 and 20-21) had undetectable prolactin levels, while the 
patients with supposedly hypothalamic failure (group B) were all 
normo- or hyperprolactinaemic. This prolactin deficiency in group A 
patients, even despite the prolactin enhancing effect of glucocorticoid 
deficiency, is highly suggestive of a pituitary lesion. 
II) In group A none of 3 GH deficient patients, none of 4 TSH deficient 
patients and none of 3 LH/FSH deficient patients responded to a 
bolus injection of respectively GRF, TRH and LHRH. 
In group В the corresponding numbers were 4 out of 5,5 out of 5 and 4 
out of 7 patients. 
III) Basal ACTH levels in group A were significantly lower than in group В 
( 16 ± 1 vs 21 ± 2 pg/ml, Ρ < 0.05) as were the basal Cortisol levels (0.03 
± 0.01 vs 0.07 ± 0.01 /umol/1, Ρ < 0.05). This fits well into the concept: 
we speculate that hypothalamic disease will result in a lesser degree of 
adrenal failure than primary pituitary disease because intact cortico-
tropic cells, even when deprived of hypothalamic stimulation, will 
probably secrete small amounts of ACTH." 
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3.4 COEXISTENCE OF HYPOTHALAMIC AND PITUITARY FAILURE AFTER SUC-
CESSFUL PITUITARY SURGERY IN CUSHING's DISEASE? ' 
A.R.M.M .Hermus, G.F.F.M. Pieters, G.J. Pesman*, E. Meijer**, A.G.H. 
Smals, Th.J. Benraad* and P.W.C. Kloppenborg 
Department of Medicine, Division of Endocrinology; Department of 
Experimental and Chemical Endocrinology*; Department of Neurosur-
gery**, University of Nijmegen, Nijmegen, The Netherlands. 
SUMMARY 
The type of secondary adrenal failure, which occurs after successful pituitary 
surgery in Cushing's disease was studied using CRH administration. Eight 
patients with Cushing's disease were studied in the immediate postoperative 
period (9-18 days) of successful pituitary surgery. The results in these 
patients were compared with those in 13 healthy subjects, 7 patients with 
secondary adrenal failure of the pituitary type and 9 patients with secondary 
adrenal failure of the hypothalamic type. In all postoperative Cushing 
patients, except one, clear ACTH and Cortisol responses occurred after 
CRH, demonstrating hypothalamic adrenal failure in these patients. This 
demonstration of hypothalamic adrenal failure after neurosurgery strongly 
argues against a pivotal role for endogenous CRH in the pathogenesis of 
Cushing's disease in these patients. The mean ACTH response to CRH in the 
postoperative Cushing patients was significantly lower than that in patients 
with adrenal failure of the hypothalamic type. This suggests the presence of 
pituitary failure in post-adenomectomy Cushing patients. 
In conclusion, this study provides arguments that the secondary adrenal 
failure after adenomectomy in Cushing's disease is caused by both hypo-
thalamic and pituitary failure. 
INTRODUCTION 
Successful treatment of Cushing's disease by pituitary surgery leads to a 
transient period of postoperative adrenal failure (1-4). It has been demon-
1
 Presented in part at the Second Meeting of the European Neuroendocrine Association 
(Abstract 14), Milan, October 15-17, 1985. 
Submitted for publication 
по 
strated that the adrenal failure in these patients is of the secondary type (1-4). 
It is not yet known whether this secondary adrenal failure is caused by 
hypothalamic or pituitary suppression, or both. Demonstration of hypo­
thalamic dysfunction after treatment for Cushing's disease has etiological 
implications, because this would strongly argue against a central role for 
endogenous CRH in the pathogenesis of Cushing's disease. 
Recently others (5,6) and we (7,8) adduced evidence that the CRH test can 
discriminate between hypothalamic and pituitary causes of secondary 
adrenal insufficiency. The present study was designed to characterize the 
type of secondary adrenal failure in patients with Cushing's disease, shortly 
after successful pituitary surgery by using CRH administration. 
PATIENTS AND METHODS 
Pituitary-adrenal responsiveness to ovine CRH was studied in eight patients 
with Cushing's disease in the preoperative and immediate postoperative 
period (9-18 days) of successful pituitary surgery. Clinical and biochemical 
data of these patients are given in Table 1. All female patients were 
premenopausal. Preoperatively all 8 patients had clear (hyper-) responses of 
ACTH and Cortisol after CRH administration. Patients 1 and 7 were 
operated via a transfrontal approach, the other six patients via the 
transsphenoidal route. On the day of surgery and during the first two 
postoperative days the patients received 75 mg prednisolone intravenously. 
Thereafter glucocorticoid therapy was tapered off and stopped seven days 
after the operation, i.e. at least 48 hrs before the postoperative CRH test. 
Postoperative endocrine evaluation revealed hypocortisolism in all cases, 
necessitating glucocorticoid replacement therapy which was started after the 
CRH test. Except in patient 1, who developed secondary hypothyroidism 
and hypogonadism after operation, no further replacement therapy was 
necessary. 
The results in these patients were compared with data from 13 healthy 
subjects (8 men, aged 24 ± 4 years (mean ± SD) and 5 women, aged 31 ± 14 
years) and with that of 16 patients with secondary adrenal failure, due to 
various causes. The clinical data and the results of the CRH tests in these 
patients have been published previously (7,8). According to the ACTH 
responses after CRH administration, these 16 patients were subdivided into 
those supposed to have pituitary (n=7) or hypothalamic (n=9) failure. 
The CRH test was performed at 9 a.m. with the subjects fasting and at bed 
rest. Ovine CRH (100/ig: Bachern, Torrance, CA) dissolved in 1 ml acid-
saline (pH 2) was given as an intravenous bolus injection. Blood samples for 
ACTH and Cortisol assay were collected at -30, 0, 5, 10, 20, 30,60, 120 and 
180 min via an indwelling i.v. cannula kept open with minute amounts of a 
diluted (10%) solution of heparin. The cannula was inserted 30 min before 
Table 1 Clinical and biochemical data of eight patients with pituitary-dependent Cushing's disease 
Patient 
no 
1 
2 
3 
4 
5 
6 
7 
8 
Age 
(years) 
53 
20 
35 
32 
40 
38 
24 
34 
Sex 
M 
F 
F 
F 
M 
M 
F 
F 
Duration 
of disease 
(years) 
I 
2 
0,5 
1 
1 
5 
2 
3 
Basal ACTHa 
(pg/ml) 
85 
51 
140 
62 
35 
49 
39 
53 
Pre-operatively 
Basal cortisolb 
<//g/dl) 
27,2 
21,0 
24,3 
21,7 
18,5 
15,2 
21,0 
27,5 
Cortisol after 
2 mg DXM q.i.d. 
for 2 days 
(pg/dl) 
2,5 
0,7 
8,7 
9,1 
2,2 
U 
7,2 
6,9 
Postoperative 
CRH test on 
day 
15 
10 
15 
18 
9 
17 
13 
10 
Post-operatively 
Length of 
follow-up 
(months) 
17 
died on day 
Glucocorti­
coid re­
placement 
(months) 
>17 
25 p.o. 
(pulmonary embolism) 
41 
15 
12 
9 
9 
35 
5=41 
11 
ЗИ2 
^ 9 
^ 9 
17 
a Basal ACTH represents the mean of 4 samples taken at 9 a.m. (normal value < 75 pg/ml). 
b Basal Cortisol represents the mean of 4 samples taken at 9 a.m. (normal range 6,9 - 19,9/ig/dl). 
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CRH administration. Plasma ACTH and Cortisol were determined by 
specific RIAs as described previously (9). The limit of detection of the ACTH 
assay was 15 pg/ml. To avoid interassay variations all samples from the 
individual patients were determined in the same run. Statistical analyses 
were performed using Wilcoxon's two sample test. The mean values ± 1 
SEM are given, unless stated otherwise. 
RESULTS (Figure 1-3, Table 2) 
Healthy subjects and patients with secondary adrenal failure of the pituitary or 
hypothalamic type 
Table 2 gives the basal values for ACTH and Cortisol and the peak values and 
maximal increments after CRH administration for these J groups. Maximal 
ACTH increases after CRH were significantly higher (P < 0,05) in the 
patients with secondary adrenal failure of the hypothalamic type than those 
in the healthy subjects, as were the maximal Cortisol increases (P < 0,05). 
However, despite ACTH hyperresponsiveness peak Cortisol levels after 
CRH were significantly lower (P< 0,05) in these patients than in the healthy 
subjects. 
Patients with Gushing's disease after successful pituitary surgery 
Figure 1 illustrates the individual ACTH and Cortisol responses to 100 yug 
ovine CRH in the immediate postoperative period in the eight patients with 
pituitary-dependent Cushing's disease. In six of the seven patients, in whom 
ACTH levels were determined, basal ACTH was close to (in one patient) or 
lower than (in five patients) the limit of detection of the ACTH assay. In all 
eight patients basal Cortisol was less than 3,3 jug/dl, except in one patient 
who had a basal Cortisol level of 7,2/L/g/dl. Figure 1 shows that in all Gushing 
patients after surgery CRH administration caused pituitary-adrenal acti-
vation, except in patient 3. This patient could not be weaned from 
glucocorticoid replacement therapy as yet (41 months after surgery). 
In Table 2 and Figure 2 the basal values for ACTH and Cortisol and their 
responses after CRH administration in the eight patients with Cushing's 
disease after operation are compared with the corresponding values before 
operation. In spite of a much higher baseline Cortisol level preoperatively, 
the ACTH response to CRH was more pronounced before surgery in 
comparison with after surgery in all patients. There was no significant 
correlation between the response of the pituitary-adrenal axis to CRH in the 
individual patients on both occasions. 
Figure 3 illustrates the mean ACTH and Cortisol responses to CRH in the 
eight Gushing patients post-adenomectomy and compares these responses 
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ACTH 
(pg/ml) 
100 
8 0 
6 0 
4 0 -
2 0 
oCRHiv 
CUSHING'S disease 
after hypox ( η = θ ) 
C o r t i s o l 
( > i g / 1 0 0 m l ) 
2 0 -
1 5 -
10-
5-
— ι 1 -
-30 О 6 0 120 180 
time (min ) 
Figure 1 Individual ACTH and Cortisol responses to an intravenous bolus injection of 100 ^g 
ovine CRH in 8 patients with pituitary-dependent Cushing's disease in the immediate 
postoperative period (9-18 days) of successful pituitary surgery (hypox. = pituitary surgery). 
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ACTH — 
( pg/ml ) 
240-
200-
160-
120 
80 
40 
oCRH ¡ ν. CUSHING'S disease (η=β) 
Cortisol 
(μς/ΙΟΟ ml) 
40-\ 
30-
20-
10-
untreated 
after hypox 
I I 
-30 О 6 0 120 1ΘΟ t ime (mm) 
Figure 2. Mean ± SEM plasma ACTH and Cortisol levels after an i.v. bolus injection of 100//g 
ovine CRH in 8 patients with pituitary-dependent Cushing's disease before and immediately 
(9-18 days) after successful pituitary surgery (= hypox ). 
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ACTH 
(pg/hnl) 
140 
100-
cortisol 
(^g/100 ml) 
•30 O 120 180 
t ime (min) 
Figure 3. Mean ± SEM plasma ACTH and Cortisol levels after an i.v. bolus injection of 100 /ig 
ovine CRH. 
• · normal subjects (n=13) 
л Δ patients with secondary adrenal failure, pituitary type (n=7) 
о о patients with secondary adrenal failure, hypothalamic type (n=9) 
π α patients with pituitary-dependent Cushing's disease, shortly after successful pit­
uitary surgery (n=8) 
116 
with those of the healthy subjects and the patients with secondary adrenal 
failure of the pituitary or hypothalamic type. The maximal ACTH and 
Cortisol responses after CRH in the Gushing patients after surgery were 
significantly higher than those in the patients with secondary adrenal failure 
of the pituitary type, but significantly lower than those in the patients with 
secondary adrenal failure of the hypothalamic type (Table 2). 
DISCUSSION 
It is still unknown whether the secondary adrenal failure associated with 
successful selective removal of ACTH secreting pituitary adenomas is 
caused by insufficient hypothalamic or pituitary drive of adrenocortical 
function, or by a combination of both. A number of studies have 
demonstrated that CRH administration discloses two subsets of patients 
with secondary adrenal failure: (i) those who have little or no ACTH 
responses to CRH and (ii) those who have prolonged and pronounced 
ACTH responses to CRH (5-8). A number of clinical and biochemical data 
support the view that the secondary adrenal failure in the first group of 
patients is caused by a pituitary lesion and in the second group by a 
hypothalamic lesion (5-8). It has to be noted that the final proof for this 
concept is still lacking. Nevertheless, a conclusion that can be safely drawn is 
that patients with secondary adrenal insufficiency, who respond to exo-
genous CRH, have at least hypothalamic failure. 
The present study illustrates that in the immediate postoperative period all 
eight patients cured of Cushing's disease were hypocortisolemic, whereas 
CRH administration caused pituitary-adrenal activation in all but one. 
Müller et al ( 10) and Chrousos et al ( 11) also demonstrated responsiveness of 
the pituitary-adrenal axis to CRH shortly after successful neurosurgery in 
one and three patients respectively. As is reasoned above, this pattern 
strongly suggests insufficient hypothalamic drive in these Gushing patients 
immediately after pituitary surgery. This observation strongly argues 
against a pivotal role for endogenous CRH in the pathogenesis of Cushing's 
disease in these patients. Recent observations of low CRH levels in 
cerebrospinal fluid (12) as well as in peripheral plasma (13) in pituitary-
dependent Cushing's disease are in line with this conclusion. 
This study also shows that the mean maximal ACTH response after CRH 
in the Gushing patients after surgery was significantly lower than that in an 
earlier published group of patients with secondary adrenal failure of the 
hypothalamic type (7,8). This suggests that at the time of testing the pituitary 
reserve in the postsurgery Gushing patients is subnormal, either due to the 
surgical procedure per se or - and that seems more likely - as a result of the 
suppressive action of preoperative hypercortisolism on the non-tumorous 
corticotrophs, which frequently show Crooke's changes (1) and contain less 
Table 2. Plasma ACTH and Cortisol: Basal values, peak values after 100//g oCRH and maximal increments after 100//g oCRH in 13 healthy subjects, 7 
patients with secondary adrenal failure of the pituitary type, 9 patients with secondary adrenal failure of the hypothalamic type and 8 patients with Cushing's 
disease (CD) before and after successful pituitary surgery 
Plasma ACTH (pg/ml)* Plasma Cortisol (/ig/dl)3 
I Healthy subjects 
II Sec.adrenal failure, 
pituitary type 
III Sec.adrenal failure, 
hypothalamic type 
IV CD before surgery 
V CD after successful 
surgery 
Basal value Peak value 
25 ± 2 67 ± 6 
16± 1 
21 ± 2 
70 ± 12 
20 ± 3 
19 ± 2 
139 ± 2 2 
249 ± 61 
45 ± 1 0 
Δ Max 
42 ± 6 
3 ± 2 
Basal value Peak value дМах 
12,3 ± 1 , 1 21,7 ± 0 , 7 9,4 ± 1 , 1 
1,1 ± 0 , 4 1,8 ± 0 , 7 0,4 ± 0 , 4 
118±22b 2,5 ± 0 , 4 15,6 ± 1,4b 1 3 , 4 ± l , l b 
179 ± 5 3 21,4 ± 1 , 8 42,0 ± 4 , 3 20,6 ± 4,0 
26 ± l i e d 2,2 ± 0 , 7 10,1 ± 1 , 8 8,0 ± 0,4C,d 
a m e a n ± S E M b P < 0 , 0 5 v s I c P < 0 , 0 5 v s I I d P < 0 , 0 5 v s I I I 
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than normal ACTH (14) in Cushing's disease. It cannot be excluded, but it 
seems unlikely, that the postoperative treatment with glucocorticoids during 
7 days has influenced the test results in these patients, who had long-standing 
hypercortisolism preoperatively. Insufficient ACTH responsiveness to CRH 
in the immediate postoperative penod after neurosurgery for Cushing's 
disease has also been suggested by Orth et al (15) in two patients and by 
Hotta et al (16) in five patients. 
In summary, our study provides arguments for the conclusion that the 
secondary adrenal failure after successful pituitary surgery for Cushing's 
disease is caused by both hypothalamic and pituitary suppression. This 
coexistence of hypothalamic and pituitary failure postoperatively fits well in 
the concept that long-term hypercortisolism suppresses the hypothalamic-
pituitary-adrenal axis at both the hypothalamic and pituitary level. 
REFERENCES 
1 Tyrrell J, Brooks R, Fitzgerald P, Cofoid P, Forsham P, Wilson С 1978 Cushing's 
disease Selective trans-sphenoidal resection of pituitary microadenomas New Engl J 
Med 298. 753. 
2 Kuwayama A, Kageyama N, Nakane T, Watanabe M, Каше N 1981 Anterior pituitary 
function after transsphenoidal selective adenomectomy in patients with Cushing's 
disease J Clin Endocrinol Metab S3. 165 
3. Fitzgerald P, Aron D, Findling J, et al 1982 Cushing's disease transient secondary 
adrenal insufficiency after selective removal of pituitary microadenomas; evidence for a 
pituitary origin. J Clin Endocrinol Metab 54 413 
4. Ludecke D 1985 Transient ACTH defect obligatory for cure of Cushing's disease 
Abstract 106, 2nd Meeting of the European Neuroendocrine Association, Milan 1985 
5 Tsukada T, Nakai Y, Koh T, et al 1984 Plasma adrenocorticotropin and Cortisol 
responses to ovine corticotropin-releasing factor in patients with adrenocortical 
insufficiency due to hypothalamic and pituitary disorders J Clin Endocrinol Metab 58 
758 
6. Schulte H, Chrousos G, Avgennos Ρ , et al 1984 The corticotropin-releasing hormone 
stimulation test a possible aid in the evaluation of patients with adrenal insufficiency. J 
Clin Endocrinol Metab 58 1064 
7 Hermus A, Pieters G, Pesman G, Smals A, Benraad T, Kloppenborg Ρ 1985a ACTH and 
Cortisol responses to ovine corticotrophin-releasing factor in patients with primary and 
secondary adrenal failure. Clin Endocrinol 22 761 
8 Hermus A, Pieters G, Pesman G, Smals A, Benraad T, Kloppenborg Ρ 1985b ACTH and 
Cortisol responses to ovine corticotrophin-releasing factor in patients with primary and 
secondary adrenal failure. Clin Endocrinol 23 724 (Letter to the Editor). 
9. Pieters G, Smals A, Pesman G, Goverde H, Meijer E, Kloppenborg Ρ 1982 ACTH and 
Cortisol responsiveness to thyrotropin-releasing hormone and luteinizing hormone-
releasing hormone discloses two subsets of patients with Cushing's disease J Clin 
Endocrinol Metab 55 1188 
10 Muller О, Dorr Η, Hagen В, Stalla G, V Werder К 1982 Corticotropin releasing factor 
(CRP)- stimulation test in normal controls and patients with disturbances of the 
hypothalamo-pituitary-adrenal axis Klin Wochenschr 60 1485 
11 Chrousos G, Schulte H, Oldfield E, Gold Ρ, Cutler G, Lonaux D 1984 The 
corticotropin-releasing factor stimulation test' an aid in the evaluation of patients with 
Cushing's syndrome New Engl J Med 310 622 
119 
12. Tomón Ν, Suda Τ, Tozawa F, Demura H, Shizume К, Mouri Τ 1983 Immunoreactive 
corticotropin-releasing factor concentrations in cerebrospinal fluid from patients with 
hypothalamic-pituitary-adrenal disorders. J Clin Endocrinol Metab 57- 1305. 
13 Suda Τ, Tomón Ν, Yajima F, el al 1985 Immunoreactive corticotropin-releasing factor 
in human plasma Abstract 991, 67th Annual Meeting of the Endocrine Society, 
Baltimore 1985. 
14 SudaT, Demura H, Demura R.Jibiki K, Tozawa F, Shizume К 1980 Anterior pituitary 
hormones in plasma and pituitanes from patients with Cushing's disease J Clin 
Endocrinol Metab 51. 1048. 
15 Orth D, DeBold С, DeCherney G, et al 1982 Pituitary microadenomas causing 
Cushing's disease respond to corticotropin-releasing factor. J Clin Endocrinol Metab 
55: 1017 
16 Hotta M, Shibasaki T, Suda Τ, Ling Ν, Shizume К 1985 The use of the corticotropin-
releasing hormone test to monitor the recovery of patients with Cushing's disease or 
Cushing's syndrome due to an adrenal adenoma after adenomectomy Endocrinol 
Japon 32. 113. 

Chapter 4 
Safety of corticotropin-releasing hormone 
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In this thesis our experience with the intravenous administration of CRH in 
man is reported. Between May 1982 and December 1985 we performed 330 
"CRH tests". 25% of the tests were done in healthy volunteers and 75% in 
patients with a variety of endocrine disorders. In 20% of the tests human 
CRH was used and in 80% ovine CRH. CRH was obtained from Bachem 
Inc., Torrance, CA, U.S.A. As described in Appendix 1, the product was 
prepared for human use by the Department of Clinical Pharmacy, Sint 
Radboud Hospital (Drs.J.H.Bakker). 
The CRH tests were carried out as described in the methods sections of the 
previous chapters. During each test blood pressure, pulse rate and electro­
cardiogram (Roche "Arteriosonde" 1225, monitor 103) were monitored. 
In the vast majority of patients the test procedure was much better 
tolerated than more classical stimulation tests of the pituitary-adrenal axis, 
e.g. the insulin-hypoglycemia test, the lysine-vasopressin test and the 
pyrogen test. In most subjects facial flushing occurred after the admini­
stration of 100-200 μg CRH, in some subjects together with mild dyspnea 
(subjective sensation of shortness of breath, accompanied by the objective 
finding of deep and more rapid respirations, lasting 30 sec or less). In seven 
tests we observed an adverse reaction. 
ADVERSE REACTIONS 
During the first year of this study we used a relatively high dose of 200 μg 
ovine CRH. In that period we observed adverse reactions in four patients. In 
two patients with pituitary-dependent Cushing's disease and in one with 
secondary adrenal insufficiency an "absence-like" loss of consciousness was 
seen which started within a few seconds of the injection of CRH and lasted 
for from 10 sec to 5 min. In one patient with secondary adrenal failure (case 
A, Appendix 2) a profound fall in blood pressure, followed by asystole 
occurred after CRH administration. 
We reported these adverse reactions in a Letter in The Lancet ( 1 ) and sent 
a vial with ovine CRH from the batch, which had given the adverse reaction 
in patient A, to Dr. P.J. Lowry (Protein Hormone Unit, St. Bartholomew's 
Hospital, London) for analysis. No impurities were found in the prepa­
ration. Schulte et al (National Institutes of Health, Bethesda, USA) (2) in a 
reaction to our report suggested that the side-effects, described by us, were 
due to the relatively high dose of CRH. From February 1983 onwards we 
lowered the dose of CRH to 100 ^g. Thereafter we never again observed a 
disturbance of consciousness after CRH injection. Our finding that 100/yg 
ovine CRH does not cause a lowering of diastolic blood pressure in healthy 
subjects, whereas 200//g ovine CRH decreases diastolic blood pressure by 14 
mm Hg on the average (Chapter 2.3) strengthened our belief of a dose-
dependency of the observed side-effects. 
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During the next three years hypotension during a CRH test occurred in 
three cases (patients В to D, Appendix 2). However, the delay of 21/2 hours 
between the injection of CRH and the fall in blood pressure in patient B, 
respectively the beginning of the symptoms before the injection of CRH in 
patient C, makes it unlikely that in these cases the fall in blood pressure is 
caused by CRH itself. In both patients a vaso-vagal reaction is more likely, 
although we cannot rule out that the symptoms were aggravated by CRH. 
A third hypotensive episode with bradycardia occurred in May 1985 in a 25 
year old woman with secondary adrenal failure after successful neurosurgery 
for pituitary-dependent Cushing's disease three months earlier (case D, 
Appendix 2). It has to be stressed that in this woman the fall in blood 
pressure occurred afterinfusion of as less as 55 μg ovine CRH, whereas bolus 
injection with 100 μg ovine or human CRH in this patient at three previous 
occasions had caused no cardiovascular adverse effects at all. 
Meanwhile we had received the answers to a questionnaire, concerning 
side-effects of CRH administration in man, which we had sent to 9 research 
centers with major experience with CRH in humans. The names of these 
centers as well as some details about the CRH preparations and their use are 
given in Table 1. One case of hypotension after CRH in a healthy subject, 
who fainted after venepuncture and before receiving CRH and whose blood 
pressure dropped further at 5 min after CRH from 90 to 60 mmHg systolic 
was reported by Espiner (Cfr. our case C). None of the other investigators 
reported hemodynamic problems after CRH administration. 
We wondered again whether the CRH preparation used by us contained 
some impurities and once more we decided to send samples from our human 
CRH preparation (from the batch, used in patient C) and from our ovine 
CRH preparation (from the batch, used in patient D) to an independent 
investigator (Dr. G.P. Chrousos, National Institutes of Health, Bethesda 
U.S.A.) for analysis. Both the human and ovine CRH vials were found to be 
sterile and non-pyrogenic by the Bureau of Biologies, FDA. HPLC analysis 
of our product compared to the NIH product showed similar retention times 
and peak heights (i.e. similar identity and quantity) and no evidence of 
impurities. 
Then we wondered whether the hypotensive reaction in patient D could be 
caused by an interaction between CRH and the heparin solution (see 
Appendix 1), still present in the intravenous cannula after flushing. A strong 
argument for an interaction between both molecules provided the obser­
vation by the NIH workers that the addition of 500 lU/ml heparin to ovine 
CRH resulted in a complete loss of the CRH peak on HPLC. Further studies 
(in collaboration with Professor C.W. Hilbers, Department of Biophysical 
Chemistry, University of Nijmegen) to prove and characterize this possible 
interaction between CRH and heparin are in progress. We think it is not 
unlikely that the hypotension in patient D is caused by an interaction 
Table I. Research centres participating in the questionnaire about the side-effects of CRH. Some details on the CRH preparations and their use in these 
centers. 
Author CRH synthesized by Dose Dissolved in 
G.P. Chrousos, NIH Bethesda, U.S.A. 
D.N. Orth, Nashville, U.S.A. 
G M. Besser, London, U.K. 
G. Copinschi, Brussels, Belgium 
O.A. Müller, München, F.R.G. 
H.M. Schulte, Essen, F.R.G. 
E.A. Espiner, Christchurch, New Zealand 
H. Imura, Kyoto, Japan 
M. Nakahara, Tokyo, Japan 
This study 
Bachem Inc. 
Dr. J. Rivier (Salk) 
Dr. D. Coy (New Orleans) 
U.C.B. Bioproducts, Brussels 
Bachem Inc. 
Bachem Inc. 
Bachem Inc. 
Peptide Institute, Osaka 
Dr. N. Ling (Salk) 
Bachem Inc. 
l^g /kg 
1 Aig/kg 
100 ¿ig 
50 μ% 
100 μ% 
l^g/kg 
200 «g 
100 ¿/g 
100 A/g 
100-200 μα 
Sterile water with 5% mannitol 
Saline, containing 10% mannitol, 0,25% 
human serum albumine and 0,9% benzyl 
alcohol. 
Acid-saline (pH 2) 
Acid-saline (pH 2) 
Acid-saline (pH 2) 
Sterile water with 5% mannitol 
Acid-saline 
0,9% NaCl 
0,9% NaCl 
Acid-saline (pH 2) 
126 
between CRH and heparin, comparable with the well-defined potentiating 
effect of heparin on protamine-induced hypotension (3). However, it has to 
be noted that in preliminary experiments m anaesthetized dogs and in 
conscious spontaneously hypertensive rats (in collaboration with Dr. J. F M. 
Smits, Department of Pharmacology, University of Maastricht) we were not 
able to prove a potentiation of the hemodynamic effects of CRH injection by 
mixing CRH with heparin (data not yet reported). 
Preliminary conclusions 
1. The experience with CRH in a number of qualified centres all over the 
world demonstrates that ovine CRH in doses of 100//g or less is a safe 
agent for testing the pituitary-adrenal axis in man. 
2 The major adverse effects observed in a small minority of patients after 
CRH injection in our center are not caused by an impurity of the 
preparation The side-effects occurring in four patients during the first 
year of this study were most likely caused by a too high dose of the 
peptide The only major hypotensive reaction, unequivocally related 
with the lower dose of CRH may be caused by a not yet delineated 
interaction between CRH and heparin Therefore we recommend to 
omit the use of heparin solutions to keep open ι v. cannulas in CRH test 
procedures. 
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APPENDIX 1 
Preparation of CRH by the Department of Clinical Pharmacy, Sint Radboud 
Hospital, University of Nijmegen, The Netherlands 
CRH, either ovine or human, obtained in lyophihzed form from Bachern 
Inc., Torrance, CA, USA, is dissolved in a 2% aqueous solution of lactose 
and sterilized by passage through a 0,2/im cellulose acetate filter (Schleicher 
and Schuell, FPO 30/3) Containers with 1 ml of solution are freezedned. 
The lyophihzed product is stored at -180C in sterile vials under vacuum (1 
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vial containing 100 μ% CRH and 20 mg lactose). Immediately before 
administration the lyophilized material is dissolved in 1 ml acidified saline 
(HCl-NaCl, pH 2)/100 //g CRH. Pyrogen tests ("Pyrogent test", Mallin-
ckrodt) are regularly carried out 
Preparation of a /0% solution of heparin, used for prevention of clotting in the 
i.v. line 
One ml of heparinum natricum (Tromboliquine, Organon Teknika, Boxtel, 
Holland; 1 ml = 5000 I.U. heparin) is diluted in 9 ml NaCl 0,9% to a final 
solution of 500 I.U. heparin/ml. 
APPENDIX 2 
Case reports 
Patient A is a 58 year old woman on cortisone and triiodothyronine 
replacement therapy after removal of a large craniopharyngioma four years 
earlier, who had a Spitz-Holter drain for treatment of internal hydroce­
phalus. 
On February 15th, 1983, she received 200/ug ovine CRH as a bolus injection 
after withdrawal of cortisone for 24 hours. Within 3 minutes of the injection 
of CRH her systolic blood pressure dropped from 109 to 64 mmHg, followed 
by a decrease in pulse rate from 81 to 39 /min after 7 minutes, at which time 
an ECG revealed an AV-junctional rhythm. Immediately afterwards 
asystole ensued, which could immediately be reversed by a precordial blow. 
Thereafter the heart regained a sinus rhythm of 72/min and the blood 
pressure returned to normal. This patient had no history of signs or 
symptoms of heart disease and an ECG was normal before and after CRH 
testing. 
Patient В is a 72 year old woman, known since 1970 with hypopituitarism, on 
replacement therapy with cortisone and thyroxine. On April 4th, 1984, she 
received a bolus of 100 ¿ig ovine CRH after withdrawal of cortisone for 24 
hours. During the first hours after CRH injection she had a stable blood 
pressure (160/90 mmHg). Two and a half hour after the administration of 
CRH she complained of dizziness, despite being in recumbent position. At 
that time the pulse rate was 50/min and blood pressure was immeasurably 
low. After injection of 1/4 mg atropine and infusion of 250 ml plasma blood 
pressure and pulse rate normalized within 5 minutes. An ECG and results of 
blood chemistry excluded the possibility of myocardial injury. 
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Patient С is a 24 year old healthy, well-trained, male medical student. A 
complete physical examination, routine biochemistry and an ECG were 
completely normal. On March 27th, 1985, he was tested with human CRH. 
An i.v. forearm cannula was inserted one hour before CRH injection. Blood 
pressure and pulse rate before the injection of the peptide were 108/77 
mmHg respectively 52/min. At the moment of injection he said he feeled 
unhappy and dizzy, which started 5 seconds before the injection. The 
injection was immediately terminated and he received only 50 //g in stead of 
100 //g human CRH. Immediately afterwards the ECG revealed an AV-
junctional rhythm of 33/min and the blood pressure was immeasurably low. 
The patient was laid down in Trendelenburg position, 1/2 mg atropine was 
injected and plasma infusion was started. Within 5 min after the start of the 
symptoms blood pressure increased to 80/60 mmHg and 10 min later after 
injection of another 1/4 mg atropine, sinus rhythm restored. An ECG 
revealed no abnormalities any longer. It has to be stressed that the patient 
never lost consciousness during this period. 
Patient D is a 25 year old woman with pituitary-dependent Cushing's 
disease. On August 29th, 1984, she was tested with a bolus injection of 100//g 
ovine CRH. On September 7th, 1984, she received 100 /ug human CRH. 
Shortly after successful pituitary surgery on February 7th, 1985, she was 
retested with 100/yg ovine CRH. No cardiovascular adverse effects occurred 
during the first three CRH tests. Because of postoperative hypocortisolism 
cortisone acetate was started. On May 7th, 1985, 36 hours after the last 
cortisone dose, a continuous i.v. infusion was given with ovine CRH (100μ% 
ovine CRH in 15 min). Two i.v. lines were inserted 1/2 hour before starting 
the infusion. Blood pressure was 120/80 mmHg before CRH. Four minutes 
after starting the CRH infusion the i.v. line was flushed with ± 3 ml of a 10% 
solution of heparin (1 ml = 5001.U. heparin) because of clotting. Within a 
few minutes after restarting the CRH infusion blood pressure dropped to 
88/53 mmHg, immediately followed by disappearance of sinus rhythm and 
appearance of an AV-junctional rhythm of 47/min. CRH infusion was 
stopped (at that time 55 μ% ovine CRH was infused) and 1/2 mg atropine was 
given i.v. Blood pressure and heart rate recovered within a few minutes. 
However periods with an AV-junctional rhythm were seen till 18 min after 
the start of the CRH infusion. 
Chapter 5 
Comments 
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Physiology and pathophysiology 
The most striking observation of this thesis, described in Chapter 2.1, is that 
the lower the basal plasma Cortisol concentration in healthy subjects, the 
higher the integrated plasma ACTH response to ovine CRH. Remarkably, 
no significant correlation, either positive or negative, was found between the 
basal plasma ACTH level and the response of this hormone to ovine CRH. 
This study was the first to demonstrate the modulatory effect of physio-
logical Cortisol levels on the ACTH response to CRH in man. These 
observations suggest that the response of the pituitary to CRH is primarily 
dictated by an extrinsic factor, i.e., by the level of circulating glucocorticoids, 
rather than by the pituitary gland itself. A pharmacological argument for 
this concept was found in the study reported in Chapter 2.4, in which we 
demonstrated a significant inverse correlation between the plasma ACTH 
and Cortisol responses to ovine CRH in healthy subjects after overnight 
suppression with increasing doses of dexamethasone and the plasma level of 
the synthetic glucocorticoid immediately before injection of CRH. In order 
to prove unequivocally that physiological concentrations of Cortisol inhibit 
the response of the hypophysis to CRH we investigated whether after 
pretreatment with the antiglucocorticoid RU-486 the CRH induced ACTH 
rise is enhanced (Chapter 2.5). First, we found that a single dose of 100 mg of 
the antiglucocorticoid at 02.00 h leads to a significant increase of the mean 
ACTH and Cortisol level six to seven hours later. The most ready 
explanation for this concurrence of elevated ACTH and Cortisol levels after 
blocking glucocorticoid activity is that the antiglucocorticoid, by occupying 
glucocorticoid receptors at the level of the pituitary and/or hypothalamus, 
attenuates the inhibitory effect of circulating Cortisol leading to elevated 
ACTH levels, which in turn leads to elevated Cortisol levels. In line with this 
effect we found that, despite a higher mean basal Cortisol level, loading with 
this competitive antagonist of Cortisol significantly increases the mean 
maximal ACTH rise to human CRH. In our opinion this observation is the 
strongest argument so far obtained for the concept that, in man, physio-
logical concentrations of Cortisol determine the response of the pituitary to 
CRH. 
After these observations in healthy subjects we analysed which factor 
determined the ACTH response to CRH in patients with Addison's disease -
a condition characterized by absence of Cortisol feedback - and in patients 
with pituitary-dependent Cushing's disease - a condition characterized by a 
deficient Cortisol feedback. We found that in both disorders the absolute 
ACTH response to ovine CRH is augmented and positively correlated with 
the basal ACTH level, whereas no correlation could be demonstrated 
between the basal plasma Cortisol level and the response of the pituitary to 
CRH (Chapters 3.1 and 3.3). As far as Addison's disease is concerned, we 
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speculate that the virtual absence of circulating Cortisol in this disorder 
reveals the primacy of the basal activity of the corticotrophs in their respon-
sivity to CRH. In Cushing's disease, however, we hypothesize that the 
primacy of the basal activity of the corticotrophs in the response to CRH 
emerges as a consequence of the primary defect in the receptiveness of the 
corticotrophs for circulating Cortisol. 
At the end of 1983 human CRH became available for clinical investi-
gations. In Chapter 2.2 we demonstrated that human CRH has a much 
shorter duration of action than ovine CRH in man. This has been confirmed 
by Schürmeyer et al (1). These workers also demonstrated that the 
stimulation of the hypophyseal-adrenal axis by human CRH is shorter than 
after ovine CRH injection and that this difference is caused by an 
approximately 3 to 4 times higher metabolic clearance rate of the former 
peptide. In Chapter 2.3 we showed that in healthy subjects bolus injections of 
200 μg of both ovine and human CRH caused a significant decrease in 
diastolic blood pressure, which was not observed after the 100 μg doses of 
both peptides. Moreover, we showed that human CRH caused more 
pronounced hypotension than ovine CRH in man, and therefore we prefer 
ovine CRH in everyday practice. 
Clinical considerations 
In Chapter 3.3 we adduced evidence that a single bolus injection of CRH 
could divide patients with secondary adrenal failure into those with 
hypothalamic and those with pituitary disease. We commented that the 
secondary adrenal failure, which occurs after successful pituitary surgery in 
pituitary-dependent Cushing's disease is caused by coexistent pituitary and 
hypothalamic failure (Chapter 3.4). 
Recently we studied the type of the transient adrenal failure after 
unilateral adrenalectomy in two patients with Cushing's syndrome due to an 
adrenal adenoma. The results of the CRH tests in these patients, before and 
after operation, are illustrated in Figure 1. It shows that in both patients the 
adrenal failure immediately after operation is of the combined hypothalamic-
pituitary and adrenal type, and that the recovery of the hypothalamic-
pituitary function precedes the recovery of the function of the remaining 
adrenal in both patients. These conclusions concur with those in the classical 
study of Liddle's group (2). 
The CRH test is of no, or at the best, of minor value in discriminating 
patients with Cushing's syndrome from healthy subjects, as 30% of the 
patients with pituitary-dependent Cushing's disease have a normal Cortisol 
response to CRH (Chapter 3.1). However, the CRH test is a reliable tool for 
subdividing patients with Cushing's syndrome into those with pituitary-
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dependent Cushing's disease, ectopic ACTH secretion and adrenal-depen­
dent Cushing's syndrome. In our study (Chapter 3.2) the diagnostic accuracy 
of the CRH test in the differential-diagnosis of Cushing's syndrome was at 
least as high as that of the "high-dose" dexamethasone suppression test 
according to Liddle, which is still considered the most reliable test for this 
purpose. 
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FIÇUI e I Plasma A C T H and Cortisol responses to an intravenous bolus injection of 100/Ug ovine 
CR F in two patients with Cushing's syndrome due to an adrenal adenoma (p.o.= post-
operatively). The shaded area represents the mean + I SD m 13 normal subjects 
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Samenvatting 
In dit proefschrift worden effekten van de intraveneuze toediening van 
"Corticotropin-releasing hormone (CRH)" bij de mens beschreven. CRH is 
een hypothalaam hormoon dat de synthese en secretie van ACTH door de 
hypofyse bevordert. Het werd door Vale en medewerkers in 1981 geïsoleerd 
uit hypothalami van schapen. In 1983 werd ook de structuur van het 
menselijke CRH opgehelderd door analyse van het pre-pro CRH gen van de 
mens. Deze beide CRH's zijn peptide-hormonen van 41 aminozuren, die niet 
geheel identiek zijn: op 7 plaatsen van de keten worden verschillende 
aminozuren gevonden. Immunologisch aantoonbare "CRH-activiteit" is 
niet beperkt tot de hypothalamus maar komt ook in een groot aantal andere 
delen van de hersenen voor. In Hoofdstuk 1 wordt onder andere de centrale 
rol van CRH bij de aanpassing van het organisme aan stress besproken. 
In Hoofdstuk 2 worden gegevens vermeld die werden verkregen bij 
bestudering van de effekten van toediening van CRH aan gezonde volwassen 
mensen. In een eerste studie (Hoofdstuk 2.1) betreffen deze gegevens 
effekten van intraveneuze injectie, bij wijze van een "bolus", van 200 μg 
CRH van schapen, toegediend te 9 uur in de morgen aan 10 gezonde 
vrijwilligers. CRH-toediening leidde tot een, voor mannen en vrouwen niet 
verschillende, verdubbeling van de spiegels van ACTH, Cortisol en aldos-
teron in plasma. Daarbij werd geen stijging waargenomen in de spiegels van 
gonadotrofinen, TSH, groeihormoon en prolactine. Er werd een zeer 
significante negatieve correlatie vastgesteld tussen de individuele basale 
spiegels van Cortisol enerzijds en het antwoord van ACTH en Cortisol na 
toediening van het CRH, gemeten aan het oppervlak onder de individuele 
ACTH- en cortisol-curven. De basale spiegels van ACTH evenwel waren 
niet gecorreleerd met de op deze wijze gemeten antwoorden van ACTH en 
Cortisol op de toediening van CRH. Deze gegevens wijzen erop dat het 
antwoord van de hypofyse op CRH primair bepaald wordt door de 
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hoeveelheid in circulatie aanwezige glucocorticoide activiteit, dus door een 
op de hypofyse inwerkende factor en niet door de activiteit van de hypofyse 
met betrekking tot de ACTH produktic ten tijde van de toediening van het 
hormoon. 
In Hoofdstuk 2.2 worden de effekten van bolus-injecties van 200/ug CRH 
van het schaap vergeleken met die van 200 /yg CRH van de mens. Bij 10 
gezonde proefpersonen bleek menselijk CRH een ongeveer gelijke stijging 
van de spiegels van ACTH en Cortisol te bewerkstelligen als CRH van het 
schaap. Het verschil tussen beide was dat het menselijke CRH een significant 
kortere werkingsduur bleek te hebben. Bovendien werd waargenomen dat 
een dergelijke hoeveelheid humaan CRH, in tegenstelling tot het CRH van 
het schaap, de secretie van prolactine door de hypofyse deed toenemen. 
Uit dierexperimenten was inmiddels gebleken dat intraveneuze toediening 
van CRH kan leiden tot een geringe daling van de bloeddruk, waarschijnlijk 
tengevolge van perifere vaatverwijding. In Hoofdstuk 2.3 worden hemo-
dynamische effekten van intraveneuze toediening van CRH in een bolus bij 
31 gezonde vrijwilligers geanalyseerd. Na injectie van 100 pg CRH van het 
schaap of de mens veranderde de bloeddruk niet. Na toediening van 200 /ug 
CRH van het schaap daalde de diastolische bloeddruk gemiddeld 14 mmHg, 
terwijl dezelfde dosis CRH van de mens de diastolische bloeddruk significant 
meer omlaag bracht, gemiddeld 23 mmHg. Daling van de systolische 
bloeddruk trad in geen der experimenten op, ook niet na toediening van 200 
/yg CRH van de mens. Deze experimenten werden niet dubbelblind 
uitgevoerd en ook het effekt van toediening van het oplosmiddel zonder 
CRH werd niet systematisch bestudeerd. Toch menen wij dat, gezien de 
sterkere daling van de diastolische bloeddruk na toediening van menselijk 
CRH vergeleken met die na toediening van CRH van het schaap, voorlopig 
de voorkeur gegeven moet worden aan CRH van het schaap bij gebruik voor 
diagnostische doeleinden in de kliniek. 
De hypothese dat het antwoord van de hypofyse-bijnieras op de toe­
diening van CRH bij de mens wordt bepaald door de in circulatie aanwezige 
hoeveelheid Cortisol, kreeg verder steun door experimenten beschreven in 
Hoofdstuk 2.4. Hierin wordt het antwoord van ACTH en Cortisol op de 
toediening van 200 μg schape-CRH bij 5 gezonde vrijwilligers bestudeerd 
nadat deze met verschillende doses van het synthetische glucocorticoid 
dexamethason waren behandeld. Dit glucocorticoid werd in de avond 
voorafgaande aan de morgen van de CRH proef toegediend in zodanige 
hoeveelheden dat ten tijde van de injectie van CRH de spiegels van ACTH en 
Cortisol in het bloed nagenoeg volledig gesupprimeerd waren. De concen­
tratie van dexamethason in het plasma onmiddellijk voor toediening van 
CRH bleek negatief gecorreleerd te zijn met de grootte van het oppervlak 
onder de curven van ACTH en Cortisol na toediening van CRH. 
In Hoofdstuk 2.5 worden waarnemingen beschreven die eveneens een 
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sterk argument vormen voor de opvatting, dat het de concentratie van 
Cortisol is, die het antwoord van de hypofyse op CRH in hoge mate bepaalt. 
Hierbij werden proefpersonen voorbehandeld met het antiglucocorticoid 
RU-486. Deze stof bezet receptoren voor Cortisol en schakelt daardoor 
effekten van glucocorticoiden op doelwitorganen uit. Indien men aanneemt, 
dat deze stof de receptoren voor Cortisol in de hypofyse blokkeert, en 
daarmee terugkoppeling van Cortisol op de hypofyse uitschakelt, verwacht 
men dat de door CRH geïnduceerde toeneming van ACTH-secretie wordt 
versterkt. Dit werd inderdaad vastgesteld. Bovendien wezen deze proeven 
uit dat toediening van 100 mg van het bovengenoemde antiglucocorticoid 
om 2 uur 's nachts de gemiddelde ACTH- en cortisol-spiegels in het bloed 6 
tot 7 uur later, dus nog voor toediening van CRH, deed toenemen. Deze 
waarneming suggereert dat het antiglucocorticoid de receptoren voor 
Cortisol in de hypofyse en/of de hypothalamus blokkeert. Daardoor kan 
circulerend Cortisol de ACTH-secretie niet remmen en ontstaat de combi-
natie van verhoogde ACTH-spiegels met daarbij, en daardoor geïnduceerd, 
verhoogde spiegels van Cortisol in het bloed. 
Na deze waarnemingen bij gezonde proefpersonen werd geanalyseerd 
welke factor het antwoord van ACTH op toediening van CRH bepaalt bij 
patiënten bij wie de terugkoppeling door Cortisol niet kan optreden, omdat 
Cortisol in de circulatie nagenoeg ontbreekt - patiënten met de ziekte van 
Addison - en bij patiënten met de zogenaamde hypofyse-afhankelijke vorm 
van het syndroom van Cushing - een aandoening die wordt gekenmerkt door 
een primair defekt in de "feedback" van Cortisol. Bij beide ziektebeelden 
bleek het absolute antwoord van ACTH op toediening van CRH van het 
schaap verhoogd te zijn. Dit antwoord was bovendien positief gecorreleerd 
met de basale spiegel van ACTH, terwijl geen significante relatie kon worden 
aangetoond tussen de basale spiegel van circulerend Cortisol en het antwoord 
van de hypofyse op CRH (Hoofdstuk 3.1 en 3.3). De resultaten van de 
onderzoekingen bij patiënten met de ziekte van Addison suggereren het 
volgende: door het vrijwel ontbreken van Cortisol in de circulatie kan van 
feedback door Cortisol natuurlijk geen sprake zijn en in die situatie komt 
blijkbaar aan de basale activiteit van de hypofyse qua produktie van ACTH 
een regulerende rol toe bij het antwoord op CRH. Bij patiënten met de ziekte 
van Cushing verklaren wij het gevonden resultaat als een rechtstreeks gevolg 
van een primair defekt in de receptie van circulerend Cortisol door de 
corticotrope cellen. Bij deze laatste groep van patiënten vonden wij ook een 
dergelijke positieve correlatie tussen de ACTH-spiegel na suppressie met 
hogere en lagere doseringen van het synthetische glucocorticoid dexame-
thason en het antwoord van de hypofyse op CRH (Hoofdstuk 3.1). 
Het syndroom van Cushing wordt veroorzaakt door primaire overproduktie 
van ACTH, hetzij door de hypofyse hetzij door een ectopische bron, of door 
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primaire overproduktie van Cortisol door een bijnieradenoom of -carci-
noom. Om deze verschillende vormen van het syndroom van Cushing te 
onderscheiden zijn verschillende diagnostische onderzoekingen in gebruik. 
Nogal eens leiden deze proeven tot resultaten die met elkaar in strijd zijn. Na 
de isolatie van CRH hebben verschillende groepen onderzoekers de waarde 
van CRH voor de differentiële diagnostiek van het syndroom van Cushing 
onderzocht. De overigens nog schaarse literatuurgegevens laten zien dat 
patiënten met een hypofyse-afhankelijke vorm van het syndroom van 
Cushing meestal een stijging van de plasma-spiegels van ACTH na 
toediening van CRH laten zien, terwijl patiënten met een bijnier-afhan-
kelijke vorm gekenmerkt worden door niet detecteerbaar lage spiegels van 
ACTH basaal, die na toediening van CRH niet stijgen. Patienten met de 
ectopische vorm van het syndroom van Cushing hebben meestal sterk 
verhoogde basale spiegels van ACTH, die niet verder stijgen na CRH-
injectie. 
Wij vergeleken de waarde van de CRH test (toediening van 100//g schape-
CRH als bolus om 9 uur 's ochtends) met die van de orale "hoge dosis" 
dexamethason suppressietest volgens Liddle voor de differentiële diag-
nostiek van het syndroom van Cushing bij 26 achtereenvolgens bestudeerde 
patiënten met dit ziektebeeld (Hoofdstuk 3.2). Een vals-negatief antwoord 
na CRH kwam voor bij 2 van 22 (9%) patiënten met de hypofyse-
afhankelijke vorm van dit ziektebeeld, terwijl een dergelijk fout antwoord 
werd gevonden bij 2 van 18 (11%) van deze patiënten bij gebruik van de 
Liddle test. Drie patiënten met het syndroom van Cushing ten gevolge van 
een bewezen bijnieradenoom reageerden volgens verwachting noch op CRH 
noch op toediening van dexamethason. Eén patient met de ectopische vorm 
van het syndroom van Cushing toonde een vals-positieve reactie van ACTH 
na toediening van dexamethason maar geen antwoord op CRH. Een fout 
antwoord van beide testen kwam bij geen van de onderzochte patiënten 
voor, met uitzondering van één patient met de ziekte van Cushing en een 
uitgesproken macronodulaire Hyperplasie van de bijnieren. Overigens moet 
hieraan worden toegevoegd dat het bij deze interessante vorm van het 
syndroom van Cushing de vraag is welk antwoord men op elk van beide 
testen theoretisch zou moeten verwachten. Uit deze studie werd gecon-
cludeerd dat de diagnostische waarde van de CRH test bij de differentiële 
diagnostiek van het syndroom van Cushing goed vergelijkbaar is met het 
resultaat van de Liddle test, tot op heden nog steeds beschouwd als de meest 
betrouwbare proef bij deze vorm van differentiële diagnostiek. Bij combi-
natie van de resultaten van beide proeven bereikt men een nagenoeg 100% 
score. Daarbij moet wel duidelijk onderstreept worden dat gebruik van de 
CRH test om poliklinische patiënten zonder het syndroom van Cushing te 
onderscheiden van patiënten met dit syndroom van weinig waarde is. 
Immers bij 30% van de patiënten met een hypofyse-afhankelijke vorm van 
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het syndroom van Cushing bleek het antwoord van Cortisol op toediening 
van CRH niet te onderscheiden van dat bij gezonde vrijwilligers. 
In Hoofdstuk 3.3 werd aangetoond dat, door bestudering van het 
antwoord op CRH, patiënten met secundaire bijnierschorsinsufficientie in 
twee groepen kunnen worden onderscheiden: patiënten die geen antwoord 
van ACTH op toediening van CRH laten zien en patiënten met wel een 
antwoord van ACTH na toediening van CRH. Deze laatstgenoemde 
patiënten bleken vaak een bifasische ACTH respons te vertonen, terwijl de 
gemiddelde ACTH respons na CRH bij deze patiënten significant hoger was 
dan bij gezonde proefpersonen. Ten aanzien van deze laatste groep van 
patiënten mag in alle redelijkheid gesteld worden dat bij hen de oorzaak van 
de bijnierschorsinsufficientie niet gelegen is in de hypofyse, maar in de 
hypothalamus of op een nog hoger niveau. Het spreekt veel minder vanzelf 
dat de oorzaak van de bijnierschorsinsufficientie bij de eerstgenoemde groep 
van patiënten in de hypofyse moet worden gezocht. Het is immers bekend 
dat bij zogenaamde hypothalame insufficientie het antwoord van de 
hypofyse op andere "releasing'^hormonen (TRH, LHRH, groeihormoon-
releasing hormoon) soms pas op gang komt na herhaalde stimulering. Een 
aantal klinische en biochemische gegevens, die in Hoofdstuk 3.3 zijn 
vermeld, maken het overigens waarschijnlijk dat de oorzaak van de 
bijnierschorsinsufficientie van deze eerstgenoemde groep toch in de hypo-
fyse moet worden gezocht. Hoewel anatomische bewijsvoering voor deze 
stellingname ontbreekt, menen wij met enige voorzichtigheid toch te mogen 
concluderen dat de CRH test nuttig gebruikt kan worden om bij patiënten 
met secundaire bijnierschorsinsufficientie het niveau van de lesie te locali-
seren. 
Patienten met de ziekte van Cushing, bij wie door middel van een 
neurochirurgische ingreep de in de hypofyse zetelende oorzaak is weg-
genomen, blijken na de operatie tijdelijk een onvoldoende bijnierschors-
functie te hebben. Deze bijnierschorsinsufficientie is van het zogenaamde 
"secundaire" type. Het is niet bekend of dit beeld veroorzaakt wordt door 
onvoldoende functie van het resterende deel van de hypofyse of het gevolg is 
van onvoldoende stimulering van de ACTH-produktie vanuit de hypo-
thalamus. In Hoofdstuk 3.4 bestudeerden wij door middel van CRH-
toedicning het functioneren van de hypofyse en de bijnierschors bij 8 
patiënten met de ziekte van Cushing, korte tijd (9 tot 18 dagen) na, blijkens 
het verdere beloop, geslaagde chirurgie van de hypofyse. Deze 8 patiënten 
waren allen na de operatie hypocortisolemisch. Niettemin leidde toediening 
van CRH bij 7 van deze patiënten tot een duidelijke toeneming van de 
spiegels van ACTH en Cortisol in bloed. Deze waarneming moet er op 
duiden dat er na deze vorm van hypofyse-chirurgie blijkbaar sprake was van 
onvoldoende stimulering van het resterende deel van de hypofyse vanuit de 
hypothalamus. Op zich pleit deze waarneming tegen een oorzakelijke rol van 
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CRH bij het ontstaan van de ziekte van Cushing. Bij vergelijking van deze 
serie resultaten met die verkregen bij een groep patiënten met onvoldoende 
bijnierschorsfunctie van het hypothalame type, zoals beschreven in Hoofd-
stuk 3.3, bleek dat de gemiddelde toeneming van de spiegels van ACTH in 
het bloed van de 8 patiënten na neurochirurgie wegens de ziekte van Cushing 
significant lager was dan de gemiddelde toeneming bij de eerstgenoemde 
groep patiënten. Het komt ons daarom voor dat patiënten met de ziekte van 
Cushing na operatie niet alleen een onvoldoende bijnierschorsfunctie 
hebben als gevolg van een gebrekkige sturing van de ACTH-secretie vanuit 
de hypothalamus maar tevens een zogenaamde "hypofysaire" insufficientie. 
Deze combinatie van gestoorde functie van hypothalamus en hypofyse na 
verwijdering van een hypofyse-adenoom wordt waarschijnlijk veroorzaakt 
door suppressie van zowel de cellen in de hypothalamus die CRH 
produceren als van de resterende hypofyse-cellen, betrokken bij de secretie 
van ACTH. Deze combinatie van afwijkingen wordt waarschijnlijk veroor-
zaakt door de in het verleden langdurig verhoogde spiegels van circulerend 
Cortisol in bloed. 
In Hoofdstuk 4 worden een aantal onverwachte reacties beschreven, die 
optraden bij enkele patiënten na toediening van CRH. Het is mogelijk dat 
enige van deze reacties (kortdurende absences en dalingen van de bloeddruk) 
veroorzaakt werden door toediening van een te grote hoeveelheid van het 
peptide. Twee andere reacties traden waarschijnlijk op zonder een directe 
relatie met de toediening van CRH. Bij één patient kwam de combinatie van 
bloeddrukdaling en bradycardie voor, die mogelijk werd veroorzaakt door 
een, vooralsnog niet bewezen, interactie tussen CRH en het héparine, dat 
gebruikt werd om de cannule voor afname van veneus bloed open te houden. 
In dit hoofdstuk wordt er op gewezen dat de studie naar de oorzaak van deze 
onverwachte reactie nog wordt voortgezet. 
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Stellingen 
1 Bij gezonde volwassenen wordt het antwoord van ACTH na toediening 
van CRH bepaald door de hoeveelheid glucocorticoide aktiviteit, die in 
de circulatie aanwezig is: hoe lager de basale Cortisol concentratie, des 
te sterker het antwoord van ACTH na CRH toediening. 
Dit proefschrift 
2 Bij patiënten met de ziekte van Cushing of de ziekte van Addison wordt 
het antwoord van ACTH na toediening van CRH niet bepaald door de 
hoeveelheid glucocorticoide aktiviteit, die in de circulatie aanwezig is, 
doch door de basale aktiviteit van de hypofyse qua produktie van ACTH : 
hoe hoger de basale ACTH concentratie, des te sterker het antwoord 
van ACTH na CRH toediening. 
Dit proefschrift 
3 De diagnostische waarde van de CRH test bij de differentiële diagnostiek 
van het syndroom van Cushing is vergelijkbaar met die van de klassieke 
dexamethason suppressietest volgens Liddle. 
Dit proefschrift 
4 De CRH test kan bij patiënten met secundaire bijnierschorsinsufficiëntie 
differentiëren tussen hypothalame en hypofysaire oorzaken van dit 
ziektebeeld. 
Dit proefschrift 
5 Bij patiënten met hypertensie en hypokaliemie dient ook het bestaan van 
een renine-producerende tumor overwogen te worden. 
A. Hermus, G. Pieters, A. Lamers et al. Hypertension and hypokalemia due to a renin-secre-
ting kidney tumour. Neth. J. Med. 1986. in press. 
6 Voor het vroegtijdig opsporen van metastasen bij patiënten, eerder 
behandeld wegens een primair mammacarcinoom is gericht onderzoek 
naar aanleiding van een bepaalde klacht nog steeds effektiever dan 
routinematige "screening" middels scans en röntgenfoto's. 
7 Een tekort aan CRH in de hersenschors speelt mogelijk een rol bij de 
ontwikkeling van presemele dementie van het type Alzheimer. 
E. De Souza, P. Whitehouse. M. Kuhar et al. Reciprocal changes in corticotropm-releasing 
factor (CRF)-like immunoreaclivity and CRF receptors in cerebral cortex of Alzheimer's 
disease. Nature (1986), 319. 593. 
8 Het verdient nader onderzoek of produktie van CRH en van ACTH 
door de placenta een rol speelt bij de ontwikkeling van het fysiologische 
hypercorticisme in de tweede helft van de zwangerschap. 
9 Bij langdurig ernstig zieke patiënten moet men bij onbegrepen hypoten-
sie, die onvoldoende reageert op toediening van pressor-aminen bedacht 
zijn op het bestaan van een relatieve bijnierschorsinsufficientie. Het 
vinden van een "normale" cortisolspiegel sluit deze diagnose onder 
dergelijke omstandigheden niet uit. Toediening van glucocorticoiden in 
voldoende hoge dosering kan bij deze patiënten de circulatoire stabiliteit 
aanzienlijk vergroten. 
Recente waarnemingen 
10 Het doorbrengen van een gedeelte van de opleidingstijd tot medisch 
specialist in een "perifeer" ziekenhuis is niet alleen opleidingstechnisch 
gewenst, doch voorkomt ook de in sommige academische kringen heer-
sende vooroordelen over "het ziekenhuis elders". 
11 De vraag om bij ernstig zieke patiënten een medische behandeling te 
staken is veel vaker van familieleden afkomstig dan van de patiënt zelf. 
12 De definitie van Gezondheid, zoals vastgesteld door de World Health 
Organization: "Een toestand van volkomen biologisch, sociaal en psy-
chisch welbevinden", is utopisch. Aldus gedefinieerd zal Gezondheid 
slechts beleefd worden in Utopia, in Nergensland dus. Een dergelijke 
voorstelling van Gezondheid wekt van de Gezondheidszorg verwachtin-
gen, die niet te vervullen zijn. 
Nijmegen, 17 april 1986 

Printed by ICG Printing, Dordrecht 
